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Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is responsible for 
approximately 1.6 million deaths per annum. Mtb has a complex cell envelope that contains 
unique polysaccharide structures that include arabinogalactan, phosphatidyl-myo-inositol 
mannosides (PIMs), lipomannan and lipoarabinomannan. These glycoconjugates appear 
throughout Corynebacteria mycobacteria nocardia (CMN) group of bacterial organisms. 
However, the mechanism by which these key cell envelope components are translocated across 
the cytoplasmic membrane, remain to be elucidated. The ABC transporter superfamily of 
proteins are responsible for the movement of a wide variety of molecular species across 
membranes and require hydrolysis of ATP to provide energy to facilitate movement. Here I 
investigated two ABC transporter systems involved in galactan and PIM translocation in 
Corynebacteriaceae. Using phenotypic analysis of deletion mutants in C. glutamicum, I 
provide evidence to support that Rv1272c/Rv1273c are directly involved in PIM translocation 
as the deletion of the C. glutamicum orthologs results in a depletion of PIM species on the cell 
surface. Through characterising protein-ligand interactions between the M. smegmatis Rv3781 
ortholog and immature galactan analogues, I present evidence to support the prediction that 
Rv3781/Rv3783 may be involved in galactan translocation 
. Finally, this study explores the effect of point mutations linked to Ethambutol (EMB) 
resistance in the key arabinosyltransferase (Emb) on the C. glutamicum cell envelope, through 
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 2 
1.1.1: Mycobacterium tuberculosis and related species: 
 
Mycobacterium tuberculosis (Mtb), is an aerobic, rod shaped bacillus belonging to the order 
Actinomycetales (Guglielmetti et al., 2015). Mtb was  first identified as the agent responsible 
for TB by Robert Koch in 1882 (Murray et al., 2015). Mtb, is responsible for an estimated 10 
million infections, and 1.6 million deaths globally in 2017 (World Health Organization, 2018).  
 
The primary site of infection for TB are the lungs (referred to as pulmonary TB), with 
transmission being largely airborne (Escombe et al., 2008). However, the infection can also 
affect other organs, then it is referred to as extrapulmonary TB (Singer-Leshinsky, 2016). 
Pulmonary TB is characterised by a chronic cough, fever, fatigue, and weight loss (Singer-
Leshinsky, 2016).  
 
In addition to causing active infections, TB is also known for its ability to infect a host and 
remain in a non-proliferative, non-symptomatic state within host macrophages (known as latent 
infection). Mtb can remain in this state until the host immune system is unable to defend itself 
before causing an active infection (Haley, 2019; Piccazzo et al., 2014; Tang and Johnston, 
2017). As individuals who are infected with latent TB do not show symptoms the estimated 
prevalence of latent TB, is a cause for some debate. Studies of the global prevalence of 
infection using different methods for the determining the incidence give a range from 25- 33 
% of the global population currently being infected (Houben and Dodd, 2016; Matteelli et al., 
2017).  
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quenced for a number of species. Mycobacterium species have
been divided into two major groups (slow growers and fast grow-
ers) depending upon their growth rates (142). The species of these
two groups generally branch distinctly in phylogenetic trees (232,
285). Their distinctness is also supported by the presence of a
longer helix between positions 451 and 482 in the 16S rRNA gene
in the slow growers than in the fast growers (232). Of these, the
slow-growing Mycobacterium species/strains are clinically impor-
tant, whereas the fast growers are ecologically important (142). In
the phylogenetic tree shown in Fig. 4, all of the sequenced Myco-
bacterium species/strains formed a strongly supported clade, and
within it, a cluster consisting of the slow-growing Mycobacterium
species was also strongly supported. We have identified a number
of CSIs and CSPs that are specific for either all sequenced Myco-
bacterium species or the slow-growing clade. Sequence informa-
tion for one of the CSIs that is specific for the genus Mycobacte-
rium is presented in Fig. 5B. In the enzyme pantoate-beta-alanine
ligase, which is involved in the metabolism of beta-alanine (200),
FIG 4 Bootstrapped neighbor-joining tree for Corynebacteriales species based upon concatenated sequences for the RpoB, RpoC, and gyrase B proteins. The
distinctness of a number of clades seen in this tree is independently supported by many identified CSIs and CSPs.
Gao and Gupta
80 mmbr.asm.org Microbiology and Molecular Biology Reviews
Figure 1.1: Phylogenetic tree of speci  from the sub rder orynebacteriales. Showing the various 
pathogenic and non-pathogenic species within the suborder, and their relative divergence.  Figure 
reproduced with permission from Gao and Gupta, 2012.  
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1.1.2: Clinical manifestations of the Corynebacterineae: 
 
The suborder Corynebacterineae contains many pathogenic agents, not limited to 
Mycobacteria, such as Corynebacterium pseudotuberculosis, and Corynebacterium 
diphtheriae (Figure 1.1) (Gao and Gupta, 2012). However, the most prevalent diseases such as 
TB and leprosy, are caused by mycobacterial species.  
 
Pathogenic mycobacteria are classified into: tuberculous, nontuberculous, or leprotic 
mycobacteria. Tuberculous mycobacteria include: Mtb, Mycobacterium bovis, and 
Mycobacterium africanum (Addo et al., 2010). While nontuberculous mycobacteria include 
Mycobacterium absessus, Mycobacterium ulcerans, Mycobacterium gordonae, and 
Mycobacterium marinum (Porvaznik et al., 2016). The major causative agent of mycobacterial 
leprosy are Mycobacterium leprae and Mycobacterium lepromatosis (Franco-Paredes et al., 
2018). 
 
Mycobacteria are unusual in that they do not stain as either Gram positive or negative but 
instead as between the two, leading to them being classified as Gram indeterminate. This has 
led to alternate staining methods to better visualize the bacteria, resulting in further 
classification as acid-fast bacteria, a status shared only with some Nocardia species (Brennan 
and Nikaido, 1995).  The cause of this unique staining phenotype is the unusual structure of 
the cell wall they produce, which results in a thick, waxy outer pseudo-membrane referred to 
as the myco-membrane. While there are differences in the cell wall and lipid composition 
between species within the corynebacteria mycobacteria nocardia (CMN) group, much of the 
structure of the cell wall and the biosynthetic pathways are very similar (Besra et al., 1995).  
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1.1.3: Mechanism of infection by Mycobacterium tuberculosis: 
 
Mtb is recognised by the macrophages of the host immune system, by a variety of receptors. 
Upon recognition it is engulfed and contained within the macrophage in a phagosome. The 
receptor that recognises the bacillum is important for the outcome of the phagocytosis process, 
as there have been different responses shown when particles are captured through different 
receptors (Pieters, 2008).  With some receptors (such as CR3 mediated uptake), being 
beneficial to the bacteria. Uptake mediated by CR3 (which is involved in uptake of cholesterol), 
leads to improved prevention of phagosome fusion with the lysosome, allowing for increased 
bacterial survival within the macrophage (Gatfield and Pieters, 2000). 
 
Phagosome-lysosome fusion is inhibited by the degradation of the phosphatidylinositol-3-
phosphate (PI3P) that is produced to phosphatidyl inositol and inorganic phosphate, as Mtb 
secretes SapM, a phosphatase which hydrolyses PI3P. The inhibition of hVP34 results in 
insufficient PI3P for phagolysosome formation, increasing bacterial survival within the 
macrophage  (Saleh and Belisle, 2000; Vergne et al., 2005, 2003). Mtb also prevents 
phagolysosome formation by secretion of PknG, a membrane embedded protein kinase 
released by mycobacteria upon entry to the phagosome, whereby it gains access to the cytosol 
of the macrophage, and inhibits the activity of protein kinase C-α (Chaurasiya and Srivastava, 
2009; Walburger, 2004). 
 
Additional to survival within the macrophage, Mtb triggers formation of granuloma, structures 
of infected macrophages, surrounded by un-infected immune cells. The interactions between 
the infected and un-infected cells maintains an immune presence at the site of infection, 
allowing for the bacteria to determine if the host immune system is functional. While in the 
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granuloma, there has been no conclusive evidence on whether the bacteria are dividing or in a 
non-replicative state, however during this stage of infection, the host shows no symptoms of 
active TB, and is defined as having latent TB (Karakousis et al., 2004; Pieters, 2008).  
 
1.1.4 Global prevalence of TB:  
 
TB is the leading cause of death by a single infectious agent, with 1.6 million deaths attributed 
to Mtb in 2017 (World Health Organization, 2018). While cases of Mtb are found worldwide, 
66 % of confirmed cases are found within eight high burden countries, the most affected of 
which is India, accounting for 27 % of global cases (World Health Organization, 2018). Mtb 
infections affect all ages groups, though 90 % of reported cases are seen in adults over the age 





















Philippines (6%), Pakistan (5%), Nigeria (4%), Bangladesh 
(4%) and South Africa (3%) (Fig. 3.3). 
The severity of national TB epidemics in terms of the 
annual number of incident TB cases relative to population 
size (the incidence rate) varied widely among countries in 
2017. There were under 10 incident cases per 100 000 
population in most high-income countries, 150–400 in 
most of the 30 high TB burden countries (Fig. 3.4), and 
above 500 in a few countries including the Democratic 
People’s Republic of Korea, Lesotho, Mozambique, the 
Philippines and South Africa (Table 3.3).
An estimated 9% (range, 7.9–11%) of the incident 
TB cases in 2017 were among pe ple living with HIV 
(Table 3.2, Table 3.3). The proportion of TB cases coin-
fected with HIV was highest in countries in the WHO 
African Region, exceeding 50% in parts of southern 
Africa (Fig. 3.5). The risk of developing TB in the 37 
million people living with HIV was 20 times higher than 
the risk in the rest of the world population (range, 17–23), 
increasing with a decreasing prevalence of HIV in the 
general population.
Estimates of the incidence of zoonotic TB are shown 
in Table 3.4.
3.1.3 Estimated trends in TB incidence, 2000–2017
Consistent with previous global TB reports, the number 
of incident cases is falling slowly, in both absolute terms 
and per capita (Fig. 3.6, Fig. 3.7). Globally, the average 
rate of decline in the TB incidence rate was 1.5% per year 
in the period 2000− 2017, and 1.8% between 2016 and 
2017. This needs to accelerate to 4–5% per year by 2020 
and to 10% per year by 2025, to achieve the milestones 
for reductions in cases and deaths set in the End TB 
Strategy (Chapter 2).
Trends are shown for the six WHO regions in Fig. 3.8 
and for the 30 high TB burden countries in Fig. 3.9.1 The 
fastest declines in the 5-year period 2013–2017 were 
in the WHO European Region (on average, 5% per year). 
In the same period, particularly impressive reductions 
(4–8% per year) occurred in southern Africa (e.g. 
Eswatini [formerly Swaziland], Lesotho, Namibia, South 
Africa, Zambia and Zimbabwe) following a peak in the 
HIV epidemic and the expansion of TB and HIV prevention 
and care (Box 3.4), and in the Russian Federation (5% per 
year) following intensified efforts to reduce the burden 
of TB and scrutiny of progress from the highest political 
levels. 
3.2  TB mortality
Deaths from TB among HIV-negative people are clas-
sified as TB deaths in the most recent version of the 
International classification of diseases (ICD-10).2 When 
1 Time series of estimates for all countries are available online. Annex 1 
explains how to access and download them.
2 World Health Organization. International statistical classification of 
diseases and health related problems, ICD-10. Geneva: WHO; 2016 
(http://apps.who.int/classifications/icd10/browse/2016/en, accessed 31 
August 2018).
FIG. 3.4 
Estimated TB incidence rates, 2017









Figure 1.2: Reported incidence of  TB globally per 100,000 population. Showing the major burden of TB is in  
sub-saharan Africa. Figure reproduced from World Health Organization, 2018.  
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Globally the incidence of TB is falling by 2 % per year, and mortality is falling at a rate of 4 
% per year, with a decrease of 42 % between 2000 and 2017, although the rate of new and 
relapse cases of Mtb  (Figure 1.3) (World Health Organization, 2018). 
 
1.2.1: Treatment of TB: 
 
Mtb has been the subject of intense research for decades, due to the high burden of infection 
and the difficulty in treating the disease. This research has led to the development of effective 
antimycobacterial molecules which have been instrumental in the improvements in the 
outcome of infection (Zumla et al., 2013). The World Health Organisation (WHO) credits the 
implementation of the Directly Observed Treatment Short (DOTS) course, where patients are 
treated with Rifampicin, Isoniazid, Pyranzinamide, and Ethambutol for two months, with 
continued treatment with Rifampicin and Isoniazid for a further four months. The DOTS course  





























Global trends in the estimated number of incident TB cases and the number of TB deaths (in millions), 
2000–2017. Shaded areas represent uncertainty intervals.
FIG. 3.7 
Global trends in estimated TB incidence and mortality rates, 2000–2017. Shaded areas represent 
uncertainty intervals.
an HIV-positive person dies from TB, the underlying 
cause is classified as HIV. For consistency with these 
international classifications, this section makes a clear 
distinction between TB deaths in HIV-negative people 
and TB deaths in HIV-positive people.
3.2.1 Methods to estimate TB mortality
TB mortality among HIV-negative people can be meas-
ured directly using data from national vital registration 
(VR) systems, provided that these systems have high 
coverage and that causes of death are accurately 
determined and coded according to ICD-10. Sample VR 
systems covering representative areas of the country (the 
approach used, for example, in China) provide an interim 
solution. Mortality surveys can also be used to estimate 
deaths caused by TB. In 2017, most countries with a high 
burden of TB l ck d national or sample VR systems, and 
few had conducted mortality surveys. In the absence of 
VR systems or mortal ty surveys, TB mortality can be 
estimated as the product of TB incidence and the case 
fatality ratio (CFR), or through ecological modelling using 
mortality data from countries with VR systems.
TB mortality among HIV-positive people is hard to 
measure, even when VR systems are in place, because 
deaths among HIV-positive people are coded as HIV 
deaths, and contributory causes (e.g. TB) are often not 
reliably assessed and recorded. TB deaths among HIV-
positive people were estimated as the product of TB 
incidence and the CFR, with the latter accounting for the 
protective effect of ART.
Until 2008, WHO estimates of TB mortality used VR 
or mortality survey data for only three countries. This 
was substantially improved to 89 countries in 2009, al-
though most of the data were from countries in the WHO 
European Region and the WHO Region of the Americas, 
which accounted for less than 10% of the world’s TB cas-
es. For the current report, VR or mortality survey data 
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TB incidence TB deaths
All TB cases
Notifications of new 
and relapse cases
HIV-positive TB cases
TB deaths among 
HIV-negative people
TB deaths among 
HIV-positive people
  Figure 1.3: Global i cid nce of TB. Global incide ce of TB showing 95 % confidence interval from 2000-2017, 
including incidence of HIV-positive patients and mortality rate of TB from HIV-negative patients. Figure 
reproduced from World Health Organization, 2018. 
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depending on a variety of factors, including: HIV status, kidney disease, and if the infection is 
disseminated (Thwaites, 2014; World Health Organization, 2018).  
 
Due to the severity of the TB epidemic, the World Health Organisation, has made it a priority 
to reduce both the incidence and mortality associated with TB by 95 % by 2035 (Figure 1.4). 
This would require significant technological advancement in preventing the development of 
active TB from the reservoir of latent TB in the global population, as well as an improvement 
in the availability of high quality treatment, especially to those in the developing world (World 
Health Organization, 2018).  
 
The cell wall of bacteria is an attractive target for antimicrobial compounds, with perhaps the 
most well-known antibiotic, Penicillin, which inhibits cell wall synthesis. While Penicillin is 
widely used to treat many bacterial infections, the expression an extended spectrum beta-






















which TB incidence falls globally, to an average of 17% 
per year. Such an acceleration will depend on a techno-
logical breakthrough that can substantially reduce the 
risk of developing TB disease among the approximately 
1.7 billion people1 (approximately one quarter of the 
world’s population) who are already infected with 
Mycobacterium tuberculosis. Examples include an effec-
tive post-exposure vaccine or  short, efficacious and 
safe treatment for latent TB infection. The latest status of 
the development pipelines for new TB diagnostics, drugs 
and vaccines is presented in Chapter 8.
To achieve the targets and milestones, the End TB 
Strategy has four underlying principles and three pillars. 
The four principles are government stewardship and 
accountability, with monitoring and evaluation; a strong 
coalition with civil society organizations and communi-
ties; protection and promotion of human rights, ethics 
and equity; and adaptation of the strategy and targets at 
country level, with global collaboration. The three pillars 
are integrated, patient-centred TB care and prevention; 
bold policies and supportive systems (including UHC, 
social protection, and action on TB determinants); and 
intensified research and innovation. The 10 components 
of the three pillars of the End TB Strategy are shown in 
Box 2.3.
WHO has defined 10 priority indicators for monitoring 
of progress in implementing the End TB Strategy. These 
are shown in Table 2.2. The table also indicates the par-
ticular chapter of this report in which available data for 
each indicator can be found.
1 Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: 
a re-estimation using mathematical modelling. PLoS Med. 
2016;13(10):e1002152 (https://www.ncbi.nlm.nih.gov/pubmed/27780211, 
accessed 21 June 2018).
Data for five of the 10 indicators cannot be captured 
routinely using the standard recording and reporting 
forms for paper-based systems that are included in the 
latest revision of WHO’s framework for TB case defini-
tions and reporting.2 Collection of data on the costs faced 
by TB patients and their households, and assessment of 
whether these are catastrophic (Indicator 3 in Table 2.2) 
requires periodic surveys of a representative sampl  of 
TB patients; further details are provided in Chapter 7. 
For the other four indicators (Indicators 4, 5, 6 and 8 in 
Table 2.2), data may already be captured routinely in 
countries that have electronic case-based systems for 
recording and reporting of data; if this is not the case, 
these systems can be adapted to capture the information. 
Alternatively, countries can undertake periodic surveys 
of the medical records or patient cards of a random 
sample of TB patients. Further guidance is provided in 
the WHO operational guidance on the End TB Strategy.3
2.3 The Moscow Declaration to end TB
The first global ministerial conference on ending TB 
was held in Moscow in November 2017. It was organ-
ized by WHO and the Ministry of Health of the Russian 
Federation, in recognition of the fact that investments 
and actions have been falling short of those needed to 
reach SDG and End TB Strategy targets and milestones. 
2 World Health Organization. Definitions and reporting framework for 
tuberculosis – 2013 revision (updated December 2014) (WHO/HTM/
TB/2013.2). Geneva: WHO; 2013 (www.who.int/iris/
bitstream/10665/79199/1/9789241505345_eng.pdf, accessed 21 June 
2018).
3 World Health Organization. Implementing the End TB Strategy: the 
essentials. Geneva: WHO, 2016 (http://www.who.int/tb/
publications/2015/The_Essentials_to_End_TB/en/, accessed 21 June 
2018). See in particular Part II, Section 2.4.
FIG. 2.1





















































TARGET FOR 2035 = 95% REDUCTION
Figure 1.4: World Health Organisation ta gets for global TB incidence and d ath rates. Showi g the target 
global incidence and mort lity rates along with projected mile tones. Figure reproduced from World H alth
Organ zation, 2018. 
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al., 2019). Due to the essentiality of the cell wall, and the lack of an orthologous structure in 
mammalian cells, disruption of many of the processes in the synthesis and maintenance of the 
bacterial cell wall is an inviting target for the development of novel antibacterial agents. As 
such the processes involved in the biosynthesis, and maintenance of the cell wall have been a 
topic of study for decades, with many anti-tubercular drugs, such as Ethambutol, Isoniazid, and 







(ART). A combination of 
antiviral drugs used for 




The random allocation  
of patients to therapeutic 
regimens after enrolment. 
Assurances on strict adherence 
to interventions and minimizing 
losses from the trial population 
throughout treatment and 
follow-up are also key elements 
of randomized clinical trials.
Repurposed drugs
In this article, these are drugs 
that were developed to treat 
other diseases and have since 
been repurposed for treating 
tuberculosis.
MTB/RIF assay provides a high sensitivity initial screen 
for MDR-TB and the WHO recommends that patients 
with rifampicin-resistant TB should receive MDR-TB 
therapy pending additional DST. High sensitivity for 
rifampicin resistance is accompanied by some false-
positive results, requiring confirmatory drug sensitivity 
testing. Widespread implementation is underway in 
Africa and Asia and this is likely to increase the dectection 
of MDR-TB cases and increase the proportion of cases 
starting MDR-TB treatment.
The 2011 WHO MDR-TB treatment guidelines recom-
mend that the intensive phase of therapy is administered 
for at least 8 months for patients newly diagnosed with 
MDR-TB (that is, not previously treated for MDR-TB)15. 
Regimens should include at least four second-line drugs 
(BOX 3) that will have nearly certain effectiveness and be 
given on a daily basis under DOT throughout the treat-
ment duration. Total duration of therapy should be for 
at least 20 months when there is no history of previous 
MDR-TB treatment, and 28 months if there was previous 
MDR treatment. Pyrazinamide (Group 1; BOX 3) and an 
injectable drug (Group 2; BOX 3) are given only during 
the intensive phase. Durations for each phase should be 
modified according to the patient’s response to therapy. 
Group 3 (BOX 3) contains the fluoroquinolones (discussed 
in more detail below), of which moxifloxacin and levo-
floxacin are most active. The optimal dose for each is not 
clearly established, although moxifloxacin is widely dosed 
at 400 mg daily and levofloxacin at 750 mg daily. Studies 
are currently planned to further refine the optimal dose 
of levofloxacin in MDR-TB. Other approved second-line 
drugs for MDR-TB treatment included in Group 4 and 
Group 5 (BOX 3) have either weak or unclear bacteriostatic 
activity, many of which also have very high rates of side 
effects and intolerance. As such, drugs in these groups are 
generally reserved for patients with MDR-TB for whom 
options available in forming an adequate treatment regi-
men are limited. Linezolid (an oxazolidinone) and clofa-
zimine (a riminophenazine) are two drugs in Group 5 that 
are undergoing additional investigation to better define 
their safety, tolerability and efficacy as potential repurposed 
drugs for MDR-TB (FIG. 1).
Extensively drug-resistant tuberculosis. XDR-TB takes 
substantially longer to treat than MDR-TB and requires 
the use of third-line anti-TB drugs, which are expen-
sive and often have more side effects than first-line or 
second-line drugs. XDR-TB is associated with high mor-
tality rates and in HIV-infected persons these may reach 
100% if treatment commences too late18,19. In certain set-
tings, aggressive and comprehensive management can 
achieve cure rates of up to 60% of patients infected with 
XDR-TB but not HIV20. Drug resistance beyond the defi-
nition of XDR-TB has been described and illustrates the 
urgent need for new drugs for drug-resistant TB21.
Totally drug-resistant tuberculosis. Some recent reports 
use the term totally drug-resistant TB (TDR-TB) to 
describe TB caused by M. tuberculosis strains that are 
resistant to all available first-line and second-line TB 
drugs22. In March 2012, the WHO convened an expert 
consultation that identified numerous concerns about this 
Table 1 | Main tuberculosis drugs in clinical use and their targets
Drug (year of discovery) Target Effect Refs
First-line drugs
Isoniazid (1952) Enoyl-[acyl-carrier-protein] reductase Inhibits mycolic acid synthesis 120
Rifampicin (1963) RNA polymerase, beta subunit Inhibits transcription 120
Pyrazinamide (1954) S1 component of 30S ribosomal 
subunit








Para-amino salicylic  
acid (1948)
Dihydropteroate synthase Inhibits folate biosynthesis 122
Streptomycin (1944) S12 and 16S rRNA components  
of 30S ribosomal subunit
Inhibits protein synthesis 120
Ethionamide (1961) Enoyl-[acyl-carrier-protein] reductase Inhibits mycolic acid biosynthesis 120
Ofloxacin (1980) DNA gyrase and DNA  
topoisomerase
Inhibits DNA supercoiling 120,123
Capreomycin (1963) Interbridge B2a between 30S  
and 50S ribosomal subunits
Inhibits protein synthesis 124
Kanamycin (1957) 30S ribosomal subunit Inhibits protein synthesis 125
Amikacin (1972) 30S ribosomal subunit Inhibits protein synthesis 124
Cycloserine (1955) d-alanine racemase and ligase Inhibits peptidoglycan synthesis 126,127
REVIEWS
390 | MAY 2013 | VOLUME 12  www.nature.com/reviews/drugdisc
© 2013 Macmillan Publishers Limited. All rights reserved
Table 1.1: Antimycobacterial drugs. Detailing the year of discovery, and mechanism of action of first and 
second line antimycobacterial drugs. Table reproduced from Zumla et. al., 2013 
Chapter 1:  Introduction 
 10 
1.2.2: Rifampicin:  
 
Rifampicin (RIF, Table 1.1, Figure 1.5), is a semisynthetic rifamycin belonging to the antibiotic 
family ansamycins. RIF is used to treat a variety of bacterial infections, but most notably TB. 
The first rifamycin was discovered after the bacterium responsible for producing it, 
Amycolatopsis mediterranei, was isolated from a soil sample in southern France. This molecule 
was then modified to improve the antibiotic potency and bioavailability to produce RIF 
(Alifano et al., 2015).  
 
RIF functions by inhibiting RNA polymerase, preventing the elongation of the transcript after 
the initiation by blocking the path of the 5’ transcript (Campbell et al., 2001). Mutations have 
been found increasingly frequently where an amino acid change in the fork domain by the 
catalytic site, or in domains 1 and 2 of the b-subunit result in an change in the binding pocket 
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Protein synthesis inhibition 
 
programme work efficiently and accurately, health providers 
must build the links between public and private practitioners. 
The health services have been adopted in over 150 countries 
to promote the public health safety [31]. In 1998, WHO ex-
tended the DOTS programme especially for the manage-
ment, diagnosis and treatment of MDR-TB in the name of 
DOTS-Plus. The main focus of DOTS-Plus implementation 
is to carry out the drug-susceptibility testing and to check the 
availability of second-line agents in addition to all other re-
quirements of DOTS. For DOTS-Plus to be successful, spe-
cial attention is needed for the quality-assured laboratory 
capacity (smear, culture and drug sensitivity testing), treat-
ment design, adherence to difficult-to-take regimens for long 
periods, side-effect management, drug procurement, record-
ing and reporting and human and financial resource con-
straints. Therefore DOTS-Plus is much more complex and 
expensive than DOTS and requires much greater commit-
ment from countries wishing to implement it [32, 33]. 
 World Health Organization recommended that the regi-
men based on 2 months of rifampicin 2HRZE/6HE (where H 
(Isoniazid), R (Rifampin), Z (Pyrazinamide), E (Ethambu-
tol)) should be discontinued and be changed to the full 6 
months based regimen of rifampicin 2HRZE/4HR to reduce 
the number of relapses and failures. Drug Susceptibility 
Testing (DST) is one of the main objectives of WHO to start 
the therapy for all previously treated patients [34]. Drug Re-
sistance Surveillance (DRS) data is helpful in identifying and 
halting the spread of MDR-TB. WHO currently recommends 
a regimen consisting of amikacin (AMK), ethionamide 
(ETH), fluoroquinolone (such as moxifloxacin, MXF) and 
PZA for the treatment of MDR-TB [35].  
 The main focus of Centers for Disease Control (CDC) is 
to control the extensively drug resistant TB (XDR-TB), 
which is a kind of MDR-TB with additional resistance to 
fluoroquinolones and to at least one of the injectable second-line 
drugs such as capreomycin, kanamycin, and amikacin. CDC 
recommends the basic regimens for the treatment of TB as 
detailed in Table 3, which might be helpful to prevent the 
MDR/XDR-TB [36]. 
Figure 1.5: Chemical structure of Rifampicin.  




Ethambutol (EMB, Table 1.1, Figure 1.6) is a small molecular inhibitor of 
arabinosyltransferases, it has been shown to cause an accumulation of the arabinofuranose 
donor, b-D-arabinofuranosyl-1-monophophodecaprenol (DPA) (Takayama and Kilburn, 
1989). This finding suggests that the primary target of EMB is the incorporation of arabinose 
into the cell wall, either as part of the arabinogalactan, or as part of the lipoarabinomannan.  
 
Resistant mutants generated to EMB have been shown to possess point mutations in the 
embCAB genes, associated with the synthesis of the arabinan domain in arabinogalactan (AG) 
and LAM. However, many of the most common mutations in resistant Mtb strains have also 
been seen in sensitive strains, and the overexpression of EmbC does result in mild resistance 
to EMB suggesting that the target of EMB is EmbA and or EmbB (Goude et al., 2009; D. Shi 
et al., 2011). The most common resistance conferring mutation to EMB is EmbB306, with the 
wild type methionine being replaced with leucine, isoleucine, or valine (Safi et al., 2008; Shi 




Figure 1.6: Chemical structure of Ethambutol.  




Pyrazinamide (PYR, Table 1.1, Figure 1.7), is a prodrug based on a nicotinamide which 
requires acidic conditions to function (Chakraborty and Rhee, 2015). PYR is activated by an 
amidase, encoded by pncA, to form pyrazinoic acid.  Pyrazinoic acid binds strongly to the RpsA 
subunit of the 30S ribosome, which rescues stalled ribosomes in a process called trans-
translation, the accumulation of pyrazinoic acid also results in disruption of the membrane 
potential (W. Shi et al., 2011; Zhang, 2003). Resistance to PYR is seen in the mutation of pncA 
to prevent activation of PYR rather than in changes to the target enzyme. This coupled to the 
fact that the compound requires acidic conditions to function has led to difficulties in the 
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programme work efficiently and accurately, health providers 
must build the links between public and private practitioners. 
The health services have been adopted in over 150 countries 
to promote the public health safety [31]. In 1998, WHO ex-
tended the DOTS programme especially for the manage-
ment, diagnosis and treatment of MDR-TB in the name of 
DOTS-Plus. The main focus of DOTS-Plus implementation 
is to carry out the drug-susceptibility testing and to check the 
availability of second-line agents in addition to all other re-
quirements of DOTS. For DOTS-Plus to be successful, spe-
cial attention is needed for the quality-assured laboratory 
capacity (smear, culture and drug sensitivity testing), treat-
ment design, adherence to difficult-to-take regimens for long 
periods, side-effect management, drug procurement, record-
ing and reporting and human and financial resource con-
straints. Therefore DOTS-Plus is much more complex and 
expensive than DOTS and requires much greater commit-
ment from countries wishing to implement it [32, 33]. 
 World Health Organization recommended that the regi-
men based on 2 months of rifampicin 2HRZE/6HE (where H 
(Isoniazid), R (Rifampin), Z (Pyrazinamide), E (Ethambu-
tol)) should be discontinued and be changed to the full 6 
months based regimen of rifampicin 2HRZE/4HR to reduce 
the number of relapses and failures. Drug Susceptibility 
Testing (DST) is one of the main objectives of WHO to start 
the therapy for all previously treated patients [34]. Drug Re-
sistance Surveillance (DRS) data is helpful in identifying and 
halting the spread of MDR-TB. WHO currently recommends 
a regimen consisting of amikacin (AMK), ethionamide 
(ETH), fluoroquinolone (such as moxifloxacin, MXF) and 
PZA for the treatment of MDR-TB [35].  
 The main focus of Centers for Disease Control (CDC) is 
to control the extensively drug resistant TB (XDR-TB), 
which is a kind of MDR-TB with additional resistance to 
fluoroquinolones and to at least one of the injectable second-line 
drugs such as capreomycin, kanamycin, and amikacin. CDC 
recommends the basic regimens for the treatment of TB as 
detailed in Table 3, which might be helpful to prevent the 
MDR/XDR-TB [36]. 
Figure 1.7: Chemical structure of Pyrazinamide 




Isoniazid (INH, Table 1.1, Figure 1.8), is also a nicotinic acid derivative, was first synthesised 
in 1912, though the anti-mycobacterial properties were not discovered until 1952 (Chakraborty 
and Rhee, 2015; Zumla et al., 2013). Isolates that were found to be resistant to INH resulted in 
inactivation of the catalase, KatG. This resulted in the determination that INH was a prodrug, 
as sensitivity could restored by the transformation of katG into resistant strains (Chakraborty 
and Rhee, 2015).  
 
1.2.6: Antibiotic resistance in Mtb: 
 
Resistance to antimycobacterial agents is significantly linked to compliance issues caused in 
part by the length of the treatment regimen. This led to issues with patient compliance and 
therefore rising levels of resistance to frontline drugs such as rifampicin, as well a rise in multi-
drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB).  
 
MDR-TB is classified as a strain of Mtb that is resistant to both Rifampicin and Isoniazid, while 
XDR-TB is a strain of MDR-TB that has an additional resistance to at least one 
Fluoroquinolone and one of the second-line injectable antimycobacterial agent such as 
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Table 1. First line drugs used for the treatment of TB.
Drug Chemical Class Structure Target 
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programme work efficiently and accurately, health providers 
must build the links between public and private practitioners. 
The health services have been adopted in over 150 countries 
to promote the public health safety [31]. In 1998, WHO ex-
tended the DOTS programme especially for the manage-
ment, diagnosis and treatment of MDR-TB in the name of 
DOTS-Plus. The main focus of DOTS-Plus implementation 
is to carry out the drug-susceptibility testing and to check the 
availability of second-line agents in addition to all other re-
quirements of DOTS. For DOTS-Plus to be successful, spe-
cial attention is needed for the quality-assured laboratory 
capacity (smear, culture and drug sensitivity testing), treat-
ment design, adherence to difficult-to-take regimens for long 
periods, side-effect management, drug procurement, record-
ing and reporting and human and financial resource con-
straints. Therefore DOTS-Plus is much more complex and 
expensive than DOTS and requires much greater commit-
ment from countries wishing to implement it [32, 33]. 
 World Health Organization recommended that the regi-
men based on 2 months of rifampicin 2HRZE/6HE (where H 
(Isoniazid), R (Rifampin), Z (Pyrazinamide), E (Ethambu-
tol)) should be discontinued and be changed to the full 6 
months based regimen of rifampicin 2HRZE/4HR to reduce 
the number of relapses and failures. Drug Susceptibility 
Testing (DST) is one of the main objectives of WHO to start 
the therapy for all previously treated patients [34]. Drug Re-
sistance Surveillance (DRS) data is helpful in identifying and 
halting the spread of MDR-TB. WHO currently recommends 
a regimen consisting of amikacin (AMK), ethionamide 
(ETH), fluoroquinolone (such as moxifloxacin, MXF) and 
PZA for the treatment of MDR-TB [35].  
 The main focus of Centers for Disease Control (CDC) is 
to control the extensively drug resistant TB (XDR-TB), 
which is a kind of MDR-TB with additional resistance to 
fluoroquinolones and to at least one of the injectable second-line 
drugs such as capreomycin, kanamycin, and amikacin. CDC 
recommends the basic regimens for the treatment of TB as 
detailed in Table 3, which might be helpful to prevent the 
MDR/XDR-TB [36]. 
Figure 1.8: Chemical structure of Isoniazid 
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Kanamycin. The global estimate for the incidence of MDR-TB, or Rifampicin resistant TB 
(RR-TB) in new infections is 3.5 %, and 18 % in previously treated cases respectively, with 









































a Figures are based on the most recent year for which data have been reported, which varies among countries. Data cover the period 2002–2018.
FIG. 3.21 
Percentage of previously treated TB cases with MDR/RR-TBa
a Figures are based on the most recent year for which data have been reported, which varies among countries. Data cover the period 2005–2018. The 
high percentages of previously treated TB cases with RR-TB in Belize, Guam and Sao Tomé and Principe refer to only a small number of notified cases 










Figure 1.9: Reported rate of MDR-TB in new cases reported to the World Health Organisation. Figure 
reproduced from World Health Organization, 2018.  
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1.3.1: Mycobacterial cell envelope:  
 
The mycobacterial cell envelope is a highly specialised, layered, structure (Figure 1.10) 
(Abrahams and Besra, 2016). The innermost layer is the cytoplasmic membrane, a 
phospholipid bilayer that surrounds the cell. The second layer is the peptidoglycan (PG), a 
structural layer formed of glycan chains cross-linked with short peptide chains (Jankute et al., 
2015; Moynihan et al., 2019). The PG structure is the base upon which the AG is built, AG is 
a polysaccharide structure made of a galactofuranose residues, the galactan chain is then 
decorated with a branching arabinofuranose polysaccharide (Alderwick et al., 2005; Besra et 
al., 1995; Birch et al., 2008).  
 
residues via β(1→ 4) linkages with side chains of
amino acids cross-linked by transpeptide bridges
(Brennan and Nikaido, 1995). Mycobacterial pep-
tidoglycan has a number of unique features that
diversifies the cell wall from the typical structure
including N-glycolyl- and N-acetyl-muramic acid
residues (Mahapatra et al. 2005a), amidation of the
carboxylic acids in the peptide stems (Mahapatra
et al. 2005b) and additional glycine or serine residues
(Vollmer et al. 2008). The function of peptidoglycan
is not only to provide shape and rigidity, but it is
responsible for counteracting turgor pressure and
hence it is essential for growth and survival
(Vollmer et al. 2008). Peptidoglycan is unique to
bacterial cells, and it is this property that has led to
numerous enzymes involved in its synthesis to be
targeted by potent antibiotics, with others represent-
ing attractive targets in the development of future
antibiotics.
PEPTIDOGLYCAN BIOSYNTHESIS
The biosynthesis of peptidoglycan is summarized in
Fig. 2. The first committed step is the generation of
uridine diphosphate-N-acetylglucosamine (UDP-
GlcNAc). This is catalysed by the acetyltransferase
and uridyltransferase activities of GlmU (Zhang
et al. 2009), where first the acetyl group from
acetyl-CoA is transferred to glucosamine-1-phosphate
(GlcN-1-P) to produce N-acetylglucosamine-1-
phosphate (GlcNAc-1-P). Secondly, uridine-5′-mono-
phosphate from UTP is transferred to GlcNAc-1-P to
yield UDP-GlcNAc (Zhang et al. 2009). The abun-
dance of GlcNAc-1-P in eukaryotes (Mio et al. 1998)
and the functional similarity of the GlmU uridyltrans-
ferase with human enzymes (Peneff et al. 2001) makes
this domain an unsuitable drug target (Rani andKhan,
2016). However, the absence of GlcN-1-P from
humansmakes the acetyltransferase domain a potential
target (Mio et al. 1998). Efforts to identify inhibitors of
this domain are underway (Tran et al. 2013). A sub-
strate analogue of GlcN-1-P has been designed and
exhibits inhibitory effect against GlmU, providing a
candidate for further optimization (Li et al. 2011).
Thenext step involves thegenerationof theUDP-N-
acetylmuramic acid (UDP-MurNAc)-pentapeptide,
which is synthesized in a sequential pathway catalysed
by the Mur ligases A–F (Barreteau et al. 2008),
whereby most of the Mtb genes have been found
through homology. MurA, a UDP-N-acetylglucosa-
mine 1-carboxyvinyltransferase, and MurB, a UDP-
N-acetylenolpyruvoylglucosamine reductase, are
involved in generating UDP-MurNAc from UDP-
GlcNAc, by first the addition of the enoylpyruvyl
moiety of PEP, followed by reduction to a lactoyl
ether moiety via NADPH. At this point, NamH, a
Fig. 1. The mycobacterial cell wall. A schematic representation of the mycobacterial cell wall, depicting the prominent
features, including the glycolipids (PIMs, phosphatidyl-myo-inositol mannosides; LM, lipomannan; LAM,
lipoarabinomannan; ManLAM, mannosylated lipoarabinomannan), peptidoglycan, arabinogalactan and mycolic acids.
Intercalated into the mycolate layer are the acyl lipids (including TMM, trehalose monomycolate; TDM, trehalose
dimycolate; DAT, diacyltrehalose; PAT, polyacyltrehalose; PDIM, phthiocerol dimycocerosate; SGL, sulfoglycolipid).
The capsular material is not illustrated.
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Figure 1.10: R presentative model f a cross-section f the mycobacterial cell w ll. Mtb cell wall model 
showing; the peptidoglycan, arabinogalactan, mycolic acids, lipomannan, lipoarabinomannan and 
mannosylated lipoarabinomannan, and surface glycolipids. Figure reproduced, with permission, from 
Abrahams and Besra, 2016.  
Chapter 1:  Introduction 
 16 
The AG layer is decorated with an additional layer of lipids, termed the mycomembrane 
(Chiaradia et al., 2017). The inner leaflet of this membrane is composed of mycolic acids, and 
fatty acids covalently bound to the AG. While the outer leaflet is composed of various different 
species of mycolic acid derivatives (Bansal-Mutalik and Nikaido, 2014, 2011; Touchette and 
Seeliger, 2017) and the lipoglycans: lipomannan (LM), and lipoarabinomannan (LAM), 
intercalated with the inner leaflet. LM and LAM are lipid anchored polysaccharides built from 
a phosphatidylinositol decorated with mannose to form LM, which is further decorated with 
arabinose to form LAM. Additionally both LM and LAM are found in the inner membrane. 
Although the presence of LM and LAM may be as an intermediate before transport to the cell 
surface (Cashmore et al., 2017; Mishra et al., 2007; Pitarque et al., 2005; Touchette and 
Seeliger, 2017). 
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microbiota also influence microbiota composition or function remains 
unexplored. In most settings, the skin flora controls skin immunity in 
an autonomous manner and independently of the gut flora29. This com-
partmentalization and specialization of responses may have evolved as 
a mechanism to constrain the adjuvant properties of commensals and 
unwanted consequences associated with systemic increases in inflam-
matory responses.
Notably, adaptive responses to members of the skin community develop 
in the absence of inflammation45, in contrast to the response to invading 
pathogens. This process, termed ‘homeostatic immunity’, may be induced 
(at least in part) by the endogenous network of skin- resident antigen- 
presenting cells45. Under steady-state conditions, the skin is populated 
by highly diverse T cells47. Thus, because of the extraordinary number 
of potential antigens expressed by the microbiota, a substantial fraction 
of these skin-resident T cells are expected to be microbiota- specific. As a 
result, primary exposure to a pathogen in the skin or exposure during an 
injury is likely to occur in the context of a much broader recall response 
against diverse microbial antigens. The consequences of this phenomenon 
for tissue responses remain unclear.
Although B cell dynamics in the skin and the role of antibodies in 
controlling skin microbes are not well understood, it is known that IgA 
is secreted on the skin surface by eccrine and sebaceous glands48,49. In the 
gut, IgA has substantial effects on microbiota composition50–52 through a 
process that involves coating commensal bacteria53; in turn, commensal 
microbes are essential to development of this antibody response54,55 and 
may protect against autoimmunity56. Skin commensals are also likely to 
affect the B cell repertoire, but the extent of this interaction and its effects 
on the microbiota are not yet known.
In light of the finding that S. epidermidis potently and specifically acti-
vates a unique branch of adaptive immunity, one major challenge is to 
dissect mechanistically how specific host cells and receptors recognize 
molecular features of S. epidermidis. Staphylococci produce a  variety 
of immune modulatory molecules, such as teichoic acids, capsular 
 polysaccharides57,58, and dipeptide aldehydes59,60. Just as Corynebacterium 
and Mycobacterium share features but can be distinguished by the host, 
S. epidermidis shares many of these molecular features with the contex-
tual pathogen S. aureus. Further studies of how, at the molecular level, 
S. aureus differs from S. epidermidis will help us understand how these 
two important human skin residents are distinguished by the immune 
system, and will highlight key host targets for more effective and specific 
therapeutic approaches.
Microbial sensing by the immune system is also likely to be controlled 
by the developmental stage of the host. Although little is understood 
about the factors that regulate the acquisition of skin microbes at birth, 
regulatory T cells, which are highly enriched in the skin tissue, have been 
proposed to control early dialogue with the microbiota. Indeed, coloniza-
tion of mouse skin with S. epidermidis early in life (but not later) induces 
tolerance to the same microbe in adulthood61 and promotes accumulation 
of S. epidermidis-specific regulatory T cells in neonatal skin62.
As well as modulating immune cells, S. epidermidis and other com-
mensals promote epithelial integrity, especially during tissue repair. For 
example, an S. epidermidis cell wall component mitigates inflammation by 
binding to TLR2, limiting tissue damage and promoting wound  healing63. 
Other commensal microbiota are also likely to contribute to wound 
 healing, which is a dynamic process associated with global shifts in the 
skin microbiome; wound bed microbiomes that fail to shift are associated 
with chronic ulcers64,65. Within chronic wounds, fungi and bacteria form 
mixed biofilms and certain fungal taxa, such as the phylum Ascomycota, 
are predictive of wounds that take more than eight weeks to heal. The 
fungal mycobiome and its interactions with commensal bacteria may 
therefore be important contributors to chronic wounds, via mechanisms 
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Figure 3 | Chemistry of microbial surfaces. Bacteria and fungi have 
diverse cell envelopes loaded with immunogenic molecules. Gram-
negative bacteria (left) have two lipid bilayers separated by a peptidoglycan 
cell wall. The outer leaflet of the outer membrane is studded with an 
immunogenic lipoglycan called lipopolysaccharide (LPS), which has 
a lipid anchor and highly variable polysaccharide region called the 
O-antigen. In Escherichia coli, for example, 184 different O-antigen 
structures are known161. Gram-positive bacteria (middle) lack an outer 
lipid bilayer but have a thicker peptidoglycan cell wall. Staphylococcus 
species have wall-bound and membrane-anchored teichoic acids, which 
are analogous to Gram-negative LPS, with a host-facing strain-specific 
branched polysaccharide. Corynebacterium and Mycobacterium species 
also have complex lipoglycans, called lipoarabinomannans. They also have 
a unique lipid outer layer made up of cell-wall-bound mycolic acids and 
other noncovalently bound glycolipids. Like Gram-positive bacteria, fungi 
(right) have only one lipid bilayer membrane. This is covered by a cell  
wall usually consisting of chitin and a β -d-glucan mesh. The outer layer  
of the fungal cell wall often contains heavily mannosylated proteins  
and sometimes a capsule of various polysaccharides. GlcNAc,  
N-acetylglucosamine.
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Figure 1.11: Cross sectional models of bacterial and fungal cell surfaces. Cell wall models highlighting the 
differences between the c ll surfac s of the Corynebacteriales a d both o her Gram-positive as well as 
Gram-negative bacterial cell surfaces, as well as highlighting the similarities between the Corynebacterial 
and Mycobacterial cell wall structures. Figure reproduced, with permission from Chen et al. 2018. 
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The outermost layer of the mycobacterial cell envelope is the capsule, a loosely associated 
structure primarily comprised of polysaccharides such as alpha-glucan, arabinomannan, and 
mannan, as well as secreted proteins and lipids (Kalscheuer et al., 2019; Koliwer-Brandl et al., 
2016; Ortalo-Magne et al., 1995, 1995).   
 
While the general architecture of the cell wall is conserved between mycobacteria and 
corynebacteria, there are some differences in the overall structure, as shown in Figure  1.11 
(Chen et al., 2018). The most notable differences in the cell wall structure are that the mycolic 
acids in corynebacterial species are shorter, containing 20- 36 carbon atoms, while 
mycobacterial mycolic acids contain 60- 90 carbon atoms (Butler and Ahearn, 1986), and 
changes in the structure of LAM, with the arabinan domains of corynebacterial LAM (Cg-
LAM) being less elaborate than mycobacterial LAM (Briken et al., 2004; Chen et al., 2018; 
Kaur et al., 2008). 
 
1.3.2: The cytoplasmic membrane:  
 
While all bacteria have a cytoplasmic membrane, the component phospholipids, and the ratios 
of phospholipids, vary from species to species (Bansal-Mutalik and Nikaido, 2014; Kawai et 
al., 2004; Sathappa and Alder, 2016). These differences in membrane composition lead to 
differing membrane fluidity. With changes in the phospholipid composition of the membrane, 
and the acyl chain length both reacting dynamically to changes in the environment (De Siervo, 
1969; Russell and Sandercock, 1980).  
 
In mycobacteria, the cytoplasmic membrane is an asymmetric structure, made up of cardiolipin 
(CL), phosphatidylinositol (PI), phosphotidylethanolamine (PE), and various species of 
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phosphotidyl-myo-inositol mannosides (PIMs) (Figure 1.12) (Bansal-Mutalik and Nikaido, 
2014, 2011; Chiaradia et al., 2017).  
 
 The most abundant of the PIM species is diacyl-phosphotidyl-myo-inositol-dimannoside 
(Ac2PIM2), which along with the other PIM species, can account for up to 42 % of the dry lipid 
mass in M. smegmatis (Bansal-Mutalik and Nikaido, 2014). The outer leaflet of the 
mycobacterial cytoplasmic membrane is thought to be composed of a majority of PIMs, with 
the PIMs acting as the anchor for the external glycoconjugates LM, and LAM (Abrahams and 
Besra, 2016; Bansal-Mutalik and Nikaido, 2014; Mishra et al., 2007, 2008a).  
 
It has been shown that, similar to other bacteria such as Bacillus subtalis and Escherichia coli, 
the mycobacterial membrane contains Functional Membrane Microdomains (FMMs) (Hayashi 
et al., 2016; Kawai et al., 2004; Maloney et al., 2011; Wagner et al., 2017). One such FMM in 
mycobacteria is CL localization to the poles of the cell, as well as the centre of the cell in 
actively dividing cells (Maloney et al., 2011). Due to the ability of CL to form non-bilayer 
Figure 1.12: Structural representation of mycobacterial phospholipid head groups. A: cardiolipin, B: 
phosphotidylethanolamine, C: phosphatidylinositol. R denotes the site of fatty acids attachment through 
esterification.  
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formations this would allow for the formation of the septum in division, while also potentially 
allowing for the curvature of the membrane at the poles (Maloney et al., 2011; Renner and 
Weibel, 2011).  
 
Simulations of membranes containing proteins show that the various proteins have a different 
affinity for CL, this could also aid in the localisation of proteins to correct cellular position 
(Renner and Weibel, 2011; Wagner et al., 2017). As this has been shown for CL, there is a 
distinct possibility that a similar phenomenon could occur in other FMMs with different 
phospholipid composition, resulting in localisation of different proteins into separate 
microdomains (Heinkel et al., 2019). Protein localisation into FMMs allows for improved 
signalling, as FMMs tend to cause the accumulation of a group of proteins related to various 
functions into the same microdomain, which has been seen in various regulated cell functions 
(Wagner et al., 2017). 
 
Another factor in the variability of the cytoplasmic membrane between bacteria is the number 
and lengths of the acyl chains within the phospholipid components. Depending on the species 
of phospholipid the number of acyl chains can vary between 2- 4 acyl chains per molecule 
(Maloney et al., 2011). It has been shown that certain phospholipids have a tendancy to be 
synthesised using specific acyl chains. In mycobacterial species the two fatty acid tails of PI 
tend to be one palmitic acid (C16:0) and one tuberculosteric acid (10-methyloctadecanoate, C19: 
0) acyl chains (Morita et al., 2011). However, under some stress conditions PI is converted to 
PI3P. PI3P has a substantially different acyl profile, with the palmitic acid of PI being replaced 
with an oleic acid (C18: 1). PI3P has been suggested to act as a signalling molecule when the 
cell undergoes high salt stress (Morita et al., 2010).  
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The various PIM species found in the mycobacterial cytoplasmic membrane have been shown 
to have differing acyl chain lengths depending on both the mannosylation state as well as the 
acylation state (Sancho-Vaello et al., 2017). This is in part due to the different numbers of acyl 
chains attached to the causing the acyl profiles to be different. However, this would not account 
for all of the differences between the acyl chains found the different mannosylation states. The 
tri-acylated PIMs, AcPIM2 and AcPIM6, have been shown to have the same acyl chain profile: 
C16: 0 and C19: 0. The tetra-acylated forms of the PIMs, Ac2PIM2 and Ac2PIM6, are split into 2 
populations, either with three C16: 0 and one C19: 0, or two C16: 0 and two C19: 0 (Gilleron et al., 
2003, 2001; Sancho-Vaello et al., 2017).  
 
The acylation positions for Ac1PIM and Ac2PIM species have been determined in both the tri-
acyl and tetra-acyl forms: two acyl chains are on the glycerol moiety, with the additional acyl 
chains being on carbon 3 of the inositol ring, and on carbon 6 of the mannose attached to carbon 
2 of the inositol ring (Gilleron et al., 2003, 2001; Sancho-Vaello et al., 2017). 
 
PI is found in a variety of living organisms, and is produced from glucose-6-phosphate in Mtb 
by the action of the D-myo-inositol 3-phosphate synthase (MIPS) encoded by Rv0046c, which 
catalyses the conversion to inositol-1-phosphate, this is then dephosphorylated to produce 
inositol (Bachhawat, 1999; Jackson et al., 2000; Morita et al., 2011). Rv0046c is essential in 
mycobacteria, with complementation possible by the addition of inositol into the media 
(Movahedzadeh et al., 2004). Three genes in the Mtb genome have been hypothesised as the 
phosphatase responsible for the removal of the phosphate from the inositol-1-phosphate, 
however each one of them is individually non-essential, suggesting that there is some 
redundancy in the genome. This redundancy reduces the phenotype of the deletion mutants, as 
such the primary inositol phosphatase remains unknown (Morita et al., 2011). The final step of 
Chapter 1:  Introduction 
 21 
PI biosynthesis is catalysed by the action of PgsA1, which catalyses the addition of inositol to 
CDP-diacyl glycerol to produce PI (Figure 1.13)  (Jackson et al., 2000; Salman et al., 1999).  
 
 Certain lipids are further elaborated upon as well as being present in their ‘base’ form in the 
cytoplasmic membrane. PI is found in the membrane both as PI, but more often it has been 
mannosylated to form the PIMs, the different species of PIM are annotated based on the extent 
of their mannosylation, and their acylation state. The major PIMs in mycobacteria are AcPIM2, 
Ac2PIM2, AcPIM6, and Ac2PIM6 (Figure 1.14) (Brennan and Nikaido, 1995), with other CMN 
bacteria such as C. glutamicum possessing many of the PIM species but not the “higher PIMs” 
(AcPIM6 and Ac2PIM6) (Bansal-Mutalik and Nikaido, 2011). 
 
Figure 1.13: Schematic representation of phosphatidylinositol biosynthesis. Showing the conversion of 
glucose-6-phosphate to inositol-1-phosphate by MIPS, through inositol-3-phosphate, followed by 
dephosphorylation of inositol. PI synthesis is the completed by PgsA1, converting and CDP-diacylglycerol into 
PI, and CMP. 
Chapter 1:  Introduction 
 22 
There are two mannose sources for biosynthetic pathways requiring the mannosylation of 
substrates: GDP-Mannose (GDP-Man), and polyprenylmannose (PPM) (Kremer et al., 2002; 
Sancho-Vaello et al., 2017).  
 
GDP-Man acts as the cytoplasmic source for the initial two additions of mannose to the PI, 
these reactions are catalysed by: PimA and PimB’. PimA catalyses the conversion of PI to 
PIM1, where the initial mannose is attached to carbon 2 of the inositol ring (Korduláková et al., 
2002). The biosynthetic pathway of PIMs is shown in Figure 1.14. The path branches briefly 
with PIM1 either being acylated or mannosylated by AcylT or PimB’ respectively. The 
acylation results in the production of AcPIM1, which can then be converted into AcPIM2 by 
the action of PimB’ (Morita et al., 2011; Schaeffer et al., 1999). If PIM1 is mannosylated by 
PimB’ the second mannose is attached at the carbon 6 position, to form PIM2, which can be 
acylated by AcylT to form AcPIM2, the acyl chain is attached to the mannose on the carbon 2 
of the inositol. AcPIM2 can then be further acylated by an unknown acyltransferase, which 
attaches an additional acyl chain to the carbon 3 of the inositol ring to the form Ac2PIM2 
(Kremer et al., 2002). The Ac-/Ac2- PIM2 can then be further mannosylated by PimC to 
PI PIM1 PIM2 AcPIM2 Ac2PIM2








Figure 1.14: Biosynthetic pathway of PIM species in Mtb. Biosynthesis of PIMs, showing the enzymes 
responsible for the biosynthetic step. Unknown processes highlighted in red.  
Chapter 1:  Introduction 
 23 
produce Ac/Ac2-PIM3 (Kremer et al., 2002; Morita et al., 2011). The enzyme responsible for 
the additional mannosylation to form Ac-/Ac2- PIM4 is as yet unknown (Morita et al., 2011).  
 
During the synthesis of PIMs beyond Ac-/Ac2- PIM2, there is a branch point after translocation 
to the outer leaflet of the plasma membrane, this is proposed to be Ac-/Ac2- PIM4. From this 
point the synthesis can either lead to the production of the higher PIMs (Ac-/Ac2 -PIM6), or 
lead into the production or LM and LAM. (Sancho-Vaello et al., 2017). 
 
1.3.3: Peptidoglycan: 
UDP-N-acetylmuramic acid hydroxylase, hydroxy-
lates UDP-MurNAc to UDP-N-glycolylmuramic
acid (UDP-MurNGlyc), providing both types of
UDP-muramyl substrates; Mtb cell walls are domi-
nated by the latter (Mahapatra et al. 2005a). This struc-
tural modification is unique to mycobacteria (and
closely related genera) and is considered to increase
the intrinsic strength of peptidoglycan, by potentially
alleviating susceptibility to lysozyme and providing
sites for additional hydrogen bonding (Raymond et al.
2005). Inhibitors of Mtb MurA and MurB are yet to
be discovered. Whilst the natural product, broad spec-
trum antibiotic, fosfomycin, targets Gram-negative
MurA, the critical residue for inhibition is absent in
Mtb, providing intrinsic resistance against this anti-
biotic (Kim et al. 1996). Consequently, an inhibitor
with a new mode of action is required to target Mtb
MurA. A limited number of inhibitors have been
reported against MurB. Molecular dynamics and
docking studies of existingMurB inhibitors (3,5-dioxo-
pyrazolidine derivatives) onto theMtbMurB structure
reveal the potential potent activity of these compounds,
which can be used to guide future structure-based drug
design (Kumar et al. 2011). Inhibitors of NamH have
not been documented; namH is not essential in
Mycobacterium smegmatis, and therefore is not condu-
sive to a characteristic target property. However, gene
deletion results in a strain hypersusceptible to β-
lactamantibiotics and lysozymeandtherefore inhibitors
of NamH could potentiate the effect of β-lactams
(Raymond et al. 2005).
The pentapeptide chain is incorporated onto the
UDP-MurNAc/Glyc substrates by the successive
addition of amino acid residues L-alanine, D-isogluta-
mate, meso-diaminopimelate (m-DAP) and D-alanyl-
D-alanine [generated by the D-Ala: D-Ala ligase
(Ddl)] by the ATP-dependent Mur ligases C-F
respectively (Munshi et al. 2013). This results in
the muramyl-pentapeptide product, UDP-MurNAc/
Glyc-L-Ala-D-isoGlu-m-DAP-D-Ala-D-Ala, also
known as Park’s nucleotide (Kurosu et al. 2007).
Despite the different amino acid specificities, the
four ligases share common properties: the reaction
mechanism; six invariant ‘Mur’ residues; an ATP-
binding consensus; three-dimensional structural
domains (Barreteau et al. 2008). Due to these similar-
ities, it is plausible that a single inhibitor could target
more than one Mur ligase and such inhibitors have
been reported in the literature (Tomasic et al. 2010).
Numerous small molecule inhibitors of the Mur
Fig. 2. Inhibitors targeting peptidoglycan biosynthesis. The roles of the key enzymes involved in peptidoglycan
biosynthesis are illustrated. Reported inhibitors are shown in red.
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Figure 1.15: Biosynthesis schematic of mycobacterial peptidoglycan. Peptidoglycan synthesis showing 
the enzymes or processes that drugs used to prevent the biogenesis of peptidoglycan. Figure 
reproduced, with permission, from Abrahams and Besra, 2016. 
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Peptidoglycan is found in almost every species of bacteria, forming a protective layer 
surrounding the cytoplasmic membrane of the bacteria. The thickness of the peptidoglycan and 
the amount of cross-linking between the glycan strands affects the rigidity and shape of the 
bacteria (Egan et al., 2017; Kim et al., 2015; Loskill et al., 2014). Peptidoglycan also resists 
the turgor pressure of the cell, caused by the osmotic difference between the cytoplasm of the 
bacteria and that of the surrounding media (Moynihan et al., 2019).  
 
Gram-positive have a thicker layer of peptidoglycan then Gram-negative bacteria (Chen et al., 
2018). Mycobacterial species have peptidoglycan much more similar to that of Gram-positive 
bacteria than Gram-negative bacteria (Figure 1.11) (Chen et al., 2018; Jankute et al., 2015). 
 
Peptidoglycan is formed from strands of polysaccharide, composed of alternating N-acetyl-
glucosamine (GlcNAc) and N-acetyl-muramic acid (MurNAc) residues (Figure 1.15) 
(Moynihan et al., 2019). Mycobacterial PG is differentiated from the PG of other bacteria, due 
to the fact that the MurNAc can instead be N-glycolylmuramic acid (MurNGlyc) (Abrahams 
and Besra, 2016; Alderwick et al., 2015; Mahapatra et al., 2005, 2000). These strands are cross-
linked by a linking unit. While the structure of the polysaccharide chains is conserved between 
bacteria the peptide cross-linking unit sequence and the position of the cross-links vary 
(Vollmer et al., 2008). In mycobacteria the crosslinking pentapeptide is built from: L-alanine 
(L-Ala), D-isoglutamate (D-isoGlu), meso-diaminopimelate (m-DAP), D-alaline (D-Ala) and 
a final D-Ala (Figure 1.15) (Kurosu et al., 2007). This pentapeptide is built upon either UDP-
MurNAc, or UDP-MurNGlyc, and when fully synthesised is referred to as Park’s nucleotide 
(Kurosu et al., 2007). Park’s nucleotide is then transferred onto decaprenylphosphate (C50-P) 
by MurX, followed by the addition of GlcNAc by MurG to form the mature lipid II.  
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Once lipid II is synthesised it must be translocated to the outer face of the membrane for 
incorporation into the PG. Lipid II is translocated across the inner membrane to the outer leaflet 
by FtsW/MurJ (Mohammadi et al., 2014; Ruiz, 2016, 2008; Sham et al., 2014). The 
polysaccharide is then built from this subunit by various enzymes with transglycosylase 
activity (Sauvage et al., 2008). These enzymes can either solely have transglycosylase activity, 
or have both transglycosylase and transpeptidase activity (Sauvage et al., 2008). The 
transglycosylation step releases the C50-P for translocation back to the inner leaflet of the 
plasma membrane for further use in cell wall biosynthesis, as C50-P acts as the anchor for many 
cell wall biosynthetic intermediates (Figure 1.14, Table 1.2).  
 
The strand of polymerised GlcNAc-MurNAc/Glyc are crosslinked by the action of 
transpeptidases, these links can be either between the m-DAP and the D-Ala in the fourth 
position (3à4), or two m-DAP residues on separate peptide chains (3à3) (Kumar et al., 2012; 
Lavollay et al., 2008; Sanders et al., 2014). The ratio of 3à4 and 3à3 linkages has been shown 
to vary between bacteria (Pandey et al., 2018; Pisabarro et al., 1985). Mycobacterial species 
have a higher ratio of 3à3 linkages, between 60- 80 %, when compared to other bacteria 
(Sanders et al., 2014). This change in the crosslinking structure of PG is thought to lead to less 
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1.3.4: Arabinogalactan:  
 
One of the unique features of the Mtb cell wall is that the peptidoglycan is decorated with 
additional polysaccharide structures only found within the sub-order of Corynebacteriales. One 
of these structures is arabinogalactan (AG), a branched polysaccharide comprised of a galactan 
core formed linear polygalactofuranose, elaborated with 3 branched chains of 
polyarabinofuranose which is found attached covalently onto the PG (Abrahams and Besra, 
2016; Jankute et al., 2015). The biosynthesis of this structure is separated into two phases; the 
synthesis of the galactan core on the inner leaflet of the plasma membrane, and the decoration 
of the galactan with arabinose in the periplasm. 
 
Synthesis of galactan is initiated by WecA, which catalyses the transfer of GlcNAc from UDP-
GlcNAc onto C50-P, resulting in the formation of: C50-P-P-GlcNAc (Jin et al., 2010). The 
resulting molecule is then rhamnoslylated by WbbL, using dTDP-L-rhamnose as a substrate, 
completing the linking unit that connects the PG and the galactan backbone (McNeil et al., 
1990; Mills et al., 2004). The linking unit is then built upon by the action of 
galactofuranosyltransferases, GlfT1 and GlfT2 (Alderwick et al., 2008). GlfT1 attaches the 
initial galactofuranose (Galf) from a UDP carrier onto the carbon 4 of the rhamnose, and an 
additional Galf onto the carbon 5 of the first Galf residue (Alderwick et al., 2008; Belanova et 
al., 2008; Mikusova et al., 2006). The resulting C50-P-P-GlcNAc-L-Rha-Galf2, is further built 
upon by GlfT2 which catalyses the elongation of the galactan to contain 25- 30 Galf residues, 
which are linked with alternating b(1à5) and b(1à6) glycosidic bonds (Figure 1.15) (Kremer 
et al., 2001a; Rose et al., 2006).  
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Once the synthesis of the galactan core is complete it is translocated to the outer leaflet of the 
plasma membrane. This translocation has been predicted that this translocation is carried out 
by Rv3781 and Rv3783 in Mtb (Dianišková et al., 2011). Rv3783 is predicted to be a 
transmembrane domain of an ABC-transporter, while Rv3781 is predicted to form the 
corresponding nucleotide binding domain, however these have not been confirmed in the 
literature (Dianišková et al., 2011). 
 







































Structure of mycobacterial arabinogalactan and roles of key enzymes that are responsible for its biosynthesis.
Adapted from Reference 51 with permission from Future Medicine.
69). However, recently it has been proposed that only two arabinan units are attached per galactan
chain (15). The inner core of the arabinan domain contains a backbone of α-5-linked α-D-Araf
residues with key branching introduced by 3,5-α-D-Araf residues (30). Galactosamine (D-GalN)
and succinyl substituents were identified on the C-2 position of some inner 3,5-α-D-Araf residues
(16, 34, 69, 102). It was estimated that one D-GalN residue per AG is present exclusively in the
walls of slow-growing mycobacteria and that up to three succinyl esters per AG are present in
both slow- and fast-growing mycobacterial species. Interestingly, only nonmycolated arabinan
chains were succinylated, and none of the decorated arabinan chains possessed both substituents
(16). The nonreducing termini of the arabinan unit consist of a characteristic hexa-arabinoside
motif, [β-D-Araf-(1→2)-α-D-Araf]2-3,5-α-D-Araf-(1→5)-α-D-Araf, where position 5 of both
the terminal β-D-Araf and the penultimate 2-α-D-Araf serves as an attachment site for mycolic
acids (79). In M. tuberculosis, mycolyl units were shown to cluster in groups of four and occupy
only about two-thirds of the available attachment sites on the terminal hexa-arabinoside motif
(79). These structural features are summarized in Figure 3.











































































Figure 1.16: Biosynthesis of arabinogalactan in Mtb. Arabinogalactan biosynthetic pathway annotated 
with enzymes responsible for biosynthesis. Figure reproduced, with permission from Jankute et al. 2015. 
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Once the galactan is transported to the external face of the cell, the galactan is decorated with 
arabinofuranose (Araf).  The source of the Araf is DPA, which is synthesised cytoplasmicly 
from phospho-α-D-ribosyl-1-pyrophosphate (pRpp). pRpp is attached to C50-P by UbiA to 
form decaprenol-1-phosphate-5-phosphoribose (Alderwick et al., 2005; Huang et al., 2008, 
2005). Decaprenol-1-phosphate-5-phosphoribose is dephosphorylated by Rv3807c to form 
decaprenol-1-phosphoribose (DPR) (Jiang et al., 2011). DPR is then epimerised into DPA, the 
sole known source of arabinose for the mycobacterial cell wall, by DprE1 and DprE2 (Kolly 
et al., 2014; Mikusova et al., 2005). The process of the translocation of the DPA to the external 
face of the membrane is not yet understood, it has been hypothesised that Rv3789 is responsible 
for the translocation. However, there is evidence to support a different role that of  the anchor 
protein which aids in the recruitment of AftA (Kolly et al., 2014).  
 
Arabinose is attached to the galactan chain at three specific residues: residues 8, 10, and 12 
(Alderwick et al., 2006, 2005). The enzyme responsible for this transfer is AftA which 
catalyses the synthesis of a β(1à6) bond, adding a priming Araf onto the galactan core. Once 
the priming Araf residue is attached the arabinan domains of the AG are extended by EmbA 
and EmbB in α(1à5) linkages (Alderwick et al., 2005; Jankute et al., 2018). The extended 
arabinan chain is then branched by the action of AftC and AftD through α(1à3) linkages, with 
AftD providing the same for the branching of the arabinose domains in mycobacterial LAM 
(Birch et al., 2008; Škovierová et al., 2009). The terminal domain of the arabinan is well 
characterised, forming a [β-D-Araf-(1à2)-α-D-Araf]2-3,5-α-D-Araf-(1à5)-α-D-Araf domain. 
This domain is synthesised by the action of EmbA, EmbB, AftB, AftC, and AftD (Alderwick 
et al., 2005; Birch et al., 2010, 2008; Escuyer et al., 2001; Jankute et al., 2017; Škovierová et 
al., 2009).  
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Table 1.2: Biosynthetic genes involved in the synthesis of arabinogalactan in Mtb. Showing the gene name 
where given, the Mtb H37Rv gene accession number, the function of the gene, and the first available reference 






Gene function Reference 
WecA Rv1302 
Addition of GlcNAc-1-P to 
decaprenol phosphate 
Jin et al., 2010 
Wbbl Rv3265c 
Addition of rhamnose to 
decaprenyl-GlcNAc-1-P α(1à3) 
McNeil et al., 1990 
GlfT1 Rv3782 
Addition of 2 Galf to linker unit, 
β(1à4) α(1à5) 
Mikusova et al., 2006 
GlfT2 Rv3808c 
Elongation of the galactan chain 
with alternating β(1à5)  β(1à6) 
Alderwick et al., 2008 
AftA Rv3792 
Addition of arabinofuranose to the 
galactan core, α(1à5) bonds 
Alderwick et al., 2006 
EmbA Rv3794 
Addition of arabinofuranose to the 
arabinan branches, α(1à5) 
Synthesis of the terminal arabinan 
region 
Alderwick et al., 2005; 
Escuyer et al., 2001 
EmbB Rv3795 
Addition of arabinofuranose to the 
arabinan branches, α(1à5) 
Synthesis of the terminal arabinan 
region 
Alderwick et al., 2005; 
Escuyer et al., 2001 
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AftC Rv2673 
Formation of arabinose branches 
within arabinan domains, α(1à3) 
Birch et al., 2008 
AftD Rv0236c 
Formation of arabinose branches 
within arabinan domains, α(1à3) 
Škovierová et al., 2009 
PrsA Rv1017c 
Transfer of pyrophosphate onto C1 
of ribose-5-phosphate to form 
phospho-α-D-ribosyl-
pyrophosphate 
Alderwick et al., 2011 
UbiA Rv3806 
Formation of DPA from C50-P and 
pRpp 















Mikusova et al., 2005 
AftB Rv3805c 
Transfer of terminal β(1à2) 
arabinofuranose residues 




Škovierová et al., 2010 
Lcp1 Rv3267 
Attachment of arabinogalactan to 
the peptidoglycan 
Harrison et al., 2016 
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After AftC catalyses the branching of the terminal arabinose domains through α(1à3) linkage, 
the terminal arabinofuranose residues are attached by the action of AftB through a through 
α(1à2) linkage which caps the domain preventing further elaboration (Alderwick et al., 2005; 
Birch et al., 2010, 2008). The two capping Araf residues are able to have mycolic acids 
esterified  onto them at the C5 position (Lea-Smith et al., 2007). The final step in AG 
maturation is the attachment onto the PG, this step is carried out by Lcp1 (Harrison et al., 
2016).  
 
The attached AG is then mycolated by the action of Antigen 85 (Ag85), there are three different 
isoforms of Ag85: A, B, and C (Backus et al., 2014). While the main function of each of these 
enzymes is the same, the transfer of mycolic acids to sugars on the external surface of the cell, 
the preferred substrate for each of these enzymes has not been determined (Backus et al., 2014). 
There is some evidence to suggest that Ag85A and Ag85B are more likely to mycolate the 
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1.3.5: Lipomannan, and lipoarabinomannan: 
 
LM and LAM (Figures 1.17, 1.18) are unique lipoglycans found only in the Corynebacteriales, 
in virulent species, such as Mtb, they are involved in immunomodulation (Pitarque et al., 2008). 
Both LM and LAM have been shown to be present in the cytoplasmic membrane and the outer 
mycomembrane, however the ratio of lipoglycans on present in the cytoplasmic membrane to 
those present in the outer membrane is as yet unknown  (Pitarque et al., 2008). The binding of 
mannosylated LAM (manLAM) acts as a key method of preventing the maturation of the 
phagolysosome, along with other interactions with the host immune system  (Hmama et al., 
2015).  














































Structure of mycobacterial tri-/tetra-acylated phosphatidyl-myo-inositol hexamannoside (Ac1/Ac2PIM6),
lipomannan and lipoarabinomannan, and roles of key enzymes that are responsible for their biosynthesis.
Abbreviation: MPI, mannosyl phosphate inositol. Adapted from Reference 51 with permission from Future
Medicine.
linear tetra-arabinoside [β-D-Araf-(1→2)-α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf ] (24, 26,
81). The arabinan motifs of LAM are further decorated by capping moieties. M. tuberculosis and
Mycobacterium leprae modify the arabinan termini with a series of α(1→2)-linked Manp residues
(ManLAM), whereas M. smegmatis possesses phosphoinositol caps (PILAM) (27, 57, 99). The
absence of capping moieties (AraLAM) in LAM has been shown in M. chelonae (44). In addition,
a unique 5-deoxy-5-methylthio-xylofuranose (MTX) substituent linked at C-4 of the terminal
Manp of the ManLAM cap was identified in M. tuberculosis (54, 119, 122, 123). Interestingly, a
similar MTX residue was also identified in the ManLAM of Mycobacterium kansasii; however, the
substituent was located on the mannan core instead of the capping Manp residues (43). Finally,
similarly to AG, succinyl groups were identified on the C-2 position of some inner 3,5-α-D-Araf
residues (31).
Biosynthesis of Phosphatidyl-myo-Inositol Mannosides, Lipomannan,
and Lipoarabinomannan
The early steps of PIM biosynthesis occur in the cytoplasm and employ GDP-Manp as the man-
nose donor. PimA (Rv2610c), an α-mannopyranosyltransferase (ManpT), initiates the transfer of
a single Manp residue from GDP-Manp to the 2 position of the myo-inositol ring of PI to yield
PIM1 (46, 60). PIM1 is then further glycosylated by PimB′ (Rv2188c), which transfers the second











































































Figure 1.17: Structure and biosynthesis of mycobacterial LM and LAM. Showing the overlap between 
the synthesis of the arabinan domains of AG and LAM, with various enzymes involved in AG synthesis 
also involved in LM and LAM synthesis. Figure reproduced with permission from Jankute et al 2015. 
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In mycobacterial species both LM and LAM are formed through elongation of the PIM species, 
which as previously described are synthesised from PI (Figure 1.18). Both LM and LAM are 
found in both the inner and outer membrane of mycobacteria (Ortalo-Magne et al., 1996).  
LM and LAM are attached through non-covalent interactions between the PIM lipid anchor 
and either the phospholipid bilayer that makes up the plasma membrane, or the covalently 
bound fatty acids and mycolic acids attached to the AG that form the outer membrane  (Ortalo-
Magne et al., 1996; Pitarque et al., 2008). While many of the biosynthetic enzymes for LM and 
LAM are involved only in the synthesis of LM and LAM, there is significant overlap with AG 
in the biosynthesis of the arabinan domains, with many of the biosynthetic enzymes used in 
formation of both of these domains, as shown in Tables 1.2 and 1.3. 
 
The synthesis of LM and LAM in mycobacteria starts from PIM species, after they have been 
translocated to the external face of the plasma membrane (Figure 1.18). With the protein 
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Figure 1.18: Biosynthetic pathway of LM and LAM from PI in Mtb. Showing genes responsible for the 
process(es). Processes without proteins known, or predicted, to provide the function highlighted in red.  
Chapter 1:  Introduction 
 34 
responsible for the transport of PIM species across the cytoplasmic membrane remaining 
unknown (Abrahams and Besra, 2016). Once on the external face of the inner membrane, LM 
and LAM biosynthesis most likely starts from Ac1/Ac2-PIM4 (Figure 1.18). This starting 
substrate is thought be channelled by a putative lipoprotein, LpqW, into either the higher PIMs 
or into LM and LAM biosynthesis (Crellin et al., 2008). The mannosyltransferases responsible 
for the extension of the mannan core, by way of α(1à6) glycosidic linkages, are MptA and 
MptB (Mishra et al., 2007, 2008a) The mannan core is decorated with α(1à2) linkages with 
monomannan side chains (Kaur et al., 2008; Mishra et al., 2012).  
  
The mature mycobacterial LM can then be further decorated with arabinose to form LAM, 
resulting in the addition of between 50 and 80 Araf residues, using DPA as the source of 
arabinose. The enzyme responsible for the priming of the LM chain is as yet unknown, however 
once the chain is primed it is elongated with the α(1à5) glycosidic bonds formed by the action 
of EmbC (Shi et al., 2006). The arabinan branches of LAM are made up of 12- 15 Araf residues, 
and the process of the addition of the arabinose is the same as the arabinose decoration of the 
arabinan domains on the AG (Alderwick et al., 2011; Shi et al., 2006).  
 
Mycobacterial LAM can then be further decorated with the addition of terminal 
mannopyranose (Manp) to form ManLAM. The initial Manp addition is catalysed by CapA, 
which introduces a α(1à5) linkage (Kaur et al., 2008). From the branch point the chain is then 
elongated with α(1à2) linkages catalysed by MptC (Kaur et al., 2008). The mannose residues 
can then be further elaborated with the addition of an α(1à4) linked 5-deoxy-5-methyl-thio-
xylofuranose (MTX) residue, with the enzyme responsible for the addition of the MTX residue 
is still unknown (Ludwiczak et al., 2002; Turnbull et al., 2004).  
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As mature lipoglycans have been detected in the cytoplasmic membrane as well as being 
exposed on the cell surface, and the amphipathic nature of lipoglycans, there is likely a 
transport mechanism responsible for shuttling LM and LAM to the cell surface. This is because 
the hydrophobic lipid anchor is unlikely to be removed from the cytoplasmic membrane solely 
by diffusion, similarly the hydrophilic mannan and arabinan domains are unlikely to pass 
through the hydrophobic outer membrane without the aid of a transport protein. The presence 
of the transport system has been predicted in mycobacteria, but as yet remains unidentified 
(Pitarque et al., 2008).  
 
Table 1.3: Biosynthetic genes involved in the synthesis of lipomannan and lipoarabinomannan in Mtb. 
Showing the gene name where given, the Mtb H37Rv accession number, the function of the gene, and the first 






Gene function Reference 
Ino1 Rv0046c 




PI synthesis from inositol and CDP-
diacylglycerol 
Jackson et al., 2000 
PimA Rv2610c 
Mannosylation of PI from UDP-
mannopyranose α (1à2) 
Korduláková et al., 
2002 
PimB’ Rv2188c 
Mannosylation of PIM1 from UDP-
mannopyranose α(1à6) 
Lea-Smith et al., 
2008 
Rv2611c Rv2611c 
Acylation of PIM1 or PIM2 to Ac1PIM1, 
or Ac2PIM1 or Ac1PIM2, or Ac2PIM2 
Korduláková et al., 
2003 
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PimC Unknown 
α (1à6) mannosylation of PIM2 to PIM 
4, with mannopyranose 
Kremer et al., 2002 
PimE Rv1159 
α (1à2) mannosylation of PIM4 to 
PIM6, with mannopyranose 
Morita et al., 2006 
MptA Rv2174 
Generation of the mannan core from 
DPM through α (1à6) linkages 
Mishra et al., 2007 
MptB Rv1459c 
Generation of the mannan core from 
DPM through α (1à6) linkages 
Mishra et al., 2008 
EmbC Rv3793 
Extension of the arabinose domains 
after addition of primary 
arabinofuranose from DPA through 
α(1à5)  linkages 
Alderwick et al., 
2011 
AftC Rv2673 
Branching of arabinan domain by 
addition of α(1à3) arabinofuranose 
from DPA 
Birch et al., 2008 
AftD Rv0236c 
Hypothesised to branch arabinan 
domain by addition of α(1à3) 
arabinofuranose from DPA 
Škovierová et al., 
2009 
AftB Rv3805c 
Transfer of terminal β(1à2) 
arabinofuranose residues from DPA 
Jankute et al., 2017 
CapA Rv1635c 
Capping of terminal arabinose of LAM 
with α (1à5) mannopyranose from 
DPM 
Dinadayala et al., 
2006 
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MptC Rv2181 
Terminal addition of α(1à2) 
mannopyranose from DPM either on 
terminal domain or mannan core  
(Mishra et al., 2011) 
Ppm1 Rv2051c 
Synthesis of polyprenyl-phosphate 
mannose from polyprenyl-phosphate 
and GDP-mannose 
Gurcha et al., 2002 
PrsA Rv1017c 
Transfer of pyrophosphate onto C1 of 
ribose-5-phosphate to form phospho- 
α-D-ribosyl-pyrophosphate 









monophosphate- 5-phosphoribose to 
decaprenyl-1-phosphoribose 











(Mikusova et al., 
2005) 
LpqW Rv1166 
Channelling of intermediates into 
synthesis of PIM6 or LM and LAM 
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1.3.6: Mycolic acids: 
 
Mycobacteria are known to produce a unique type of lipid, the mycolic acid, which are found 
on the outer layers of the cell wall. Mycolic acids are either covalently bound to the 
arabinogalactan, or non-covalently in the outer membrane, as free mycolates, or attached to 
various sugar containing moieties such as trehalose to form trehalose monomycolate (TMM) 
or trehalose dimycolate (TDM) (Bhatt et al., 2008, 2007; Butler and Ahearn, 1986; Gande et 
al., 2004).  
 
Mycolic acids are only found in species belonging to: Mycobacteria, Corynebacteria, 
Nocardia, and Rhodococcus (Brennan, 2003; Brennan and Nikaido, 1995; Butler and Ahearn, 
1986). While mycolic acids are found in these species they vary significantly between genus’. 
Mycobacterial mycolic acids are the largest and most complex, while also showing significant 
variability in size between species, with mycobacterial mycolic acids containing 60- 90 carbons 
(Butler and Ahearn, 1986). Corynebacteria produce the smallest of mycolic acids, containing 
between 22- 36 carbon atoms, while nocardial and rhodococcal mycolic acids contain 36- 66 
carbons (Alshamaony et al., 1976; Butler and Ahearn, 1986; Minnikin et al., 1977).  
 
In mycobacteria mycolic acids are essential for viability, as they are involved in maintaining 
the hydrophobic nature of the external cell surface, especially in virulent strains where this 
impermeable barrier is essential in the prevention of the uptake of various antibiotics  (Lanéelle 
et al., 2001; Liu et al., 1996). Mycobacterial mycolic acids are formed of a meromycolate fatty 
acid chain (C42- 62), condensed with an additional saturated fatty acid chain (C24-26), to produce 
a unique α-alkyl-β-hydroxy fatty acid (Figure 1.19) (Brennan and Nikaido, 1995; Butler and 
Ahearn, 1986).  
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In order to produce these unique lipids, mycobacteria possess two different fatty acid synthases 
(FAS). FAS I is a multifunctional polypeptide, encoded by Rv2524c (Bhatt et al., 2007), 
responsible for the generation of fatty acids with a variety of lengths depending on if the 
requirements for phospholipid biosynthesis or mycolic acid biosynthesis (Takayama et al., 
2005). The longer chain fatty acids (C20 and C26), can either become the saturated α-branch, or 
be elongated by FAS II to become the meromycolate chain (Bhatt et al., 2007; Takayama et 
al., 2005). The synthesis of fatty acids by both FAS I and FAS II are well understood, with a 
sequential series of reactions leading to the addition of two carbons after each cycle (Figure 
1.19).  
 cations containing oxygen functions in the distal portion of
the meromycolate chain, whereas non-polar modifica-
tions, i.e. cyclopropane rings and unsaturations, are found
in both the proximal (closest to the b-hydroxy group) and
distal positions of the chain (Kremer et al., 2000a).
Mycolic acids give rise to important characteristics, includ-
ing resistance to chemical injury, resistance to dehydra-
tion, low permeability to hydrophobic antibiotics, virulence
(Dubnau et al., 2000; Glickman et al., 2000; Glickman and
Jacobs, 2001), acid-fast staining (Bhatt et al., 2007),
biofilm formation (Ojha et al., 2005) and the ability to
persist within the host (Daffe and Draper, 1998; Yuan
et al., 1998; Glickman et al., 2000; Bhatt et al., 2007).
In addition, the enzymes involved in mycolate biosyn-
thesis are essential for mycobacterial survival and thus
represent excellent drug targets.
The biosynthetic pathway of mycolates involves two
types of fatty acid-synthesizing systems, the type I and
type II fatty acid synthases, FAS-I and FAS-II respectively.
The eukaryotic-like FAS-I catalyses the de novo synthesis
of fatty acids from acetyl-CoA. In contrast, FAS-II is similar
to systems found in bacteria, apicomplexa parasites and
plants, and is composed of four dissociable enzymes that
act successively and repetitively to elongate the growing
acyl chain. Acyl-primers are continually activated via a
thioester linkage to the prosthetic group of coenzyme A
(CoA) for FAS-I, or of an acyl carrier protein (ACP) for
FAS-II. The biosynthesis involves five distinct stages,
which have been detailed in a recent review (Takayama
et al., 2005) and are illustrated in Fig. 1: (i) the synthesis
of the C26 saturated straight chain fatty acids by FAS-I to
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Fig. 1. Fatty acid/mycolic acid biosynthesis in mycobacteria. FAS-I is involved in the synthesis of C16 and C26. The C16 acyl-CoA product acts
as a substrate for the synthesis of meromycolic acids by FAS-II, whereas the C26 fatty acid constitutes the a-branch of the final mycolic acid.
MtFabH has been proposed to be the link between FAS-I and FAS-II by converting C14-CoA generated by FAS-I to C16-AcpM, which is
channelled into the FAS-II cycle. This latter comprises four enzymes which will act successively and repeatedly to ensure fatty acid elongation,
ultimately leading to meromycolates (C56). These enzymes are the condensing enzymes KasA and KasB, the keto-reductase MabA, an
unidentified dehydratase, and the enoyl-reductase InhA. Finally, the polyketide synthase Pks13 catalyses the condensation of the a-branch
and the meromycolate to produce mycolic acids. Targets for the action of activated isoniazid (INH), ethionamide (ETH), triclosan (TRC), or
thiolactomycin (TLM) are indicated. FAS-II enzymes are labelled in black, excepted the condensing enzymes, which are indicated in red. The
relative contribution of FAS-I and FAS-II activities in fatty acid/mycolic acid biosynthesis is represented in green and purple respectively.
The mycobacterial FAS-II condensing enzymes 1443
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Molecular Microbiology, 64 , 1442–1454
Figure 1.19: Biosynthetic pathway of mycolic acids in mycobacterial species. Showing synthesis of de-novo 
fatty acids into the α branch by the action of FAS-I, and the extension of FAS-I products to generate the 
meromycolate by FAS-II. Figure reproduced, with permission, from: Bhatt et al 2007	
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The  further elongation of the short chain fatty acid depends on the availability of malonyl-
CoA, and the acyl-carrier protein: AcpM (Kremer et al., 2001b). The acyl chain is transferred 
to the AcpM, and channelled into the FAS II, where it is extended in cycles. Each cycle 
catalyses the addition of two carbons onto the acyl chain until the meromycolate chain reaches 
the mature length (C42- 62). The meromycolate chain is then modified by the addition of 
methoxy groups, methyl groups, keto groups, and cis-/trans-cyclopropanation to form the 
mature meromycolate (Figure 1.20) (Barkan et al., 2010; Bhatt et al., 2007; Dubnau et al., 
2000; Glickman, 2003; Glickman et al., 2000). The meromycolate and the short chain fatty 
acid are then linked through the action of Pks13 to produce a α-alkyl-β-keto-mycolic acid 
(Gande et al., 2004; Portevin et al., 2004). The mature mycolate undergoes a final reduction 
step, catalysed by Rv2509 in Mtb (Figure 1.19) (Bhatt et al., 2008).  
 
In Mtb mycolic acids are classified as either; α-, methoxy-, or keto- mycolic acids, depending 
on the modifications on the meromycolate chain (Figure 1.20). The methylation patterns of 
mycolates in mycobacterial species vary, with mycolic acids extracted from Mtb, only having 
INTRODUCTION
Tuberculosis (TB) is one of the world’s deadliest diseases
(19). The Centers for Disease Control and Prevention has
reported that each year, eight million people around the world
become sick with TB and there are over two million TB-related
deaths worldwide. Moreover, one-third of the world’s popula-
tion is infected with TB. Thus, Mycobacterium tuberculosis (the
causative agent of TB) is clearly the most predominant global
human pathogen. Two decades ago, it was thought that TB was
under control and that it was a matter of time before it would
be eradicated. Today, this disease has reestablished itself due
to several factors. The lack of drug compliance, the appearance
of multiple-drug-resistant strains, and the AIDS epidemic are
a few factors that have led to the resurgence in TB. Drug re-
sistance arises following inadequate compliance, and AIDS
patients with weakened immune system are very susceptible to
M. tuberculosis and the usual cause of death.
The cell envelope of M. tuberculosis is distinctive and is
associated with its pathogenicity. Features that are very prom-
inent in the cell envelope are the presence of arabinogalacta -
mycolate covalently linked to the cell wall peptidoglycan via a
phosphodiester bond located on the inner leaflet of the outer
membrane (9, 56, 63, 69) and of a free glycolipid called treha-
lose dimycolate (TDM), which accumulates in a cord-like fash-
ion on the surface of the cells (72, 73). This provides a thick
layer of lipid on the outer part of the cell and protects the
tubercle bacillus from noxious chemicals and the host’s im-
mune system. Mycolic acids are the major constituents of this
protective layer. They also play other important roles as struc-
tural components of the cell wall and envelope (5, 11, 55, 65).
More specifically, the cyclopropane rings in mycolic acids of M.
tuberculosis contribute to the structural integrity of the cell wall
complex (39) and protect the bacillus from oxidative stress
(hydrogen peroxide) (123).
Deletion of the proximal cyclopropane ring of !-mycolic
acid (41) or of methoxy- and keto-mycolates (31) in M. tuber-
culosis leads to a significant attenuation in growth of the two
mutants in the mouse model of infection (structures are shown
below). A deletion of the keto-mycolates leads to restricted
growth of this mutant in macrophages (124). Thus, the fine struc-
ture of mycolic acids is associated with virulence of M. tuber-
culosis.
MYCOLIC ACIDS IN M. TUBERCULOSIS
As defined by Asselineau and Lederer (8) mycolic acids are
"-hydroxy fatty acids with a long !-alkyl side chain. They exist
as homologous series of fatty acids differing by 28 atomic mass
units (a two-carbon unit), and in M. tuberculosis they are char-
acterized by very hydrophobic C54 to C63 fatty acids with C22 to
C24 ! side chains. Three distinct structural classes of mycolic
acids are found in M. tuberculosis, and they are !-, methoxy-
and keto-mycolic acids, as shown in Fig. 1. The !-mycolic acid
is the most abundant form (# 70%), whereas methoxy- and
keto-mycolic acids are the minor components (10 to 15%) (82).
The !-mycolic acid is a cis, cis-dicyclopropyl fatty acid. There
are two structural variations of this mycolic acid, depending on
the source. These variations are in the length of the terminal
alkyl group and the number of methylene groups between the
cyclopropane rings and the carboxyl group. Thus, !-mycolic acids
from strains H37Ra and Test represent one group, and !-mycolic
acids from strains Brevanne, DT, PN, C, and Canetti represent
the other group (6, 35, 38, 66, 68, 82, 100). The !-mycolic acid
from the H37Ra strain and the clinical strains are different. Both
methoxy- and keto-mycolic acids have structural series containing
either cis- or trans-cyclopropane rings (67).
In recent years, many excellent reviews on the biosynthesis
of mycolic acids have appeared (7, 11, 30, 49, 50). However,
these reviews lack the details on how mycolic acids are
synthesized and processed into the final products. Consid-
erable knowledge has accumulated in the last 20 years, and
today we are sitting on the cusp of this problem. To move this
field forward, we have now critically examined and reviewed
numerous old and new data in the literature and used them to
develop a novel and plausible scheme of how mycolic acids are
synthesized and processed in M. tuberculosis. We have per-
formed computational genetic analyses to try to fill in the gaps
in the current knowledge. The validity of parts of this proposed
pathway can now be tested experimentally, and a more com-
plete picture should emerge.
BIOSYNTHESIS OF MYCOLIC ACIDS IN
M. TUBERCULOSIS
Biosynthesis of Normal Fatty Acid Precursors
of Mycolic Acids by FAS-I
A study of how Mycobacterium synthesizes C16 to C18 and
C24 to C26 fatty acids in a bimodal product pattern by the
malonyl coenzyme A (malonyl-CoA) pathway dates back to the
work of Bloch and associates in the early 1970s (16). They
showed that Mycobacterium smegmatis contains both type I
fatty acid synthetase (FAS-I), a multienzyme complex found in
eukaryotes and advanced prokaryotes, and type II fatty acid
synthetase (FAS-II), a disaggregated synthetase system found
in plants and bacteria. The FAS-I and FAS-II systems of M. tu-
berculosis were shown to be similar to those of M. smegmatis
(G. S. Besra, unpublished results).
The mycobacterial FAS-I system elongates acetyl group by
FIG. 1. Chemical structures of mycolic acids from M. tuberculosis.
There are five forms of mycolic acids in M. tuberculosis, illustrated with
!-mycolic acid from the H37Ra strain and methoxy- and keto-mycolic
acids from M. tuberculosis subsp. hominis strains DT, PN, and C. Both
cyclopropane rings in !-mycolic acid have the cis configuration. The
methoxy- and keto-mycolic acids can have either the cis or trans con-
figuration on the proximal cyclopropane ring.
82 TAKAYAMA ET AL. CLIN. MICROBIOL. REV.
Figur  1.20: Structures of mycobacterial mycolic acids. Figure reproduced with permission 
from Takaya a et al, 2005. 	
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methyl groups on carbons that originally were the 2 position of the acetate during synthesis, 
while in Mycobacterium smegmatis the opposite is seen, with methyl groups only on carbons 
that were in the 1 position of the acetate (Schroeder and Barry, 2001).  
 
The mechanism of the translocation of the synthesised mycolic acids from the site of 
cytoplasmic synthesis to the external site of attachment to the cell wall and insertion in the 
outer membrane has been determined to be conducted by Mmpl3, with TMM being the 
transported substrate (Su et al., 2019). This hypothesis is supported by discovery that Antigen 
85 is able to transfer mycolates from TMM to the arabinogalactan and onto TMM to form 
TDM, suggesting that TMM acts as a primary source of mycolic acids (Abrahams and Besra, 
2016; Backus et al., 2014; Takayama et al., 2005). 
 
1.3.7: The mycobacterial capsule 
 
The mycobacterial capsule is the outermost layer of the mycobacterial cell envelope, and is 
comprised of polysaccharides, secreted proteins, and lipids (Dinadayala et al., 2008; Koliwer-
Brandl et al., 2016; Raynaud et al., 1998). The mycobacterial capsule is not covalently bound 
to the surface of the cell, and is able to be shed into the growth medium (Lemassu et al., 1996).  
 
The primary component of the capsule are the α-glucans, a branched homopolysaccharide of 
α-D-glucose, where the monosaccharides are connected by α(1à4)  glycosidic linkages, and 
the branch points are connected by α(1à6) glycosidic linkages. α-glucan is a large 
polysaccharide, with a mass of approximately 100 kDa (Dinadayala et al., 2008). The 
remaining polysaccharide component of the capsule is comprised of mannan and 
arabinomannan, which are structurally similar to LM and LAM respectively, and as such have 
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been hypothesised to be the cleaved from surface exposed LM and LAM (Kalscheuer et al., 
2019). 
 
The remaining capsular material is composed of species specific proteins and lipids 
(Kalscheuer et al., 2019; Ortalo-Magne et al., 1995; Raynaud et al., 1998). With the Mtb 
capsule having been shown to contain LpqH, PstS1and components of the Ag85 complex 
(Ortalo-Magne et al., 1995), with the other studies focussing on the enzymatic activity of the 
capsule showing the association of proteins such as: BlaC, Adh, and SodA (Raynaud et al., 
1998). As with the protein composition, the lipid composition of the capsule varies depending 
on the mycobacterial species, with the most abundant lipid species in the capsule being PIMs, 
and diacylated trehaloses such as TDM (Ortalo-Magné et al., 1996). 
 
1.4.1: Membrane associated proteins and transmembrane proteins: 
 
Membrane proteins account for between 15- 30 % of bacterial genes and have been determined 
to make up approximately 50 % of the bacterial cytoplasmic membrane, performing a range of 
functions many of which are essential for viability (Rawlings, 2016; Strahl and Errington, 
2017). However, the biological characterisation of these proteins has fallen behind that of 
soluble proteins due to the increased difficulty of purification while maintaining functionality 
(Rawlings, 2016; Strahl and Errington, 2017; Teo et al., 2019; Wang et al., 2017).  
 
Membrane proteins can be separated into two categories: membrane associated proteins, and 
integral membrane proteins. Membrane associated proteins can associate with the membrane 
either through a covalently bound lipid anchor at the C-terminus of the protein, or through 
amino acid residues preferentially interacting with either the hydrophobic interior of the 
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phospholipid bilayer, or with interactions between both the hydrophobic core and the 
hydrophilic head groups of the bilayer. Membrane associated proteins that interact with the 
hydrophobic core do not span the membrane. Membrane associated proteins that are not bound 
to the membrane using a lipid anchor are often found to have a helical domain which provides 
the interactions with the membrane. These helices are usually hydrophobic on one face and 
hydrophilic on the other providing a substantial interaction with the membrane (Strahl and 
Errington, 2017).  
 
Transmembrane proteins can span membranes, either through a single a-helix or multiple a-
helices, or as a b-barrel. a-helical structures in membrane proteins are typically found in the 
cytoplasmic membrane, with proteins having different numbers of transmembrane a-helices 
depending on the protein function (Braibant et al., 2000; Tommassen, 2010). A single spanning 
region typically are predicted to act as an anchor to the cytoplasmic membrane, such as is 
predicted in the case of Lcp1 (Harrison et al., 2016). While multiple spanning a-helices are 
required for transporters to function, as multiple transmembrane helices are necessary in order 
to form a pore for the transported molecule to pass through. Though it is common for 
transporters in the inner membrane to form dimers in order to form a fully functional pore 
(Braibant et al., 2000; Beis, 2015, Locher, 2016).  
 
Proteins that span the bacterial outer membrane tend to be found in a b-barrel architecture, 
where the membrane spanning region is composed of b-sheets. This structure is more stable 
and therefore better able to withstand exposure to the surrounding environment (Kuhn et al., 
2017; Tommassen, 2010). The b-barrel structure is also less hydrophobic compared to a-
helices which reduces the likelihood of aggregation during synthesis, as the primary structure 
of the protein is less hydrophobic than is required for an a-helix. This alternative structure also 
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ensures they reach the appropriate destination, as the majority of membrane proteins are 
translocated across the inner membrane by the same pathway (Kuhn et al., 2017; Tommassen, 
2010).  
 
The amount of structural information on transmembrane proteins is significantly smaller than 
that of soluble proteins, due to the environment they are located in making them more difficult 
to purify (Shimizu et al., 2018). Transmembrane proteins have also been seen to favour specific 
phospholipid environments, adding an additional layer of difficulty for study, as detergent 
based purification methods tend to remove all associated lipids (Postis et al., 2015; Rothnie, 
2016; Seeger, 2018). While it is possible to reconstitute purified proteins back into a membrane 
bilayer environment with native lipids requires additional steps and does not ensuring that the 
protein is in the correct environment for any assay on activity to be guaranteed to representative 
of the in vivo activity (Prabudiansyah et al., 2015; Teo et al., 2019).   
 
1.4.2: Insertion of proteins into the membrane: 
 
Both inner and outer membrane proteins can be inserted or transported respectively by the Sec 
translocon. The majority of inner membrane proteins are translated and translocated 
simultaneously. This prevents aggregation of the transported protein by reducing the exposure 
of the hydrophobic membrane spanning regions to the aqueous cytosol (Kuhn et al., 2017).  
 
Translocation of proteins by the Sec pathway is conserved throughout all domains of life 
(Denks et al., 2014). The core transmembrane region of the Sec pathway being formed by 
SecYEG complex formed of SecY, SecE and SecG (Andersson and von Heijne, 1993; 
Frauenfeld et al., 2011). SecY spans the inner membrane ten times to form the pore through 
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which proteins are transported. This pore has two exits where hydrophobic and hydrophilic 
regions can exit the transmembrane region through either the lateral gate or the pore ring 
respectively. The lateral gate is formed by four of the transmembrane helices in SecY, and is 
essential for the function of the protein (Frauenfeld et al., 2011; Plath et al., 1998). The channel 
of the SecYEG pore is hydrophobic and so the translocation of hydrophilic sections of protein 
through the pore requires the use of an ATPase, SecA, to overcome the energetic barrier. One 
exception to this is the case of small hydrophilic regions, where the translocation is coupled to 
the energetically favourable insertion of a transmembrane region (Andersson and von Heijne, 
1993; Deitermann et al., 2005; Wang et al., 2017).  
 
SecA additionally functions as a mediator between the ribosome and the SecYEG complex, 
resulting in simultaneous translation and translocation of inner membrane proteins. This is 
done by interactions between SecA and the nascent polypeptide exit tunnel of the 70S 
ribosome, as well as the nascent polypeptide itself (Huber et al., 2011; Singh et al., 2014; 
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engaged but freely moving polypeptide can undergo 
passive diffusion through the dilated channel without 
the requirement of energy45,135,149. Finally, acting as 
a ‘break’, SecA prevents chain back-sliding to enable 
PMF-driven or Brownian forward motion16,46.
Once most of the mature domain is translocated, 
SecA loses contact sites45 and hence ATPase stimula-
tion. SecA–ADP is now peripherally associated with the 
translocase16,144.
In the final step, the peripherally bound SecA–ADP 
protomer dissociates from SecYEG41,144, re-dimerizes in 
the cytoplasm and can repeat the translocation cycle.
Pre-protein maturation and release. Signal pepti-
dases (SPase I for secretory proteins and SPase II for 
lipoproteins; FIG. 5c, left) cleave the signal peptide of a 
pre-protein that was fully, or at least 80%, translocated 
through SecYEG and release the mature domain at the 
REV IEWS
























Figure 1.21: Sec mediated transloaction of proteins. Showing the steps by which the SecYEG complex interacts 
with SecA, and the substrate protein in order to translocate the substrate protein across the plasma membrane 
into the periplasm. Figure reproduced with permission from Tsirigotaki et al., 2017. 
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into the inner membrane are exposed to the hydrophilic cytosol as little as possible during 
translation to prevent mis-folding (Wang et al., 2017).  
 
While the Sec membrane insertion and translocation mechanism is an important mechanism 
for the insertion of proteins into the membrane, it is not always required. Various proteins have 
been found to be inserted without the use of the Sec machinery, with some proteins using YidC 
rather than the Sec translocon to insert into the membrane (Kiefer and Kuhn, 2018). YidC is 
also used for the insertion of proteins into the membrane, functioning either independently of 
the Sec pathway or through interaction with the SecYEG complex (Kiefer and Kuhn, 2018; 
von Heijne, 1994). The size of the periplasmic domain to be inserted into the membrane plays 
a large role in the determination of the translocation system, with alterations to the size of 
periplasmic domains changing the proteins required for translocation from YidC to the 




ATP binding cassette (ABC) transporters are an important superfamily of membrane proteins 
found in all domains of life (ter Beek et al., 2014). ABC-transporters are one of the protein 
families that transport molecules across membranes, functioning when energy is required for 
translocation. Energy can be required either due to a concentration gradient resisting the 
movement, or due to energetically unfavourable interactions with the membrane (Seeger, 2018; 
Yamaguchi and Mano, 2019). The molecules transported by these proteins range from the 
import of nutrients and micronutrients, to the export of cell wall precursors and signalling 
molecules (Bi et al., 2018; Locher, 2016). The energetic cost of ABC-transporters has been 
estimated to vary between 10- 60 % of the total hydrolysis of ATP by cells depending on the 
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conditions (Rees et al., 2009). Braibant et al. 2000 found that there are at least 37 complete and 
incomplete ABC-transporters in the Mtb genome.  
 
ABC-transporters are capable of both importing and exporting molecules coupled the 
conversion of ATP to ADP and inorganic phosphate (Ford and Beis, 2019; Locher, 2016). They 
contain at least four domains; two membrane spanning domains (MSDs) typically comprised 
of four to eight transmembrane helices each, and two nucleotide binding domains (NBDs) 
(Braibant et al., 2000). These domains can be transcribed either independently as individual 
domains required to form a tetramer to function, or as a multi-domain polypeptides, which can 
contain all four domains or form either a homo- or hetero- dimer to function (Braibant et al., 
2000; Locher, 2016).  The pairs of MSDs and NBDs that make up an ABC-transporter tend to 
be either similar or identical (Higgins and Linton, 2004). 
 
Lipopolysaccharide ABC transporter LptB2FG
The cell surface of gram-negative bacteria comprises lipopolysaccharides (LPS) that are essential for pathogen-
esis and drug resistance. The LPS, which is composed of lipid A, core oligosaccharide, and O-antigen polysac-
charides, is synthesised in the inner membrane. The lipid A and the core oligosaccharide are transported across
the inner membrane by MsbA [9], whereas the LPS is extracted from the inner membrane outer leaflet by the
ABC transporter LptB2FG that contains two TMDs, LptF and LptG, and two NBDs, LptB2. The crystal struc-
tures of LptB2FG from Klebsiella pneumoniae [17] and Pseudomonas aeruginosa [18] have been determined in
their apo state. The TMD of LptB2FG is composed of 6 TMs from LptF and 6 TMs from LptG and TM1 of
each subunit interfaces with TM5 of the other (Figure 2a). TM1 (from LptF)/TM5 (from LptG) and TM5
Figure 1. Schematic representation of the transport cycle for alternating access and outward-open only mechanism.
(a) Alternating access mechanism based on the MsbA and Sav1866 structures; in the absence of nucleotides, the TMD adopts
an inward-open conformation, whereas lipid A can access the open cavity. ATP binding induces an outward-open
conformation, coupled to NBD dimerisation. ATP hydrolysis resets the system to the inward-open state. A similar cycle can
also occur in the absence of substrate. (b) McjD adopts an occluded TMD in the presence of nucleotides and absence of
substrate (not shown here). Both the presence of ATP and antibacterial peptide MccJ25 are required for the McjD to adopt a
transient outward-open conformation that collapses to an occluded conformation upon substrate release. ATP hydrolysis
results in an inward-occluded conformation. In the absence of substrate, the TMD of McjD remains occluded. (c) Crystal
structure of the LLO flippase PglK. The apo inward-open (left panel) is irrelevant during the transport cycle. ATP binding
induces a transient nucleotide-bound outward-open state, whereas LLO (depicted in ball and stick) can access the cavity. ATP
hydrolysis pushes LLO out of the cavity and PglK adopts a nucleotide-bound outward-occluded conformation. Dotted boxes
delineate the transient nucleotide-bound outward-open state for McjD and PglK.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 3
Biochemical Society Transactions (2019)
https://doi.org/10.1042/BST20180147
Figure 1.22: Structure of the ABC transporter MsbA. Showing the transmemberane domain 
(TMD, helicies labelled 1-6) and the nucleotide binding domain (NBD). Left to right showing the 
open conformation of MsbA (left) to allow for the binding of lipid A (centre), and the 
conformational change to allow release of lipid A upon addition of ATP (right). Figure 
reproduced with permission Ford and Beis, 2019. 
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The superfamily of ABC-transporters has been classified into twelve different sub-families, of 
which Mtb is predicted to express members of nine different sub-families (Figure 1.24) 
(Braibant et al., 2000; Rees et al., 2009).  
 
In addition to the core components of ABC-transporters that function as importers have an 
additional protein, called a substrate binding protein (SBP). SBPs are periplasmic proteins 
which in Gram positive bacteria are either attached to the membrane by an anchoring lipid tail, 
or bound to the transporter. SBPs  bind to the substrate of transporter and present it to the 
binding site of the ABC-transporter for import (Berntsson et al., 2010).  
 
All 15 putative SBPs in Mtb have a predicted lipid attachment site. The presence of a lipid 
attachment site is expected, as while mycobacteria are known to possess an pseudo outer 
membrane, they are most closely related to Gram positive bacteria (Braibant et al., 2000; Gao 
and Gupta, 2012). This results in the presence of a Gram positive SBP motif as opposed to the 
SBP being freely mobile in the periplasm organisation commonly seen in Gram negative bacilli 
(Berntsson et al., 2010).   
 
1.5.2: Nucleotide binding domains of ABC-transporters: 
 
The NBDs of ABC-transporters are themselves formed from two sub-domains: a catalytic core, 
and an a-helical domain (Beis, 2015). The catalytic core is the more conserved of the two 
subdomains, and contains the motifs required for ATP binding and hydrolysis. Such as the 
Walker A motif (also called the P-loop), the Walker B motif, as well as the Q-loop, A-loop and 
the H-motif (Figure 1.23) (Ambudkar et al., 2006; Beis, 2015; Rees et al., 2009). While the a-
helical domain contains the ABC-signature motif, a peptide sequence of LSSGQ, which is 
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required for binding the nucleotide, though single point mutations in the consensus sequence 
can be tolerated (Braibant et al., 2000; Locher, 2016). The orientation of the a-helical domain 
is determined by the nucleotide binding state of the complex (Karpowich et al., 2001).  
 
The A-loop is a generally conserved region upstream of the Walker A motif which has been 
shown to interact with the adenosine of ATP through an aromatic residue, most commonly 
tyrosine (Ambudkar et al., 2006). While the A-loop is involved in the binding of ATP, it is not 
found in all ABC-transporters (Ambudkar et al., 2006).  Residues in both the Walker A and 
16). This was consistent with previous mutational studies that
demonstrated that transport function and ATP hydrolysis
were abolished when Y16 was substituted with S [14]. Subse-
quently, the crystal structures of both free and nucleotide-
bound NBDs of several ABC transporters have been reported.
It has been shown that in HlyB [15], MsbA [16], MJ0796 [17]
and Tap1 [18] NBDs a tyrosine residue interacts with the ade-
nine ring of ATP. Similarly, structures of MJ1267 [19] and
GlcV [20] show that a phenylalanine residue is involved in
the recognition of the adenine base. Finally, the structure of
the MalK NBD indicates that the adenine base interacts with
a tryptophan residue through van der Waals contacts [21].
Thus, analysis of structures of nucleotide-bound ABCs demon-
strates that the adenine ring of the nucleotide interacts with an
aromatic residue.
Recently Mao and coworkers [22] used a data mining and
quantum chemical approach to identify residues involved in
adenine binding in nucleotide-binding proteins. Their study
identified three principal forms of interaction between the ade-
nine base and the nucleotide-binding pocket: (i) hydrogen
bonding, (ii) p–p stacking and (iii) cation–p interactions. This
study endeavored to quantify the relative importance of these
interactions and determined that on average, there are four
non-bonded intermolecular interactions required for binding
the adenine base to a protein: 2.7 hydrogen bonding interac-
tions, 1.0 p–p stacking interaction, and 0.8 of a cation–p inter-
action between the adenine base and the protein. Most
significant, however, was the conclusion that there is a comple-
mentary relationship between hydrogen bonding and the other
two forms of non-bonded intermolecular interactions. Stacking
interactions that involve aromatic residues from both enzyme
and substrate are thus a critical component of the binding of
nucleotides to ATP-binding proteins. Based on the individual
structures of NBDs and the molecular characteristics for nucle-
otide-binding, it would be reasonable to expect that a conserved
aromatic residue is an integral part of the ABC, and is involved
in the recognition of the adenine ring of ATP.
3. A highly conserved aromatic residue subdomain within the
ABC
Recently we have taken a comprehensive approach to identi-
fying conserved aromatic residues that may have interactions
with the adenine base of ATP in ABC transporters.1 The first
step was to mine the non-redundant protein database for
matches to the pattern characteristic of distinct conserved mo-
tifs for the ATP-binding site. This search identified a total of
18514 domains, and matched regions (!25–30 residues up-
stream of the Walker A motif to !175 residues downstream)
were combined into a multiple alignment. The alignment
showed that 15614 of these domains (84.3%) contain an aro-
Fig. 1. Schematic showing residues in conserved subdomains of NBD1 and NBD2 of human Pgp interacting with ATP. ATP is sandwiched between
the Walker A and B, and A, Q and H loops of the NBD1 and the C (signature) region and D-loop of the NBD2 (top) and vice versa (bottom). The
diagram was generated based on the structure of the E171Q mutant MJ0796 NBD dimer [6], sequence alignment, and mutational analyses of a
majority of these residues in mammalian Pgps by several groups (Table 1 in [7]).
1Kim, I.W., Peng, X.H., Sauna, Z.E., FitzGerald, P.C., Xia, D.,
Muller, M., Nandigama, K. and Ambudkar, S.V., submitted for
publication.
1050 S.V. Ambudkar et al. / FEBS Letters 580 (2006) 1049–1055
Figure 1.23: Interactions between the nucleotide binding domain of a human ABC-transporter and ATP.  
Showing the residues of the conserved ABC-transporter motifs and where they interact with ATP in 
uman Pg . Figure reproduce  with permission from Ambudka  et al 2006.	
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Walker B motifs interacting with a chelated Mg2+ which is essential for the binding of ATP 
through interactions with the a and b phosphates (Figure 1.23) (Ambudkar et al., 2006; Beis, 
2015). The Walker A motif is a conserved sequence of nucleotide binding domains, with a 
consensus sequence of: (A/G)XXXXGK(S/T), where “X” notes any amino acid and residues 
in parenthesis denoting multiple amino acids capable of forming the motif (Braibant et al., 
2000). The Walker B motif is formed of DEØØØØD, where “Ø” notes a hydrophobic amino 
acid (Rees et al., 2009).  
 
The Q-loop is a flexible region of the nucleotide binding domain which is responsible for the 
majority of the interactions with the membrane spanning domains, it is approximately nine 
residues long, beginning with a conserved glutamine, followed by either seven or eight amino 
acids. This region is flexible, and the interactions it makes with the active site by the conserved 
glutamine is thought to be involved in regulating the changes in the conformational state of the 
protein to cause either transport or release of the substrate (Beis, 2015; Jones and George, 
2002).  
 
The H-motif is formed of a short loop of hydrophobic amino acids followed by a histidine, 
downstream of the Walker B motif, this interacts with the gamma-phosphate of the ATP and 
has been shown to be essential for several ABC-transporters to function (Figure 1.20) 
(Ambudkar et al., 2006; Walter et al., 1992).  
 
While the motifs found in the NBDs of ABC-transporters are generally conserved, and the 
consensus sequences are usually maintained there are some discrepancies in the literature as to 
the required sequences, and to the degree of conservation required for functionality of the ABC 
transporter (Braibant et al., 2000; Rees et al., 2009). 
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In order for the full ATP binding site to be formed, the two NBDs must dimerise, with dimer 
formation exclusively occurring in a head-to-tail structure. This is due to the requirement of 
motifs in both proteins to form a functional active site for each ATP binding site. The binding 
of ATP causes a conformational change that brings the two domains closer together which 
allows for the nucleophilic attack of an activated water molecule onto the g-phosphate of ATP. 
The conserved glutamic acid of the Walker B motif is responsible for activating  the water 
(Beis, 2015). The production of ADP and inorganic phosphate from this reaction disrupts the 
interface between the nucleotide binding domain, and allows for the release of the products 
(Hohl et al., 2014).  
 
1.5.3: Membrane spanning domains of ABC-transporters: 
 
MSDs are less well conserved than nucleotide binding domains, with some motifs that are only 
seen in a subset of the sub-families. Typically a MSD will contain four to eight transmembrane 
helices, and are encoded the same operon as the nucleotide binding domain that they associate 
with if they are expressed as separate proteins (Braibant et al., 2000).  
 
The coupling of the energy released by ATP hydrolysis to the transport of the substrate is 
mediated through a structurally conserved, but sequentially variable a-helix located in the 
cytoplasmic loops between transmembrane domains (Beis, 2015). The overall structure of 
transmembrane domains shows significant variability, with structures being separated into 
three categories; importer type I, importer type II, and exporter (Rees et al., 2009). However 
due to the relative scarcity of structures of membrane proteins, and therefore by extension 
MSDs it is difficult to draw a consensus on structural similarities of these domains. The 
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determination of a structural consensus is likely to be further complicated by the differences in 
the substrates being transported ranging from relatively small molecules, such as lipids, to large 
polysaccharides which is likely to have a substantial effect on the quaternary structure of the 
complex (Beis, 2015). 
 
1.5.4: Mycobacterial ABC-transporters: 
 
15 of the predicted Mtb ABC-transporters are formed of clusters of genes comprising only one 
of the four domains required for a functional transporter. However, none of these is a cluster 
of four separate genes suggesting that the MSDs, and NBDs dimerise. The remaining 
transporters all contain at least one fused domain (protein contains either two fused MSDs, or 
one MSD and one NBD), to form a total of 25 complete predicted ABC-transporters (Figure 
1.21), of which 15 have an associated SBP. Leading to the prediction of 15 ABC-transporters 
functioning as importers, with the remaining 10 being extruders (Braibant et al., 2000).  
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Of the complete transporters predicted within the Mtb genome, two have not been categorized 
into a sub-family, Rv0655, and Rv3781 (Braibant et al., 2000).  Comparison between the Mtb 
genome and the genomes of Escherichia coli, and Bacillus subtilis, show that E. coli is 
predicted to express 57 ABC-transporters, of which only 13 are presumed to be extruders, while 
B. subtilis encodes for a predicted 78 ABC-transporters, of which 40 are predicted to be 
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Figure 1.24: Classification of the ABC-transporters in Mtb. Showing the predicted importers and 
exporters along with the predicted ABC-transporter subfamily. Figure reproduced, with permission 
from Braibant et al 2000. 	
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extruders showing that Mtb encodes for a relatively small number of ABC-transporters as 
opposed to other bacteria, which is fitting considering the reduced range of environments that 
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1.6: Aims and Objectives:  
 
To determine and characterize the currently unidentified protein or proteins responsible for the 
transport of PIMs across the plasma membrane in Mycobacteria. 
 
To determine the effect of the gene deletions causing Ethambutol sensitivity in C. glutamicum 
and point mutations restoring Ethambutol resistance on the composition of the cell envelope. 
 
To recombinantly express, and purify, the proteins predicted to be responsible for the transport 
of galactan in M. smegmatis, and to determine the binding affinities of galactan analogues to 
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2.1: Introduction:  
 
C. glutamicum is used as a model organism for Mtb, due to the highly similar cell wall structure, 
while having an increased tolerance to cell wall mutations that would be lethal in Mtb 
(Alderwick et al., 2005). This reduces the need for the generation of conditional knockouts for 
the investigation into the function of genes essential in mycobacterial species. This has allowed 
for insights into the function of various genes conserved in clinically significant mycobacterial 
species, with investigations into the biosynthetic pathways of AG, PIM, LM and LAM 
(Alderwick et al., 2006; Batt et al., 2010; Jankute et al., 2017; Mishra et al., 2012). 
 
The corynebacterial cell wall shares much of the cell wall core that is found in Mtb, including 
various cell wall polysaccharides such as the lipid anchored LM and LAM, which are 
synthesised from PIMs, a major component of the mycobacterial membrane (Jankute et al., 
2015). The core structure of these lipopolysaccharides is conserved between Mtb and C. 
glutamicum, with the exception of an additional lipid anchor for Cg-LM and Cg-LAM found 
in C. glutamicum, formed of a di-acylglycerol attached to a glucuronic acid (Gl-A) (Tatituri et 
al., 2007). A second major difference between Cg-LAM and mycobacterial LAM is the 
truncated arabinan domains in Cg-LAM (Tatituri et al., 2007).   
 
Mycobacterial LM and LAM is anchored through either Ac2PIM or Ac1PIM (Crellin et al., 
2008). The mannan core of the polysaccharide is built by the addition of Manp through α(1à6) 
glycosidic linkages on the mannose extending from the C6 of the inositol ring. The addition of 
these mannose residues is catalysed by the action of PimB’, PimC, MptA and MptB, to build 
the mannan core decorated with single Manp residue branches to form LM (Mishra et al., 2007, 
2008a).  
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The LM core can then be further built upon by the action of an unknown arabinosyl transferase 
(AraT) which primes the addition of further arabinofuranose residues to create LAM 
(Abrahams and Besra, 2016). Once the mannan core has been primed with single 
arabinofuranose to form the base of the branch, the branches are built by the action of EmbC, 
AftC, AftB, and potentially AftD to build the base arabinan domains using DPA as the source 
of arabinose (Alderwick et al., 2011; Jankute et al., 2017; Škovierová et al., 2009). These 
arabinan domains can then be further capped with mannose residues by the action of CapA and 
MptC to form ManLAM (Dinadayala et al., 2006; Mishra et al., 2011). 
 
While the core structure of LM an LAM is conserved within mycobacterial species the 
structural differences found between mycobacterial species results in significant changes to the 
immune response (Birch et al., 2010; Stoop et al., 2013). The importance of these molecules in 
the immune response and virulence during infection has resulted in research into both the 
immunological and biosynthetic aspects of these molecules (Ishikawa et al., 2017; Nigou et al., 
2004).  
 
In mycobacteria LM and LAM have been found to be exposed on the cell surface. These 
lipoglycans have been indicated in the activation of signalling pathways that lead to apoptosis 
of macrophages, and the induction of interleukin 12 (IL-12) from infected cells (Dao et al., 
2004). LM and LAM have been shown to interact with various signalling proteins expressed 
by macrophages including: toll-like receptor 1 and 2 (TLR-1 and -2), as well as C-type lectin 
receptors such as SIGNR3 (Elass et al., 2005; Ishikawa et al., 2017; Tanne et al., 2009). These 
interactions are altered by the different forms of LM and LAM produced by Mtb. Purified 
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ManLAM from Mtb does not cause the same phenotypic response as purified LAM, despite 
still inducing the expression of IL-12 transcript (Dao et al., 2004).  
 
LAM is also involved in the prevention of the activation of macrophages, by inhibiting the 
activation of mitogen-activate protein kinase (MAPK). MAPK acts as an activator for 
signalling  cascades, and is activated by the protein phosphatase SHP-1, preventing the transfer 
of signals, resulting in an altered immune response favouring the bacteria (Knutson et al., 1998; 
Pieters, 2008).  
 
C. glutamicum possesses a singular Emb gene (as opposed to the three Emb proteins found in 
mycobacterial species), Cg-Emb provides the same functions as EmbA and EmbB in 
mycobacteria, acting as an porcessive AraT responsible for extension of the arabinan domains 
of AG (Alderwick et al., 2005; Jankute et al., 2018). However, Cg-Emb does not elongate the 
arabinose domains in LAM which is catalysed by the action of EmbC. The fact that Cg-Emb 
does not catalyse the extension of arabinan domains of Cg-LAM results in LAM with single 
arabinose residues as opposed to the extended arabinan domains in mycobacteria.  
 
While the synthesis of PIMs LM and LAM (from synthesis of inositol for the core lipid that 
forms the PIMs, and elaboration of PI to the various PIM mannosylation and acylation states) 
has been largely identified (Table 1.3), the process by which PIMs are transported from the 
inner leaflet of the cytoplasmic membrane to the outer leaflet has yet to be identified (Abrahams 
and Besra, 2016; Jackson et al., 2000). Translocation of the PIMs to the outer leaflet of the 
cytoplasmic membrane is essential for both the biosynthesis of mature LM and LAM, and the 
maintenance of the plasma membrane. This is due to the PIM species forming a significant 
proportion of the lipid mass of mycobacteria, as well as their function as the anchor for LM 
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and LAM (Bansal-Mutalik and Nikaido, 2014; Lea-Smith et al., 2008). As such, determining 
the process by which PIMs are transported to the outer leaflet of the mycobacterial plasma 
membrane is important for our understanding of how the mycobacterial membrane is 
synthesised, as well as how the cell surface is synthesised.  
 
Due to the amphipathic nature of the PIM species it is unlikely that the process for transfer to 
the outer leaflet of the cytoplasmic membrane does not require the input of energy by the action 
of a dedicated transporter. This energy requirement has been shown in the transport of other 
lipid molecules exported to the external face of the cytoplasmic membrane, supporting the need 
for a transporter for translocation of PIMs to the external leaflet of the membrane (Xie et al., 
2015). One example of a lipid transporter in E. coli is MsbA (Figure 1.21), an extensively 
characterized ABC-transporter, responsible for the export of lipid A to the outer leaflet of the 
cytoplasmic membrane (H. Singh et al., 2016). Due to the structural similarity of lipid A and 
PIMs (Figure 2.1) it is likely that the transport proteins for the translocation to the periplasmic 
face of the cytoplasmic membrane for these lipids share some similarity. As the 
Corynebacteriales suborder does not produce lipid A, a transporter homologous to MsbA may 
transport molecules similar to Lipid A.  
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Here we aim to identify and characterise the genes responsible for translocating PIMs from the 
inner to the outer leaflet of the cytoplasmic membrane in Corynebacteriacea. We used MsbA 
(the well characterised Gram-negative lipid A flippase), as an archetypal lipid transporter to 
mine the genomes of CMN bacteria in order to detect and identify putative PIM transport genes. 
The function of these putative PIM transporters was determined by a comprehensive 





Figure 2.1: Lipid structure comparison of E. coli lipid A, and Ac2PIM2. A) Lipid A, with R1-R4 corresponding to 
the acyl chains attached in their respective positions, B) Ac2PIM2, i and ii being the two acyl chains predominantly 
found in PIM species, (C16:0 and C18:1 respectively), with the exact positions of each chain unconfirmed. Lipid A is 
the transport substrate of MsbA, is a multiply acylated sugar containing phospholipid, similar to Ac2PIM2.  




2.2.1: Bioinformatic analysis of Mycobacterial MsbA homologs:  
 
MsbA has been shown to be the transporter of lipid A across the inner membrane in E. coli 
(Xie et al., 2015). Due to the similarity of the structures of Lipid A and PIM species (Figure 
2.1), we predicted that the Mtb ABC-transporter responsible for the export of PIMs to the 
periplasmic leaflet of the cytoplasmic membrane would show homology to MsbA.  
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 1       10        20        30        40        50        60
MsbA                           P                              D G     R I  FK LIVA VA ILN A FM SL LL D K DMHNDKDLSTWQTF RLWPT A AG G L A SDT L LKP FG T
NCgl0926                       P                              D G     ML IL LK LIL VII QLAQSI SL LPTLNA II  VV GD....... WS VRF... AWP T F T L D N T
MSMEG_5008                      P                              D G     ML ALLRQ VR YR LLAVVAVLQVISNMASLYLPTVNAAII D VAKGD....... W Y... W
ML1114c                        P                              D G     ML ALLRQ IR YR LVAVLMVLQLVSTLASLYLPTINAAII D V KG....... L Y... R S N
Rv1273c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
Mb1304c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
MMAR_4147                      P                              D G     ML ALLRQ IR YR LVAALMALQLISTLASLYLPTVNAAII D VAKGD....... L Y... R
        70        80        90       100       110       120
MsbA                                              R   F               LV MPLVVIGL L I Y S M L HMM KRSV W MI RG TSYVSS CI WVSGKVVMT RR G GMPVSFFD QS
NCgl0926                                          R   F               I H G IML LT VQVACAI VY GSK GRDL AI KVVNFSERE FGIGY W T G A L AG F LSMRV S G MGQ
MSMEG_5008                                         R   F               T IV LGAVMLGVT LQVVCAVGAVF G R FGHDL AV HV TFS E RFGAR E A F A AATG A T T AE AG
ML1114c                                           R   F               T IVRLGIVML VT LQALC VGAVY GSR FGRDL AM HI TFSERE RFGAI A G S F TGMS S D T TA
Rv1273c                                           R   F               T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
Mb1304c                                           R   F               T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
MMAR_4147                                         R   F               T IIRLGVVMLGVT LQVLCAVGAVY G R FGRDL AM HVITFSERE RFGNT G F A TGTG A E TA
       130       140       150       160       170       180
MsbA         L  R T D                       G   M       L     V  P    GT LS   QV S L VV GA I I M  S ILI A IV IT I Y SE ASSS GA IT RE SI LF FYYSWQ I L S
NCgl0926     L  R T D                       G   M       L     V  P    APS IT N N V QV LVQMT TLMISAPML I GII AVRQDL  SWLMV SI VLIIQ QM S A G
MSMEG_5008    L  R T D                       G   M       L     V  P    A S LT T N V I LVQLTVTMLITAPIM I GI  ALHQDA  SWLLL SV VL LA GH QQ S F G G
ML1114c      L  R T D                       G   M       L     V  P    APT LT T N V QI LVQIS TVLVT PIM I GIV AI QEA  TWLLL SV ILAVR QY G P C Y A
Rv1273c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
Mb1304c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
MMAR_4147    L  R T D                       G   M       L     V  P    A T LT S N V QI LVQ TATVLV APIM I GII AVHQEA  TWLLL SV ILALS R VF T A S A
       190       200       210       220       230       240
MsbA                     MQ             L G      F     E   F          A V R I K   N M VT A   K V I  R VSN MIRV SK FRN S N T GQ TS EQM K H E L GGQEV TK DK R RLQ
NCgl0926                 MQ             L G      F     E   F          V II RMVPLF   ID IN IIREQ T IRVIRA RE  R R AS VVAL V QT KR R Q V DV E TT KD ADI
MSMEG_5008                MQ             L G      F     E   F          ANYWII HLMPVF   SLID INRVLRDQ S IRVIRA RE  R R ANQ LR TR G A PL V AE T SDS
ML1114c                  MQ             L G      F     E   F          NYWII HMLPLFR   SLID INRVMRDQ  IRVIRA RE  R R AN LT S S D A T SF N ER IA SNA
Rv1273c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
Mb1304c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
MMAR_4147                MQ             L G      F     E   F          ANYWIM HMLPLFR   LID INRVLRDQ S VRVVRA RE  R R ANT LT S A G T PF D AQ A AST
       250       260       270       280       290       300
MsbA                  P   L                        G                  M M S S I  I Q ASL A VLY SLTA TI V S I LM LG K V A S SD I I AL F AASFPSVMD T VF SM A RP KS
NCgl0926              P   L                        G                  V GN ALM  A  MNLS VAVIWFG VESG QI TL AFLQY MQILM VMMG RT LM F VM I A AFQ ET F I G
MSMEG_5008             P   L                        G                  AL AG WQALML VTT INVSSVALIWFGGL ID GQMQV SL AFL YFMQILMAVLME R V R A I A
ML1114c               P   L                        G                  AL AGNWQALML T  INVSSVALIWFGGL IDSGQMQI SL AFLTYF QILMAVLMN T A T R A T
Rv1273c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
Mb1304c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
MMAR_4147             P   L                        G                  AL AGNWQALML VTT INVSSVAVIWFGGL IDQG MQV SL AFLSYFAQILMAVLMR T L R S
       310       320          330       340       350       
MsbA               R           L                    G       TF YPG   PLT A  A L I GK AT V V  T   D  NVN QFQ GM ACQT FT ...DSEQEKDE RVIER D EFRN R V
NCgl0926           R           L                    G       TF YPG   PA VMVP A V ADRI EV T V P P P  I A     AD  AFMF A S G E TPS QA ET AQ S.TSA E VFNN A D
MSMEG_5008          R           L                    G       TF YPG   PAT LVI P A VCADRI EV ST AI NP P P I  I V A     AD  FM F A G QT T AD VR A.A A D G HD C R
ML1114c            R           L                    G       TF YPG   PAT LVVLP A VCA RI EV ST AV NP PH P VT V L V  T    MA S Q T RP G PC I RGK V R DG TNH
Rv1273c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
Mb1304c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
MMAR_4147          R           L                    G       TF YPG   PAT LVVLP A VCAERI EV ST AL NP PR P IT V L I  S   AD  MT A T PA N QH F AAG A R EN C
 360       370       380       390       400       410      
MsbA       L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A IN I    LV S    S IAS I  Y I  ILM G  L EY  N.N LK PA K V R T F DE E H TLAS R
NCgl0926   L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V N VS V P S T II ST    T LI  V  LF VT  V V G  V EF K WN FR A G P E D T T EPL D
MSMEG_5008  L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDVS TV  T T VV ST    S LIS IC LY VT  L I GV V D E  WSF PR S S R LDI Q
ML1114c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A QDIS TA P T T VV ST    S LV  IC LY VT  VLV V V Y ER WSF L A A A E N NA
Rv1273c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
Mb1304c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
MMAR_4147  L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS SA P  T IV ST    S LIS IC LY VT  VLL GI V DY ER WL P A G A QT A
1       10        20        30        40        50        60
MsbA                           P                              D G     R I  FK LIVA VA ILN A FM SL LL D K DMHNDKDLSTWQTF RLWPT A AG G L A SDT L LKP FG T
NCgl0926                       P                              D G     ML IL LK LIL VII QLAQSI SL LPTLNA II  VV GD....... WS VRF... AWP T F T L D N T
MSMEG_5008                      P                              D G     ML ALLRQ VR YR LLAVVAVLQVISNMASLYLPTVNAAII D VAKGD....... W Y... W
ML1114c                        P                              D G     ML ALLRQ IR YR LVAVLMVLQLVSTLASLYLPTINAAII D V KG....... L Y... R S N
Rv1273c        P       D G   ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
Mb1304c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
MMAR_4147                      P                              D G     ML ALLRQ IR YR LVAALMALQLISTLASLYLPTVNAAII D VAKGD....... L Y... R
        70        80        90       100       110       120
MsbA                                              R   F               LV MPLVVIGL L I Y S M L HMM KRSV W MI RG TSYVSS CI WVSGKVVMT RR G GMPVSFFD QS
NCgl0926                                          R   F               I H G IML LT VQVACAI VY GSK GRDL AI KVVNFSERE FGIGY W T G A L AG F LSMRV S G MGQ
MSMEG_5008                                         R   F               T IV LGAVMLGVT LQVVCAVGAVF G R FGHDL AV HV TFS E RFGAR E A F A AATG A T T AE AG
ML1114c                                           R   F               T IVRLGIVML VT LQALC VGAVY GSR FGRDL AM HI TFSERE RFGAI A G S F TGMS S D T TA
Rv1273c            R F       T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
Mb1304c                                           R   F               T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
MMAR_4147                                         R   F               T IIRLGVVMLGVT LQVLCAVGAVY G R FGRDL AM HVITFSERE RFGNT G F A TGTG A E TA
       130       140       150       160       170       180
MsbA         L  R T D                       G   M       L     V  P    GT LS   QV S L VV GA I I M  S ILI A IV IT I Y SE ASSS GA IT RE SI LF FYYSWQ I L S
NCgl0926     L  R T D                       G   M       L     V  P    APS IT N N V QV LVQMT TLMISAPML I GII AVRQDL  SWLMV SI VLIIQ QM S A G
MSMEG_5008    L  R T D                       G   M       L     V  P    A S LT T N V I LVQLTVTMLITAPIM I GI  ALHQDA  SWLLL SV VL LA GH QQ S F G G
ML1114c      L  R T D                       G   M       L     V  P    APT LT T N V QI LVQIS TVLVT PIM I GIV AI QEA  TWLLL SV ILAVR QY G P C Y A
Rv1273c   L R T D       G  M L   V P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA TWLLL SV ILAVR LF C A
Mb1304c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
MMAR_4147    L  R T D                       G   M       L     V  P    A T LT S N V QI LVQ TATVLV APIM I GII AVHQEA  TWLLL SV ILALS R VF T A S A
       190       200       210       220       230       240
MsbA                     MQ             L G      F     E   F          A V R I K   N M VT A   K V I  R VSN MIRV SK FRN S N T GQ TS EQM K H E L GGQEV TK DK R RLQ
NCgl0926                 MQ             L G      F     E   F          V II RMVPLF   ID IN IIREQ T IRVIRA RE  R R AS VVAL V QT KR R Q V DV E TT KD ADI
MSMEG_5008                MQ             L G      F     E   F          ANYWII HLMPVF   SLID INRVLRDQ S IRVIRA RE  R R ANQ LR TR G A PL V AE T SDS
ML1114c                  MQ             L G      F     E   F          NYWII HMLPLFR   SLID INRVMRDQ  IRVIRA RE  R R AN LT S S D A T SF N ER IA SNA
Rv1273c      MQ      L G   F E   F    ANYWII HMLPLFR SLID INRVMRDQ S VRVVRA RE R K ANT LS R G T GY D AQ A SNA
Mb1304c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
MMAR_4147                MQ             L G      F     E   F          ANYWIM HMLPLFR   LID INRVLRDQ S VRVVRA RE  R R ANT LT S A G T PF D AQ A AST
       250       260       270       280       290       300
MsbA                  P   L                        G                  M M S S I  I Q ASL A VLY SLTA TI V S I LM LG K V A S SD I I AL F AASFPSVMD T VF SM A RP KS
NCgl0926              P   L                        G                  V GN ALM  A  MNLS VAVIWFG VESG QI TL AFLQY MQILM VMMG RT LM F VM I A AFQ ET F I G
MSMEG_5008             P   L                        G                  AL AG WQALML VTT INVSSVALIWFGGL ID GQMQV SL AFL YFMQILMAVLME R V R A I A
ML1114c               P   L                        G                  AL AGNWQALML T  INVSSVALIWFGGL IDSGQMQI SL AFLTYF QILMAVLMN T A T R A T
Rv1273c      P L         G       AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
Mb1304c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
MMAR_4147             P   L                        G                  AL AGNWQALML VTT INVSSVAVIWFGGL IDQG MQV SL AFLSYFAQILMAVLMR T L R S
       310       320          330       340       350       
MsbA               R           L                    G       TF YPG   PLT A  A L I GK AT V V  T   D  NVN QFQ GM ACQT FT ...DSEQEKDE RVIER D EFRN R V
NCgl0926           R           L                    G       TF YPG   PA VMVP A V ADRI EV T V P P P  I A     AD  AFMF A S G E TPS QA ET AQ S.TSA E VFNN A D
MSMEG_5008          R           L                    G       TF YPG   PAT LVI P A VCADRI EV ST AI NP P P I  I V A     AD  FM F A G QT T AD VR A.A A D G HD C R
ML1114c            R           L                    G       TF YPG   PAT LVVLP A VCA RI EV ST AV NP PH P VT V L V  T    MA S Q T RP G PC I RGK V R DG TNH
Rv1273c     R    L      G TF YPG PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T ADMT S T PA G DN F TDG V R AG C
Mb1304c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
MMAR_4147          R           L                    G       TF YPG   PAT LVVLP A VCAERI EV ST AL NP PR P IT V L I  S   AD  MT A T PA N QH F AAG A R EN C
 360       370       380       390       400       410      
MsbA       L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A IN I    LV S    S IAS I  Y I  ILM G  L EY  N.N LK PA K V R T F DE E H TLAS R
NCgl0926   L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V N VS V P S T II ST    T LI  V  LF VT  V V G  V EF K WN FR A G P E D T T EPL D
MSMEG_5008  L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDVS TV  T T VV ST    S LIS IC LY VT  L I GV V D E  WSF PR S S R LDI Q
ML1114c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A QDIS TA P T T VV ST    S LV  IC LY VT  VLV V V Y ER WSF L A A A E N NA
Rv1273c   L  G T A G GSGK T L  R D G   D D R   LV QDIS TA P T T IV ST   S LVS IC LY VT VLV GI V EY ER WSL R A A HT
Mb1304c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
MMAR_4147  L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS SA P  T IV ST    S LIS IC LY VT  VLL GI V DY ER WL P A G A QT A
1       10        20        30        40        50        60
MsbA                           P                              D G     R I  FK LIVA VA ILN A FM SL LL D K DMHNDKDLSTWQTF RLWPT A AG G L A SDT L LKP FG T
NCgl0926                       P                              D G     ML IL LK LIL VII QLAQSI SL LPTLNA II  VV GD....... WS VRF... AWP T F T L D N T
MSMEG_5008                      P                              D G     ML ALLRQ VR YR LLAVVAVLQVISNMASLYLPTVNAAII D VAKGD....... W Y... W
ML1114c                        P                              D G     ML ALLRQ IR YR LVAVLMVLQLVSTLASLYLPTINAAII D V KG....... L Y... R S N
Rv1273c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
b1304c ML ALL Q R YR LVAMLMMLQLVSTLASLYLPTVNAAIV VA G....... L H... R
MMAR_4147 AL RQ IR YR VAALMAL ISTLA Y V A D AKL Y R
70 80 90 100 110 120
MsbA                                              R   F               LV MPLVVIGL L I Y S M L HMM KRSV W MI RG TSYVSS CI WVSGKVVMT RR G GMPVSFFD QS
NCgl0926                                          R   F               I H G IML LT VQVACAI VY GSK GRDL AI KVVNFSERE FGIGY W T G A L AG F LSMRV S G MGQ
MSMEG_5008                                         R   F               T IV LGAVMLGVT LQVVCAVGAVF G R FGHDL AV HV TFS E RFGAR E A F A AATG A T T AE AG
ML1114c                                           R   F               T IVRLGIVML VT LQALC VGAVY GSR FGRDL AM HI TFSERE RFGAI A G S F TGMS S D T TA
Rv1273c                                           R   F               T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
b1304c T I RLGA ML VT QVLCAIGAV G R FGRDL AM IITFSERE RFGAT G L TGAG S E TA
MMAR_4147 T IRL VV GV L L VGA R F M H IT RNT G A TGTG A E TA
130 140 150 160 170 180
MsbA         L  R T D                       G   M       L     V  P    GT LS   QV S L VV GA I I M  S ILI A IV IT I Y SE ASSS GA IT RE SI LF FYYSWQ I L S
NCgl0926     L  R T D                       G   M       L     V  P    APS IT N N V QV LVQMT TLMISAPML I GII AVRQDL  SWLMV SI VLIIQ QM S A G
MSMEG_5008    L  R T D                       G   M       L     V  P    A S LT T N V I LVQLTVTMLITAPIM I GI  ALHQDA  SWLLL SV VL LA GH QQ S F G G
ML1114c      L  R T D                       G   M       L     V  P    APT LT T N V QI LVQIS TVLVT PIM I GIV AI QEA  TWLLL SV ILAVR QY G P C Y A
Rv1273c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
b1304c AP T S N V I LVQMTATVL TAPIM V GI AIHQEA TWL L SV LAVR LF C A
MMAR_4147 T L S I A VLV IM H EA T LL V I ALS R VF T A S A
190 200 210 220 230 240
MsbA                     MQ             L G      F     E   F          A V R I K   N M VT A   K V I  R VSN MIRV SK FRN S N T GQ TS EQM K H E L GGQEV TK DK R RLQ
NCgl0926                 MQ             L G      F     E   F          V II RMVPLF   ID IN IIREQ T IRVIRA RE  R R AS VVAL V QT KR R Q V DV E TT KD ADI
MSMEG_5008                MQ             L G      F     E   F          ANYWII HLMPVF   SLID INRVLRDQ S IRVIRA RE  R R ANQ LR TR G A PL V AE T SDS
ML1114c                  MQ             L G      F     E   F          NYWII HMLPLFR   SLID INRVMRDQ  IRVIRA RE  R R AN LT S S D A T SF N ER IA SNA
Rv1273c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
b1304c NYWII HMLPLFR SLID INRVMRDQ S VRV RA RE R K ANT LS R G T GY D AQ A SNA
MMAR_4147 ANYW M H L R L RVL D S V V NT LT S A G T PF D AQ A ST
250 260 270 280 290 300
MsbA                  P   L                        G                  M M S S I  I Q ASL A VLY SLTA TI V S I LM LG K V A S SD I I AL F AASFPSVMD T VF SM A RP KS
NCgl0926              P   L                        G                  V GN ALM  A  MNLS VAVIWFG VESG QI TL AFLQY MQILM VMMG RT LM F VM I A AFQ ET F I G
MSMEG_5008             P   L                        G                  AL AG WQALML VTT INVSSVALIWFGGL ID GQMQV SL AFL YFMQILMAVLME R V R A I A
ML1114c               P   L                        G                  AL AGNWQALML T  INVSSVALIWFGGL IDSGQMQI SL AFLTYF QILMAVLMN T A T R A T
Rv1273c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
b1304c AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFL YFAQILMAVLMS T R I
MMAR_4147 AL A WQ L VTT I V S GL IDQ M V S S FA A LT L R S
310 320 330 340 350
MsbA               R           L                    G       TF YPG   PLT A  A L I GK AT V V  T   D  NVN QFQ GM ACQT FT ...DSEQEKDE RVIER D EFRN R V
NCgl0926           R           L                    G       TF YPG   PA VMVP A V ADRI EV T V P P P  I A     AD  AFMF A S G E TPS QA ET AQ S.TSA E VFNN A D
MSMEG_5008          R           L                    G       TF YPG   PAT LVI P A VCADRI EV ST AI NP P P I  I V A     AD  FM F A G QT T AD VR A.A A D G HD C R
ML1114c            R           L                    G       TF YPG   PAT LVVLP A VCA RI EV ST AV NP PH P VT V L V  T    MA S Q T RP G PC I RGK V R DG TNH
Rv1273c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
b1304c A L VLP A VCAERI EV ST AL NP P P V L A AMT S T PA G N F TDG V R AG C
MMAR_4147 T L VL C E S AL N R IT V L I SMT T PA N QH F AAG A R E C
360 370 380 390 400 410
MsbA       L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A IN I    LV S    S IAS I  Y I  ILM G  L EY  N.N LK PA K V R T F DE E H TLAS R
NCgl0926   L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V N VS V P S T II ST    T LI  V  LF VT  V V G  V EF K WN FR A G P E D T T EPL D
MSMEG_5008  L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDVS TV  T T VV ST    S LIS IC LY VT  L I GV V D E  WSF PR S S R LDI Q
ML1114c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A QDIS TA P T T VV ST    S LV  IC LY VT  VLV V V Y ER WSF L A A A E N NA
Rv1273c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
b1304c V QD S TA P T T I ST LV C L VT V V I V ER WSR A A HT
MMAR_4147 QDI SA V S S IC Y LL I DY ERL P A G A QT A
1       10        20        30        40        50        60
MsbA                           P                              D G     R I  FK LIVA VA ILN A FM SL LL D K DMHNDKDLSTWQTF RLWPT A AG G L A SDT L LKP FG T
NCgl0926                       P                              D G     ML IL LK LIL VII QLAQSI SL LPTLNA II  VV GD....... WS VRF... AWP T F T L D N T
MSMEG_5008                      P                              D G     ML ALLRQ VR YR LLAVVAVLQVISNMASLYLPTVNAAII D VAKGD....... W Y... W
ML1114c                        P                              D G     ML ALLRQ IR YR LVAVLMVLQLVSTLASLYLPTINAAII D V KG....... L Y... R S N
Rv1273c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
b1304c ML ALL Q R YR LVAMLMMLQLVSTLASLYLPTVNAAIV VA G....... L H... R
MMAR_4147 AL RQ IR YR VAALMAL ISTLA Y V A D AKL Y R
        70        80        90       100       110       120
MsbA   R FLV MP VVIGL L Y S M HMMRSV W MI RG TS VSS CI WVSGK VMT RR G GMPVSFFD QS
NCgl 926 R FI H G IM LT VQVACAI VY GSK GRDL AI KVVNFSERE FGIGY W T G A L AG F LSMR S G MGQ
SMEG_5008 R FT IV LGAVM GVT LQVVCAVGAVF G R FGHDL AV HV TFS E RFGAR E A F A ATG A T AE AG
ML1114c                                           R   F               T IVRLGIVML VT LQALC VGAVY GSR FGRDL AM HI TFSERE RFGAI A G S F TGMS S D T TA
Rv1273c                                           R   F               T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
b1304c T I RLGA ML VT QVLCAIGAV G R FGRDL AM IITFSERE RFGAT G L TGAG S E TA
MMAR_4147 T IRL VV GV L L VGA R F M H IT RNT G A TGTG A E TA
       130       140       150       160       170       180
MsbA   L R T D M L V PG LS QV S L V GA I I M S ILI A IV II Y SE ASSS G IT RE SI LF FYYSWQ L S
NCgl 926 L R T D M L V PAPS IT N N V QV L QMT TLMISAPML I GII AVRQDL SWLMV SI VLIIQ QM S A G
SMEG_5008 L R T D M L V PA S LT T N V I L QLT TMLITAPIM I GI ALHQDA SWLLL SV VL LA H QQ S F G G
ML1114c      L  R T D                       G   M       L     V  P    APT LT T N V QI LVQIS TVLVT PIM I GIV AI QEA  TWLLL SV ILAVR QY G P C Y A
Rv1273c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
b1304c AP T S N V I LVQMTATVL TAPIM V GI AIHQEA TWL L SV LAVR LF C A
MMAR_4147 T L S I A VLV IM H EA T LL V I ALS R VF T A S A
       190       200       210       220       230       240
MsbA   MQ L G F E FV R I K N M V A K V I R N MIRV SK FRN S N T GQ TS EQM K H E L GG V TK DK R RLQ
NCgl 926 MQ L G F E FV II RMVPLF ID IN IIREQ T IRV RA RE R R A VVA V T KR R Q V DV E TT KD ADI
SMEG_5008 MQ L G F E FNYWII HLMP F SLID INRVLRDQ S RV RA RE R R ANQ LTR G A PL V AE T SDS
ML1114c                  MQ             L G      F     E   F          NYWII HMLPLFR   SLID INRVMRDQ  IRVIRA RE  R R AN LT S S D A T SF N ER IA SNA
Rv1273c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
b1304c NYWII HMLPLFR SLID INRVMRDQ S VRV RA RE R K ANT LS R G T GY D AQ A SNA
MMAR_4147 ANYW M H L R L RVL D S V V NT LT S A G T PF D AQ A ST
       250       260       270       280       290       300
MsbA   P L GM M S S I I Q ASL A LY SLTA TI V S I LM LG K V A S SD I I AL F AASFPSVMD T VF SM RP KS
NCgl 926 P L GV GN A M A MNLS VA IWFG ESG QI TL AFLQY MQILM VMMG RT LM F V I A AFQ ET F I G
SMEG_5008 P L GL AG WQA M VTT INVSSVALIWFGGL ID GQMQV SL AFL YFMQILMAVLME R V R A I A
ML1114c               P   L                        G                  AL AGNWQALML T  INVSSVALIWFGGL IDSGQMQI SL AFLTYF QILMAVLMN T A T R A T
Rv1273c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
b1304c AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFL YFAQILMAVLMS T R I
MMAR_4147 AL A WQ L VTT I V S GL IDQ M V S S FA A LT L R S
       310       320          330       340       350       
MsbA   R L G TF YPG PLT A A L I GK AT V V T DNVN QFQ GM ACQT FT ...DSEQEKDE RVIER D E RN R V
NCgl 926 R L G TF YPG PVMVP A V ADRI EV T V P P P A DAFMF A S G E TPS QA ET AQ S.TSA E V NN A D
SMEG_5008 R L G TF YPG PT LVI P A VCADRI E T AI NP P P I I V A DFM F A G QT T AD VR A.A A D G HD C R
ML1114c            R           L                    G       TF YPG   PAT LVVLP A VCA RI EV ST AV NP PH P VT V L V  T    MA S Q T RP G PC I RGK V R DG TNH
Rv1273c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
b1304c A L VLP A VCAERI EV ST AL NP P P V L A AMT S T PA G N F TDG V R AG C
MMAR_4147 T L VL C E S AL N R IT V L I SMT T PA N QH F AAG A R E C
 360       370       380       390       400       410      
MsbA   L G T A G G GK T L R D G D D R LIN I LV S S IAS I Y I ILM G L EY N.N LK P K V R T F E E H TLAS R
NCgl 926 L G T A G G GK T L R D G D D R LV N VS V P S T I ST T I V L VT V G V EF K WN FR A G P E D T T E L D
SMEG_5008 L G T A G G GK T L R D G D D R LV QDVS TV T T VV ST S IS IC LY VT L I GV V D E WSF PR S S R LDI Q
ML1114c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A QDIS TA P T T VV ST    S LV  IC LY VT  VLV V V Y ER WSF L A A A E N NA
Rv1273c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
b1304c V QD S TA P T T I ST LV C L VT V V I V ER WSR A A HT
MMAR_4147 QDI SA V S S IC Y LL I DY ERL P A G A QT A
1       10        20        30        40        50        60
MsbA                           P                              D G     R I  FK LIVA VA ILN A FM SL LL D K DMHNDKDLSTWQTF RLWPT A AG G L A SDT L LKP FG T
NCgl0926                       P                              D G     ML IL LK LIL VII QLAQSI SL LPTLNA II  VV GD....... WS VRF... AWP T F T L D N T
MSMEG_5008                      P                              D G     ML ALLRQ VR YR LLAVVAVLQVISNMASLYLPTVNAAII D VAKGD....... W Y... W
ML1114c                        P                              D G     ML ALLRQ IR YR LVAVLMVLQLVSTLASLYLPTINAAII D V KG....... L Y... R S N
Rv1273c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
b1304c ML ALL Q R YR LVAMLMMLQLVSTLASLYLPTVNAAIV VA G....... L H... R
MMAR_4147 AL RQ IR YR VAALMAL ISTLA Y V A D AKL Y R
        70        80        90       100       110       120
MsbA   R FLV MP VVIGL L Y S M HMMRSV W MI RG TS VSS CI WVSGK VMT RR G GMPVSFFD QS
NCgl 926                                          R   F               I H G IM LT VQVACAI VY GSK GRDL AI KVVNFSERE FGIGY W T G A L AG F LSMR S G MGQ
SMEG_5008                                         R   F               T IV LGAVM GVT LQVVCAVGAVF G R FGHDL AV HV TFS E RFGAR E A F A ATG A T T AE AG
ML1114c                                           R   F               T IVRLGIVML VT LQALC VGAVY GSR FGRDL AM HI TFSERE RFGAI A G S F TGMS S D T TA
Rv1273c                                           R   F               T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
b1304c                T I RLGA ML VT QVLCAIGAV G R FGRDL AM IITFSERE RFGAT G L TGAG S E TA
MMAR_4147                                                           T IRL VV LGV L L VGA R F  M H IT RNT G A TGTG A E TA
130 140 150 160 170 180
MsbA   L R T D M L V PG LS QV S L V GA I I M S ILI A IV II Y SE ASSS G IT RE SI LF FYYSWQ L S
NCgl 926     L  R T D                          M       L     V  P    APS IT N N V QV L QMT TLMISAPML I GII AVRQDL  SWLMV SI VLIIQ QM S A G
SMEG_5008    L  R T D                          M       L     V  P    A S LT T N V I LVQLT TMLITAPIM I GI  ALHQDA  SWLLL SV VL LA H QQ S F G G
ML1114c      L  R T D                       G   M       L     V  P    APT LT T N V QI LVQIS TVLVT PIM I GIV AI QEA  TWLLL SV ILAVR QY G P C Y A
Rv1273c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
b1304c        G         APT T S N V I LVQMTATVL TAPIM V GI  AIHQEA TWL L SV LAVR LF C A
MMAR_4147                               G                     T L  S  I V A VLV IM   H EA  T LL V I ALS R VF T A S A
190 200 210 220 230 240
MsbA   MQ L G F E FV R I K N M V A K V I R N MIRV SK FRN S N T GQ TS EQM K H E L GG V TK DK R RLQ
NCgl 926                 MQ             L G      F     E   F          V II RMVPLF   ID IN IIREQ T IRV RA RE  R R A VVAL V QT KR R Q V DV E TT KD ADI
SMEG_5008                MQ             L G      F     E   F          ANYWII HLMPVF   SLID INRVLRDQ S IRVIRA RE  R R ANQ LR TR G A PL V AE T SDS
ML1114c                  MQ             L G      F     E   F          NYWII HMLPLFR   SLID INRVMRDQ  IRVIRA RE  R R AN LT S S D A T SF N ER IA SNA
Rv1273c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
b1304c                   ANYWII HMLPLFR SLID INRVMRDQ S VRV RA RE R K ANT LS R G T GY D AQ A SNA
MMAR_4147                                                      ANYW M H L R   L RVL D  S V V    NT LT S A G T PF D AQ A ST
250 260 270 280 290 300
MsbA   P L GM M S S I I Q ASL A LY SLTA TI V S I LM LG K V A S SD I I AL F AASFPSVMD T VF SM RP KS
NCgl 926              P   L                        G                  V GN A M  A  MNLS VA IWFG ESG QI TL AFLQY MQILM VMMG RT LM F VM I A AFQ ET F I G
SMEG_5008             P   L                        G                  L AG WQA ML VTT INVSSVALIWFGGL ID GQMQV SL AFL YFMQILMAVLME R V R A I A
ML1114c               P   L                        G                  AL AGNWQALML T  INVSSVALIWFGGL IDSGQMQI SL AFLTYF QILMAVLMN T A T R A T
Rv1273c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
b1304c                     AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFL YFAQILMAVLMS T R I
MMAR_4147                                                          AL A WQ L L VTT I V S V GL IDQ M V S S FA A LT L R S
310 320 330 340 350
MsbA   R L G TF YPG PLT A A L I GK AT V V T DNVN QFQ GM ACQT FT ...DSEQEKDE RVIER D E RN R V
NCgl 926           R           L                    G       TF YPG   PVMVP A V ADRI EV T V P P P  A     D  AFMF A S G E TPS QA ET AQ S.TSA E V NN A D
SMEG_5008          R           L                    G       TF YPG   PT LVI P A VCADRI E  T AI NP P P I  I V A     D  FM F A G QT T AD VR A.A A D G HD C R
ML1114c            R           L                    G       TF YPG   PAT LVVLP A VCA RI EV ST AV NP PH P VT V L V  T    MA S Q T RP G PC I RGK V R DG TNH
Rv1273c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
b1304c                   A L VLP A VCAERI EV ST AL NP P P V L A A  MT S T PA G N F TDG V R AG C
MMAR_4147                                                    AT L VL  C E  S AL N R IT V L I  S   A  MT T PA N QH F AAG A R E C
360 370 380 390 400 410
MsbA   L G T A G G GK T L R D G D D R LIN I LV S S IAS I Y I ILM G L EY N.N LK P K V R T F E E H TLAS R
NCgl 926   L         G T A  G  G GK T   L  R  D   G    D  D R      L  V N VS V P S T I  ST    T I  V  L  VT  V V G  V EF K WN FR A G P E D T T EPL D
SMEG_5008  L         G T A  G  G GK T   L  R  D   G    D  D R      L  V QDVS TV  T T VV ST    S IS IC LY VT  L I GV V D E  WSF PR S S R LDI Q
ML1114c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A QDIS TA P T T VV ST    S LV  IC LY VT  VLV V V Y ER WSF L A A A E N NA
Rv1273c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
b1304c        S       V QD S TA P T T I  ST LV  C L VT  V V I V ER WSR A A HT
MMAR_4147                 S                            QDI SA    V     S L S IC Y  LL I  DY ER L P A G A QT A
1       10        20        30        40        50        60
MsbA                           P                              D G     R I  FK LIVA VA ILN A FM SL LL D K DMHNDKDLSTWQTF RLWPT A AG G L A SDT L LKP FG T
NCgl0926                       P                              D G     ML IL LK LIL VII QLAQSI SL LPTLNA II  VV GD....... WS VRF... AWP T F T L D N T
MSMEG_5008                      P                              D G     ML ALLRQ VR YR LLAVVAVLQVISNMASLYLPTVNAAII D VAKGD....... W Y... W
ML1114c                        P                              D G     ML ALLRQ IR YR LVAVLMVLQLVSTLASLYLPTINAAII D V KG....... L Y... R S N
Rv1273c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
b1304c ML ALL Q R YR LVAMLMMLQLVSTLASLYLPTVNAAIV VA G....... L H... R
MMAR_4147 AL RQ IR YR VAALMAL ISTLA Y V A D AKL Y R
        70        80        90       100       110       120
MsbA   R FLV MP VVIGL L Y S M HMMRSV W MI RG TS VSS CI WVSGK VMT RR G GMPVSFFD QS
NCgl 926 R FI H G IM LT VQVACAI VY GSK GRDL AI KVVNFSERE FGIGY W T G A AG F LSMR S G M Q
SMEG_5008 R FT IV LGAVM G T LQVVCAVGAVF G R FGHDL AV HV TFS E RFGAR E A F A ATG A T AE AG
L1114c   R FT IVRLGIVM VT LQALC VGAVY GSR FGRDL AM HI TFSERE RFGAI A G S F TGMS S D T T
Rv 273 R FT IVRLGAVM GVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
b 304 T I RLGA M VT QVLCAIGAV G R FGRDL AM IITFSERE RFGAT G L TGAG S E T
MAR_ 147 T IR VV GV L L VG R F H IT RNT G TGTG A E T
130 140 150 160 170 180
MsbA   L R T D M L V PG LS QV S L V GA I I M S ILI A IV II Y SE ASSS G IT RE SI LF FYYSWQ L S
NCgl 926 R T D M L PAPS IT N N V QV L QMT TLMISAPML I GII AV QDL SWL V I VLIIQ QM S A
SMEG_5008 L R T D M L V PA S LT T N V I L QLT TMLITAPIM I GI ALHQDA SWLLL SV VL LA H QQ F G
L1114c   L R T D M L V PAPT LT T N V QI L QIS TVLVT PIM I GIV AI QEA TWLLL SV ILAVR QY G P C Y A
Rv 273 L R T D G M L V PAPT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA TWLLL SV ILAVR LF C A
b 304 AP T S N V I L QMTATVL TAPIM V GI AIHQEA TWL L SV LAVR LF C A
MAR_ 147 L S I A VLV IM H EA T LL V I ALR VF A A
190 200 210 220 230 240
MsbA   MQ L G F E FV R I K N M V A K V I R N MIRV SK FRN S N T GQ TS EQM K H E L GG V TK DK R RLQ
NCgl 926 MQ L G F E FV II RMVPLF ID IN II Q T RV RA RE R R A VVA V T KR R Q V DV E TT KD AD
SMEG_5008 MQ L G F E FNYW I HLMP F SLID INRVLRDQ S RV RA E R R ANQ LTR G A P V AE T SDS
L1114c   M L G F E FNYWII HMLPLFR SLID INRVMRDQ RV RA RE R R AN LT S S D A T SF N ER IA SNA
Rv 273 MQ L G F E FNYWII HMLPLFR SLID INRVMRDQ S VRVVRA RE R K ANT LS R G T GY D AQ A SNA
b 304 NYWII HMLPLFR SLID INRVMRDQ S RV RA RE R K ANT LS R G T GY D AQ A SNA
MAR_ 147 NYW M H L R L R L D V NT LT S A G T PF D AQ A T
250 260 270 280 290 300
MsbA   P L GM M S S I I Q ASL A LY SLTA TI V S I LM LG K V A S SD I I AL F AASFPSVMD T VF SM RP KS
NCgl 926 P LV GN A M A MNLS VA IWFG ESG QI TL AFLQY MQILM VMMG T LM F V I A AFQ ET F I G
SMEG_5008 P L GL AG WQA M V T INVSSVAL WFGGL D GQMQ SL AFL YFMQILMAVLME R V R A I A
L1114c   P L GL AGNWQALML T INVSSVALIWFGGL DSGQMQI SL AFLTYF QILMAVLMN A T R A T
Rv 273 P L GAL AGNWQA M VTT INASSVALIWFGGL DSGQMQV SL AFLSYFAQILMAVLMS T R I
b 304 L AGNWQA M VTT INASSVALIWFGGL IDSGQMQV SL AFL YFAQILMAVLMS T R I
MAR_ 147 L A WQ VTT I V S GL IDQ M V S S FA AT L S
310 320 330 340 350
MsbA   R L G TF YPG PLT A A L I GK AT V V T DNVN QFQ GM ACQT FT ...DSEQEKDE RVIER D E RN R V
NCgl 926 R L G TF YPG PVMVP A V ADR EV T V P P P A DAF F A S G E TPS Q ET AQ . SA E NN D
SMEG_5008 R L G TF YPG PT LVI P A VCADR E T AI NP P P I V A DFM F A G QT T AD VR A.A A D G HD C R
L1114c   R L G TF YPG PT LVVLP A VCA RI E T AV NP PH P T V L V TM S Q T RP G PC I RGK V R DG TNH
Rv 273 R L G TF YPG PT LAVLP A VCAERI E T AL NP PK P VT V L A T DMT S T PA G DN F TDG V R AG C
b 304 L VLP A VCAERI EV T AL NP P P L AMT S T PA G N F TDG V R AG C
MAR_ 147 T L VL C E AL N R IT V L I SMT T PA N QH F AAG A R E C
360 370 380 390 400 410
MsbA   L G T A G G GK T L R D G D D R LIN I LV S S IAS I Y I ILM G L EY N.N LK P K V R T F E E H TLAS R
NCgl 926 L G T A G G GK T L R D G D D R LV VS V P S T I ST T I V L VT V G EF K WN FR A G P E D T T E L D
SMEG_5008 L G T A G GK T L R D G D D R LV QDVS TV T T VV ST S IS IC LY VT L GV V D E WSF PR S S R LDI Q
L1114c   L G T A G GK T L R D G D R LQDIS TA P T T VV ST S LV IC LY VT VLV V V Y ER WSF L A E N NA
Rv 273 L G T A G G GK T L R D G D D R LV QDIS TA P T T IV ST S LVS I LY VT VL GI EY ER WSL A A HT
b 304 V QD S TA P T T I ST V C L VT V I V ER WSA A HT
MAR_ 147 QDI SA V S S IC Y LL I DY EL P A QT A
1       10        20        30        40        50        60
MsbA                           P                              D G     R I  FK LIVA VA ILN A FM SL LL D K DMHNDKDLSTWQTF RLWPT A AG G L A SDT L LKP FG T
NCgl0926                       P                              D G     ML IL LK LIL VII QLAQSI SL LPTLNA II  VV GD....... WS VRF... AWP T F T L D N T
MSMEG_5008                      P                              D G     ML ALLRQ VR YR LLAVVAVLQVISNMASLYLPTVNAAII D VAKGD....... W Y... W
ML1114c                        P                              D G     ML ALLRQ IR YR LVAVLMVLQLVSTLASLYLPTINAAII D V KG....... L Y... R S N
Rv1273c        P       D G   ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
Mb1304c                        P                              D G     ML ALLRQ IR YR LVAMLMMLQLVSTLASLYLPTVNAAIV D VAKGD....... L H... R
MMAR_4147                      P                              D G     ML ALLRQ IR YR LVAALMALQLISTLASLYLPTVNAAII D VAKGD....... L Y... R
        70        80        90       100       110       120
MsbA               R F     LV MPLVVIGL L I Y S M L HMM KRSV W MI RG TSYVSS CI WVSGKVVMT RR G GMPVSFFD QS
NCgl0926                                          R   F               I H G IML LT VQVACAI VY GSK GRDL AI KVVNFSERE FGIGY W T G A L AG F LSMRV S G MGQ
MSMEG_5008                                         R   F               T IV LGAVMLGVT LQVVCAVGAVF G R FGHDL AV HV TFS E RFGAR E A F A AATG A T T AE AG
ML1114c                                           R   F               T IVRLGIVML VT LQALC VGAVY GSR FGRDL AM HI TFSERE RFGAI A G S F TGMS S D T TA
Rv1273c            R F       T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
Mb1304c            R F     T IVRLGAVMLGVT LQVLCAIGAVY GSR FGRDL AM HIITFSERE RFGAT G L TGAG S E TA
MMAR_4147                                         R   F               T IIRLGVVMLGVT LQVLCAVGAVY G R FGRDL AM HVITFSERE RFGNT G F A TGTG A E TA
130 140 150 160 170 180
MsbA      L R T D     G  M L   V P    GT LS  QV S L VV GA I I M S ILI A IV IT I Y SE ASSS GA IT RE SI LF FYYSWQ I L S
NCgl0926     L  R T D                       G   M       L     V  P    APS IT N N V QV LVQMT TLMISAPML I GII AVRQDL  SWLMV SI VLIIQ QM S A G
MSMEG_5008    L  R T D                       G   M       L     V  P    A S LT T N V I LVQLTVTMLITAPIM I GI  ALHQDA  SWLLL SV VL LA GH QQ S F G G
ML1114c      L  R T D                       G   M       L     V  P    APT LT T N V QI LVQIS TVLVT PIM I GIV AI QEA  TWLLL SV ILAVR QY G P C Y A
Rv1273c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
Mb1304c      L  R T D                       G   M       L     V  P    APT LT S N V QI LVQMTATVLVTAPIM V GII AIHQEA  TWLLL SV ILAVR LF C A
MMAR_4147    L  R T D                       G   M       L     V  P    A T LT S N V QI LVQ TATVLV APIM I GII AVHQEA  TWLLL SV ILALS R VF T A S A
190 200 210 220 230 240
MsbA         MQ      L G   F E   F    A V R I K N M VT A K V I R VSN MIRV SK FRN S N T GQ TS EQM K H E L GGQEV TK DK R RLQ
NCgl0926                 MQ             L G      F     E   F          V II RMVPLF   ID IN IIREQ T IRVIRA RE  R R AS VVAL V QT KR R Q V DV E TT KD ADI
MSMEG_5008                MQ             L G      F     E   F          ANYWII HLMPVF   SLID INRVLRDQ S IRVIRA RE  R R ANQ LR TR G A PL V AE T SDS
ML1114c                  MQ             L G      F     E   F          NYWII HMLPLFR   SLID INRVMRDQ  IRVIRA RE  R R AN LT S S D A T SF N ER IA SNA
Rv1273c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
Mb1304c                  MQ             L G      F     E   F          ANYWII HMLPLFR   SLID INRVMRDQ S VRVVRA RE  R K ANT LS R G T GY D AQ A SNA
MMAR_4147                MQ             L G      F     E   F          ANYWIM HMLPLFR   LID INRVLRDQ S VRVVRA RE  R R ANT LT S A G T PF D AQ A AST
250 260 270 280 290 300
MsbA         P L         G       M M S S I I Q ASL A VLY SLTA TI V S I LM LG K V A S SD I I AL F AASFPSVMD T VF SM A RP KS
NCgl0926              P   L                        G                  V GN ALM  A  MNLS VAVIWFG VESG QI TL AFLQY MQILM VMMG RT LM F VM I A AFQ ET F I G
MSMEG_5008             P   L                        G                  AL AG WQALML VTT INVSSVALIWFGGL ID GQMQV SL AFL YFMQILMAVLME R V R A I A
ML1114c               P   L                        G                  AL AGNWQALML T  INVSSVALIWFGGL IDSGQMQI SL AFLTYF QILMAVLMN T A T R A T
Rv1273c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
Mb1304c               P   L                        G                  AL AGNWQALML VTT INASSVALIWFGGL IDSGQMQV SL AFLSYFAQILMAVLMS T R I
MMAR_4147             P   L                        G                  AL AGNWQALML VTT INVSSVAVIWFGGL IDQG MQV SL AFLSYFAQILMAVLMR T L R S
310 320 330 340 350
MsbA        R    L       G    TF YPG   PLT A  A L I GK AT V V T D  NVN QFQ GM ACQT FT ...DSEQEKDE RVIER D EFRN R V
NCgl0926           R           L                    G       TF YPG   PA VMVP A V ADRI EV T V P P P  I A     AD  AFMF A S G E TPS QA ET AQ S.TSA E VFNN A D
MSMEG_5008          R           L                    G       TF YPG   PAT LVI P A VCADRI EV ST AI NP P P I  I V A     AD  FM F A G QT T AD VR A.A A D G HD C R
ML1114c            R           L                    G       TF YPG   PAT LVVLP A VCA RI EV ST AV NP PH P VT V L V  T    MA S Q T RP G PC I RGK V R DG TNH
Rv1273c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
Mb1304c            R           L                    G       TF YPG   PAT LAVLP A VCAERI EV ST AL NP PK P VT V L A  T   AD  MT S T PA G DN F TDG V R AG C
MMAR_4147          R           L                    G       TF YPG   PAT LVVLP A VCAERI EV ST AL NP PR P IT V L I  S   AD  MT A T PA N QH F AAG A R EN C
360 370 380 390 400 410
MsbA      L    G T A  G GSGK T L  R D G  D D R  LA IN I LV S S IAS I Y I  ILM G L EY N.N LK PA K V R T F DE E H TLAS R
NCgl0926   L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V N VS V P S T II ST    T LI  V  LF VT  V V G  V EF K WN FR A G P E D T T EPL D
MSMEG_5008  L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDVS TV  T T VV ST    S LIS IC LY VT  L I GV V D E  WSF PR S S R LDI Q
ML1114c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  A QDIS TA P T T VV ST    S LV  IC LY VT  VLV V V Y ER WSF L A A A E N NA
Rv1273c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
Mb1304c    L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS TA P T T IV ST    S LVS IC LY VT  VLV GI V EY ER WSL R A A HT
MMAR_4147  L         G T A  G  GSGK T   L  R  D   G    D  D R      L  V QDIS SA P  T IV ST    S LIS IC LY VT  VLL GI V DY ER WL P A G A QT A
 420       430       440         450       460       470    
MsbA         LV Q   LF  T A N  Y               A   A A  F      GL     V      N  V  I  S I E ARM  D I   IQ A S NVH D N A ARTEQ..Y REQ E Y M NKMDN DTV G
NCgl0926     LV Q   LF  T A N  Y               A   A A  F      GL     IG  P K F  SG I  LR G ATE LW  L I  D V   IAR S S NED... TQ Q A Q A REMPE DSE
MSMEG_5008    LV Q   LF  T A N  Y               A   A A  F      GL     AIG  P R Y  SG V E LR G ATD MWE LRV  D V   VAG RAD... DE A A RAHPQ DMP
ML1114c      LV Q   LF  T A N  Y               A   A A  F      GL     VIG  P R Y  SG V D LR G ITD MWE LHM  E I   VAC ATPGQV DQ D E RAHND HMR
Rv1273c      LV Q   LF  T A N  Y               A   A A  F      GL     AIG  P R Y  SG V D LR G VTE MWE LRV   V   VAS GGPDQV QE A DG QT..D QTR
Mb1304c      LV Q   LF  T A N  Y               A   A A  F      GL     AIG  P R Y  SG V D LR G VTE MWE LRV   V   VAS GGPDQV QE A DG QT..D QTR
MMAR_4147    LV Q   LF  T A N  Y               A   A A  F      GL     AIG  P R Y  SG V D LR G ATD MWE LRV  E V   VAG KSD... EE A E RA..H QMR
   480       490       500       510       520       530    
MsbA        G   SGGQRQR AIARA          D   SALD                  T     V        I     LLR I I  EA     SE I L L  LVIEN LL DSP L L T TE RA QAA DE QKNR S
NCgl0926    G   SGGQRQR AIARA          D   SALD                  T    QG N        L     LLK P IYIF D F    V TDA LR L DA LIVT V Q E S S A RA STNLP K
MSMEG_5008   G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     VIRRP IYLF DAF    VHTDARVR LR V DA VVIVA DA E AA
ML1114c     G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     IIRHP IYLF DAF    VHTD RV LR M DV IIVVT S SKS E FR
Rv1273c     G   SGGQRQR AIARA          D   SALD                  T    QG VNF       L     VIRRP IYVF DAF    VHTDAKVH LR V DA IIVVA AS Q SG
Mb1304c     G   SGGQRQR AIARA          D   SALD                  T    QG VNF       L     VIRRP IYVF DAF    VHTDAKVH LR V DA IIVVA AS Q SG
MMAR_4147   G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     II RP VYLF DAF    VHTDARVR VR L  IIIVG A AA E ATKS
   540       550       560       570       580              
MsbA        R S    AD   V   G     GTH  LL     Y      Q                 L TI   IV VE  IV      G  A  QAH EK E D V ER ND EHR V QLHKM FG .......
NCgl0926    R S    AD   V   G     GTH  LL     Y      Q                Q V TI   QIV LD  VVG    N  CG  E V S A RD N E I T NT T R I E ETAQAQS...
MSMEG_5008   R S    AD   V   G     GTH  LL     Y      Q                SQ I TVI   QVV ID  RVVG    DT  ADCP  AEFA S TE D I I E AL AGEPR..
ML1114c     R S    AD   V   G     GTH  LL     Y      Q                TQ I TAA   QVI VD  KLAG    ES  ADC  AEFA S Q D S TI Y SFGGGVRDSQ
Rv1273c     R S    AD   V   G     GTH  LL     Y      Q                TQ I NAA   QVI VD  KIVG    ET  ADCP  AEFA S SQ N T T A SL ATVGGVG
Mb1304c     R S    AD   V   G     GTH  LL     Y      Q                TQ I NAA   QVI VD  KIVG    ET  ADCP  AEFA S SQ N T T A SL ATVGGVG
MMAR_4147   R S    AD   V   G     GTH  LL     Y      Q                TQ V TAA   QVI ID  RVVG    DS  IDCP  AEFA S TQ D A T V SV ADIRGVS
 
 420       430       440         450       460       470    
sbA   LV Q LF A N Y A A F GLV N V I S I E ARM I IQ A NVH D N A ARTEQ..Y REQ E Y M NKMDN DTV G
NCgl0926     LV Q   LF  T A N  Y               A   A A  F      GL     IG  P K F  SG I  LR G ATE LW  L I  D V   IAR S S NED... TQ Q A Q A REMPE DSE
MSMEG_5008    LV Q   LF  T A N  Y               A   A A  F      GL     AIG  P R Y  SG V E LR G ATD MWE LRV  D V   VAG RAD... DE A A RAHPQ DMP
ML1114c      LV Q   LF  T A N  Y               A   A A  F      GL     VIG  P R Y  SG V D LR G ITD MWE LHM  E I   VAC ATPGQV DQ D E RAHND HMR
Rv1273c     LV Q LF  T A N Y     A A A  F GL AIG P R Y  SG V D LR G VTE MWE LRV  V   VAS GGPDQV QE A DG QT..D QTR
Mb1304c      LV Q   LF  T A N  Y               A   A A  F      GL     AIG  P R Y  SG V D LR G VTE MWE LRV   V   VAS GGPDQV QE A DG QT..D QTR
MMAR_4147    LV Q   LF  T A N  Y               A   A A  F      GL     AIG  P R Y  SG V D LR G ATD MWE LRV  E V   VAG KSD... EE A E RA..H QMR
   480       490       500       510       520       530    
MsbA        G   SGGQRQR AIARA          D   SALD                  T     V        I     LLR I I  EA     SE I L L  LVIEN LL DSP L L T TE RA QAA DE QKNR S
NCgl0926    G   SGGQRQR AIARA          D   SALD                  T    QG N        L     LLK P IYIF D F    V TDA LR L DA LIVT V Q E S S A RA STNLP K
MSMEG_5008   G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     VIRRP IYLF DAF    VHTDARVR LR V DA VVIVA DA E AA
ML1114c     G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     IIRHP IYLF DAF    VHTD RV LR M DV IIVVT S SKS E FR
Rv1273c   G   SGGQRQR AIARA    D SALD      TQG VNF L  VIRRP IYVF DAF   VHTDAKVH LR V DA IIVVA AS Q SG
Mb1304c     G   SGGQRQR AIARA          D   SALD                  T    QG VNF       L     VIRRP IYVF DAF    VHTDAKVH LR V DA IIVVA AS Q SG
MMAR_4147   G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     II RP VYLF DAF    VHTDARVR VR L  IIIVG A AA E ATKS
   540       550       560       570       580              
MsbA        R S    AD   V   G     GTH  LL     Y      Q                 L TI   IV VE  IV      G  A  QAH EK E D V ER ND EHR V QLHKM FG .......
NCgl0926    R S    AD   V   G     GTH  LL     Y      Q                Q V TI   QIV LD  VVG    N  CG  E V S A RD N E I T NT T R I E ETAQAQS...
MSMEG_5008   R S    AD   V   G     GTH  LL     Y      Q                SQ I TVI   QVV ID  RVVG    DT  ADCP  AEFA S TE D I I E AL AGEPR..
ML1114c     R S    AD   V   G     GTH  LL     Y      Q                TQ I TAA   QVI VD  KLAG    ES  ADC  AEFA S Q D S TI Y SFGGGVRDSQ
Rv1273c   R S AD  V G  GTH LL    Y Q  TQ I NAA QVI VD KIVG   ET ADCP AEFA S SQ N T T A SL ATVGGVG
Mb1304c     R S    AD   V   G     GTH  LL     Y      Q                TQ I NAA   QVI VD  KIVG    ET  ADCP  AEFA S SQ N T T A SL ATVGGVG
MMAR_4147   R S    AD   V   G     GTH  LL     Y      Q                TQ V TAA   QVI ID  RVVG    DS  IDCP  AEFA S TQ D A T V SV ADIRGVS
 
 420       430       440         450       460       470    
MsbA         LV Q   LF  T A N  Y               A   A A  F      GL     V      N  V  I  S I E ARM  D I   IQ A S NVH D N A ARTEQ..Y REQ E Y M NKMDN DTV G
NCgl0926     LV Q   LF  T A N  Y               A   A A  F      GL     IG  P K F  SG I  LR G ATE LW  L I  D V   IAR S S NED... TQ Q A Q A REMPE DSE
SMEG_5008    LV Q LF  T A N  Y            A  A A  F   G      IG  P R Y  SG V E LR G ATD MWE LRV   V   VAG RAD... DE A A RAHPQ DMP
ML1114c L Q LF A N Y A A A F GLIG P Y G V D LR G ITD MWE LHM E I VAC ATPGQV DQ D E RAHND HMR
Rv1273c   L Q LF A N Y A A A F GLAIG P R Y SG V D LR G VTE MWE LRV VAS GPDQV QE A DG QT..D QTR
b 30 LV Q LF A N Y A A F GLIG P R Y SG V D LR G VTE MWE LRV VAS GPDQ QE A DG QT..D QTR
MMAR_4147 LV Q LF A N Y A A F GLAIG P R Y SG V D LR G ATD MWE LRV E V VAG KSD... EE A E RA..H QMR
480 490 500 510 520 530
MsbA        G   SGGQRQR AIARA          D   SALD                  T     V        I     LLR I I  EA     SE I L L  LVIEN LL DSP L L T TE RA QAA DE QKNR S
NCgl0926    G   SGGQRQR AIARA          D   SALD                  T    QG N        L     LLK P IYIF D F    V TDA LR L DA LIVT V Q E S S A RA STNLP K
MSMEG_5008   G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     VIRRP IYLF DAF    VHTDARVR LR V DA VVIVA DA E AA
ML1114c     G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     IIRHP IYLF DAF    VHTD RV LR M DV IIVVT S SKS E FR
Rv1273c   G   SGGQRQR AIARA    D SALD      TQG VNF L  VIRRP IYVF DAF   VHTDAKVH LR V DA IIVVA AS Q SG
Mb1304c     G   SGGQRQR AIARA          D   SALD                  T    QG VNF       L     VIRRP IYVF DAF    VHTDAKVH LR V DA IIVVA AS Q SG
MMAR_4147   G   SGGQRQR AIARA          D   SALD                  T    QG INF       L     II RP VYLF DAF    VHTDARVR VR L  IIIVG A AA E ATKS
540 550 560 570 580
MsbA        R S    AD   V   G     GTH  LL     Y      Q                 L TI   IV VE  IV      G  A  QAH EK E D V ER ND EHR V QLHKM FG .......
NCgl0926    R S    AD   V   G     GTH  LL     Y      Q                Q V TI   QIV LD  VVG    N  CG  E V S A RD N E I T NT T R I E ETAQAQS...
MSMEG_5008   R S    AD   V   G     GTH  LL     Y      Q                SQ I TVI   QVV ID  RVVG    DT  ADCP  AEFA S TE D I I E AL AGEPR..
ML1114c     R S    AD   V   G     GTH  LL     Y      Q                TQ I TAA   QVI VD  KLAG    ES  ADC  AEFA S Q D S TI Y SFGGGVRDSQ
Rv1273c   R S AD  V G  GTH LL    Y Q  TQ I NAA QVI VD KIVG   ET ADCP AEFA S SQ N T T A SL ATVGGVG
Mb1304c     R S    AD   V   G     GTH  LL     Y      Q                TQ I NAA   QVI VD  KIVG    ET  ADCP  AEFA S SQ N T T A SL ATVGGVG
MMAR_4147   R S    AD   V   G     GTH  LL     Y      Q                TQ V TAA   QVI ID  RVVG    DS  IDCP  AEFA S TQ D A T V SV ADIRGVS
 Figure 2.2: Multiple sequence alignment of E. coli K12 MsbA and Mycobacterial and C. glutamicum orthologs 
of Rv1273c. Predicted end of MSD and beginning of NBD marked by black line, at residue 308. Similar sections 
highlighted by blue boxes, residues conserved in all proteins in white on red, residues in a position with 
conserved charge in red, gaps in the alignment indicated with “.”. Method 6.1.1. 
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Figure 2.3: Multiple sequence alignment of E. coli K12 MsbA and Mycobacterial and C. glutamicum orthologs 
of Rv1272c. Predicted end of MSD and beginning of NBD marked by black line, at residue 308. Similar sections 
highlighted by blue boxes, residues conserved in all proteins in white on red, residues in a position with 
conserved charge in red, gaps in the alignment noted as “.”. Method 6.1.1 
                1       10        20              30        
MsbA                                    RL                            K W T   IAP K IV AG V................MHND DLST Q FR WPT F AGL ...... ......
NCgl0925                                RL                            R A P K F PSA   L R I VI L VL L VLMSNTAGPRG SHQ DAA NQ AQN G K FGI GHD NTL F F A SVG T G
MSMEG_5009                               RL                            R L P RT DF GSA   AR LLPQR TLAVI LGV G IGVI........M RGA PQA LE R K I R AL L G IA G
ML1113c                                 RL                            M P RS DFY TI   LK LVPQR SL VI LGI G IGIIV...........VT ATA AT C C R Q RL T T T TA
MMAR_4148                               RL                            R RS DFWGSA   VK LAPQR SLAVI LGIVG IGVAV..VTAALNQ PRGGAP.APT R T R RR A TA
Rv1272c                                 RL                            R A P RS DFWGSA   VK LAPQR SIAVI LGIAG IGVIV..VTAPPGA PRA SPP NM R A R RL T TT
Mb1303c                                 RL                            R A P RS DFWGSA   VK LAPQR SIAVI LGIAG IGVIV..MTAPPGA PRA SPP NM R A R RL T TT
      40        50        60                             70 
MsbA         L                  G  K                     M            I ASD LL L   VL  VAL NA TFMLS KPL DD FG TDRS............. VW P........LV
NCgl0925     L                  G  K                     M            P L GKAT VVF G L K MP  AS IIA L A G N A MM  LVPGSGIDFW N E F S R A ED Q Q A KH Q S ED N EK
MSMEG_5009    L                  G  K                     M            P I GHATDLLFNGVIGR LP  LT QAV ARARGD T ADLLSG IVPGQGVDF AR E A E EA G F D G
ML1113c      L                  G  K                     M            P V GH TDLLFNGVIGR LP  IS QAVA AR RGD ADLLSG LVPGQGVDF AW T Q K T A T NAL N V
MMAR_4148    L                  G  K                     M            P I GHATDLLFNGVIGR LP  IT QAIA ARARGD T AELLSG V PGQGVDF AR Q A A G N F K T G
Rv1272c      L                  G  K                     M            P I GHATDLLFNGVIGR LP  IT QAVA ARARGD T ADLLSG VVPGQGVDF AR G G A S N F N A
Mb1303c      L                  G  K                     M            P I GHATDLLFNGVIGR LP  IT QAVA ARARGD T ADLLSG VVPGQGVDF AR G G A S N F N A
       80        90               100       110       120   
MsbA                 Y                         R          P S  D    G I IL I  V I WVS K VM M L HM M V FF S  GLM RG TS SSYC S G ........V T RR FG MG KQ T T
NCgl0925             Y                         R          P S  D    G L L LVI A LI LL QARMLN VQ M L EVEEKIHRL L YF R DAMI G G GS SLF RI SA HR M SIK
MSMEG_5009            Y                         R          P S  D    G V RTLALAL L LV LL WVQARLLNVTVQR MV L EV EKIHRL L YF QR EG G AA V T A A Q SR
ML1113c              Y                         R          P S  D    G V RTL LAL L LV LL WAQARLLNVTVQR M L DVEDKVHRL L Y  QR EG G S YT T I FA S C TR
MMAR_4148            Y                         R          P S  D    G V RTLALAL L LI LL W QARLLNVTVQR VA L DVE KLHRL L YF QR EV A AS I G T A A H GR
Rv1272c              Y                         R          P S  D    G V RTLALAL L LA LM WAQARLLNLTVQK MV L DVEDKVHRL L YF QR EE A AA I T R T GQ
Mb1303c              Y                         R          P S  D    G V RTLALAL L LA LM WAQARLLNLTVQK MV L DVEDKVHRL L YF QR EE A AA I T R T GQ
    130       140       150       160       170       180   
MsbA       LSR T D      S                     M   S  L        P       L   I  EQV S S L TVV ASII L IM   II IV A I IA RY S A S GA I REG G F FYY WQ S L L VS I
NCgl0925   LSR T D      S                     M   S  L        P       L   V N VDNI Q LQ TLSQAITSLLTVI VLVM I PL ALV LVSI VTIVVTG Q G FI A V
MSMEG_5009  LSR T D      S                     M   S  L        P       V   V N VDNIQN VSMTISQLLTSVLTV AVLVM I PL L VVTV ASL VTRF .T T FT W
ML1113c    LSR T D      S                     M   S  L        P       L   V N IDNLQS LSITLSQLLTSLLTVVAVLVV V PL ALV LLTV MSLLATRVS A
MMAR_4148  LSR T D      S                     M   S  L        P       L   V N IDNIQS LSMTISQLVT ILTVVAVL M I PL ALI LLTV LSLLVTRA S VW T
Rv1272c    LSR T D      S                     M   S  L        P       L   V N IDNLQS LSMTISQLVTSILTMVAVLAM I GL ALI LLTV LSLLVTRVS T
Mb1303c    LSR T D      S                     M   S  L        P       L   V N IDNLQS LSMTISQLVTSILTMVAVLAM I GL ALI LLTV LSLLVTRVS T
    190       200       210       220       230       240   
MsbA          R            G      E    G   V  FG        F             VVSK I NT  VT A     Q V  VS MFRN SKNMQ M Q TS QMLK HKE LI G E ETKR DK NR RLQGMK
NCgl0925      R            G      E    G   V  FG        F             VV  SQ LFA W QT LNARV ETYS V K   HQ V E  N VY A FGAS K EQ K I HA V KD Q A EEE QA K S
MSMEG_5009     R            G      E    G   V  FG        F             ITR SQ LFVA W NT RL AHL ETYS TI KT  H AA  LN E Q FGW P Q R A F RE AGK AE S TQ SS
ML1113c       R            G      E    G   V  FG        F             AI  SQ LFVA WTS  RLNAHI ETYS TV KT  HQ AA E  VN DVYQA FAQ Q Q A L T R Q RN N S S
MMAR_4148     R            G      E    G   V  FG        F             AITR SQ LFVA WTST RLNAHI ETYS TV KT  HQ AA E  LN DVYQA FGR H F A R Q HN D S
Rv1272c       R            G      E    G   V  FG        F             AITR SQ LFVA WTST RLNAHL ETYS TV KT  HQ AA E  LN DVYQA FGP H F A R R HE D G
Mb1303c       R            G      E    G   V  FG        F             AITR SQ LFVA WTST RLNAHL ETYS TV KT  HQ AA E  LN DVYQA FGP H F A R R HE D G
    250       260       270       280       290       300   
MsbA          S    P       L                    G              P      M A I  I I S A VL A V SLTA TITV S M  L SLVS S SD IQL A AL F Y ASFPS MD VF S IALMR K TN
NCgl0925      S    P       L                    G              P      AQFI GII  MFVGN YVAIAVVGGLQVASGSLSI VQ FIQY RQFT  LSQLM TM S G S S Q GS
MSMEG_5009     S    P       L                    G              P      AQF  GLVS ATMFIGN YVAVAVVGGLQVATGQITL SIQAFIQYVRQFN  LTQVAF S Q G
ML1113c       S    P       L                    G              P      AQF  GLVS ATMFI N YVVVAALGGLQVATG ITL NIQAFIQYVRQFN  LSQVAF S G H M G
MMAR_4148     S    P       L                    G              P      AQ L GLVQ AT FIGN YVAVAVMGGLQVATGQITL SVQAFIQYVRQFN  VSQVAL T G T A
Rv1272c       S    P       L                    G              P      AQFL GLVQ ATAFIGN YVAVAVAGGLQVATGQITL SIQAFIQYIRQFN  LSQLAG M G
Mb1303c       S    P       L                    G              P      AQFL GLVQ ATAFIGN YVAVAVAGGLQVATGQITL SIQAFIQYIRQFN  LSQLAG M G
    310       320       330                 340       350   
MsbA           Q G A     F   D                             EF  V F Y  V   M L IL E EG I ATG V   T  GNAQF R ACQT T SEQ KD KR..........V ER D RN T P
NCgl0925       Q G A     F   D                             EF  V F Y  M N L S V SAERV ELI E E DP V RL   S  A L D QDS AQP........NT AAGAN KD G SE
MSMEG_5009      Q G A     F   D                             EF  V F Y  MYN L S I SAERV DLL EE D A TGRV   S  PT TE SA SPR..........R DVR EH S V
ML1113c        Q G A     F   D                             EF  V F Y  IYN L S L SAERV DLL E EE DP V INGRV   S  T P LP MLALPPPH...GQ PR QQ A RT
MMAR_4148      Q G A     F   D                             EF  V F Y  MYN L S V SAERV ELL E EE DP A LTGRV   N  PS P AA ASALQPPVSRTGR PA ER A H
Rv1272c        Q G A     F   D                             EF  V F Y  MYN L S V SAERV DVL E EE EP L LTGRV   N  PA P SP EP..........E PN EH A L
Mb1303c        Q G A     F   D                             EF  V F Y  MYN L S V SAERV DVL E EE EP L LTGRV   N  PA P SP EP..........E PN EH A L
            1       10      20              30       
MsbA                                    RL                            K W T   IAP K IV AG V................MHND DLST Q FR WPT F AGL ...... ......
NCgl0925                                RL                            R A P K F PSA   L R I VI L VL L VLMSNTAGPRG SHQ DAA NQ AQN G K FGI GHD NTL F F A SVG T G
MSMEG_5009                               RL                            R L P RT DF GSA   AR LLPQR TLAVI LGV G IGVI........M RGA PQA LE R K I R AL L G IA G
ML1113c                                 RL                            M P RS DFY TI   LK LVPQR SL VI LGI G IGIIV...........VT ATA AT C C R Q RL T T T TA
MMAR_4148    RL     R RS DFWGSA VK LAPQR SLAVI LGIVG IGVAV..VTAALNQ PRGGAP.APT R T R RR A TA
Rv1272c                                 RL                            R A P RS DFWGSA   VK LAPQR SIAVI LGIAG IGVIV..VTAPPGA PRA SPP NM R A R RL T TT
Mb1303c                                 RL                            R A P RS DFWGSA   VK LAPQR SIAVI LGIAG IGVIV..MTAPPGA PRA SPP NM R A R RL T TT
      40        50        60                             70 
MsbA         L                  G  K                     M            I ASD LL L   VL  VAL NA TFMLS KPL DD FG TDRS............. VW P........LV
NCgl0925     L                  G  K                     M            P L GKAT VVF G L K MP  AS IIA L A G N A MM  LVPGSGIDFW N E F S R A ED Q Q A KH Q S ED N EK
MSMEG_5009    L                  G  K                     M            P I GHATDLLFNGVIGR LP  LT QAV ARARGD T ADLLSG IVPGQGVDF AR E A E EA G F D G
ML1113c      L                  G  K                     M            P V GH TDLLFNGVIGR LP  IS QAVA AR RGD ADLLSG LVPGQGVDF AW T Q K T A T NAL N V
MMAR_4148 L     G K  M   P I GHATDLLFNGVIGR LP IT QAIA ARARGD T AELLSG V PGQGVDF AR Q A A G N F K T G
Rv1272c      L                  G  K                     M            P I GHATDLLFNGVIGR LP  IT QAVA ARARGD T ADLLSG VVPGQGVDF AR G G A S N F N A
Mb1303c      L                  G  K                     M            P I GHATDLLFNGVIGR LP  IT QAVA ARARGD T ADLLSG VVPGQGVDF AR G G A S N F N A
       80        90               100       110       120   
MsbA                 Y                         R          P S  D    G I IL I  V I WVS K VM M L HM M V FF S  GLM RG TS SSYC S G ........V T RR FG MG KQ T T
NCgl0925             Y                         R          P S  D    G L L LVI A LI LL QARMLN VQ M L EVEEKIHRL L YF R DAMI G G GS SLF RI SA HR M SIK
MSMEG_5009            Y                         R          P S  D    G V RTLALAL L LV LL WVQARLLNVTVQR MV L EV EKIHRL L YF QR EG G AA V T A A Q SR
ML1113c              Y                         R          P S  D    G V RTL LAL L LV LL WAQARLLNVTVQR M L DVEDKVHRL L Y  QR EG G S YT T I FA S C TR
MMAR_4148   Y      R    P S D   GV RTLALAL L LI LL W QARLLNVTVQR VA L DVE KLHRL L YF QR EV A AS I G T A A H GR
Rv1272c              Y                         R          P S  D    G V RTLALAL L LA LM WAQARLLNLTVQK MV L DVEDKVHRL L YF QR EE A AA I T R T GQ
Mb1303c              Y                         R          P S  D    G V RTLALAL L LA LM WAQARLLNLTVQK MV L DVEDKVHRL L YF QR EE A AA I T R T GQ
    130       140       150       160       170       180   
MsbA       LSR T D      S                     M   S  L        P       L   I  EQV S S L TVV ASII L IM   II IV A I IA RY S A S GA I REG G F FYY WQ S L L VS I
NCgl0925   LSR T D      S                     M   S  L        P       L   V N VDNI Q LQ TLSQAITSLLTVI VLVM I PL ALV LVSI VTIVVTG Q G FI A V
MSMEG_5009  LSR T D      S                     M   S  L        P       V   V N VDNIQN VSMTISQLLTSVLTV AVLVM I PL L VVTV ASL VTRF .T T FT W
ML1113c    LSR T D      S                     M   S  L        P       L   V N IDNLQS LSITLSQLLTSLLTVVAVLVV V PL ALV LLTV MSLLATRVS A
MMAR_4148 LSR T D S       M S L   P    L V N IDNIQS LSMTISQLVT ILTVVAVL M I PL ALI LLTV LSLLVTRA S VW T
Rv1272c    LSR T D      S                     M   S  L        P       L   V N IDNLQS LSMTISQLVTSILTMVAVLAM I GL ALI LLTV LSLLVTRVS T
Mb1303c    LSR T D      S                     M   S  L        P       L   V N IDNLQS LSMTISQLVTSILTMVAVLAM I GL ALI LLTV LSLLVTRVS T
    190       200       210       220       230       240   
MsbA          R            G      E    G   V  FG        F             VVSK I NT  VT A     Q V  VS MFRN SKNMQ M Q TS QMLK HKE LI G E ETKR DK NR RLQGMK
NCgl0925      R            G      E    G   V  FG        F             VV  SQ LFA W QT LNARV ETYS V K   HQ V E  N VY A FGAS K EQ K I HA V KD Q A EEE QA K S
MSMEG_5009     R            G      E    G   V  FG        F             ITR SQ LFVA W NT RL AHL ETYS TI KT  H AA  LN E Q FGW P Q R A F RE AGK AE S TQ SS
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MSMEG_5009 ............................................................
ML1113c   RTSFIIAHHL TIRDAD ILVV  G IVE GSH  LLA RGAYY M  A                     P      H    AA K   Q   AK   R     R TQ ...........
MMAR_4148 RTSFIIAHRLSTIRDAD ILVV G IVE GTH ELLA RGAYY M A        Q    QA Q H  A N   A TR ...........
Rv1272c   RTSFIIAHRLSTIRDAD ILVV  G IVE GNH ELLA RGVYY M  A                            H    QT Q   R   A    R     Q TR ...........
Mb1303c   RTSFIIAHRLSTIRDAD ILVV  G IVE GNH ELLA RGVYY M  A                            H    QT Q   R   A    R     Q TR ...........
                                                            
MsbA      .....                                                   
NCgl0925  ADGDH                                                       
MSMEG_5009 .....                                                       
ML1113c   .....                                                       
MMAR_4148 .....
Rv1272c   .....                                                       
Mb1303c   .....                                                       
 
    360       370       380       390       400             
sbA   G A G G K T L RFY G I D DA NL I V S I I D LM GRDVP LN K PA K R S DE ..... H RE
NCgl0925 G A G G K T L RFY G I D DPLI L L V I I PT A T LVN IM D S L V I TDR NN D E RS N S T GETA A R
SMEG_5009 G A G G K T L RFY G I D DG PVI DL L EP V I PT A T LVN LM DV S I GV I ST E R T .....
L1113c  G A G G K T L RFY G I D DG PVI DLSM VEP S V I PT A T LVN LM D S LI GV I TT D D Q ..... T
MAR_4148 G T A VG G GK T L RFY G I D DG PVI DLSL EP V I PT A T VN LM EV S LV GI I TH H D R ..... T
Rv1272c  G A VG G GK T L RFY G I D DG PVI DLSL EP V I PT A T LVN LM EI S LI GV I ST R G R ..... A
Mb 303 G A VG G GK T L RFY G I D DG PVI DLSL EP V I PT A T LVN LM EI S LI GV I ST R G R ..... A
410       420       430       440       450       460        
sbA   LR V Q T NI Y R A A FN V L F V A E E I E ARM YA I M GY S NVH ND AN A YSR Q E MD K DN
NCgl0925 LR V Q L T NI Y R A A FR R GM D W F I D G PEAT E ML KA YVDR V LA ED T R E. S R PE
SMEG_5009 LR V Q L T NI Y R A A FVSR IG L D W F I D A G PDA D IE A A YVDR V TE A A Y DE. T H ....
L 11 LR V Q L T NI Y R A A FVSR SRIGM L D W F I E A G P AS D VME AKA YVDR V LHA A D A Q E. H S
MAR_4148 LR V Q L T NI Y R A A FVSR SHIGM L DTW F G I E A G PEAS DD I AKA YVDR V LR D S P. Q HM P
Rv1272c  LR V Q L T NI Y R A A FVSR SRIGM L DTW G I E A G PEAT DEIVE ARA VDR V TL GQ D A . H N P
Mb 303 LR V Q L T NI Y R A A FVSR SRIGM L DTW G I E A G PEAT DE VE ARA VDR V TLQ D A . H N P
470 480 490 500 510 520
sbA   T I G LS G RQ I IAR L ILILD A S LDT SE AI A ELD V GEN VL G Q R A L RD P A E QA LD QKN
NCgl0925 Y T E NLSVGERQ ITIARAFLA LLILDEATSSVDTR ELLI A DD V DD AM N R Q MSK RQ
SMEG_5009 .............................. ....................
L 11 Y T V DG NISAGEKQ I IAR FLA P LLILDEATSSI T E LI A D DQ R SG D R Q A TH LQ
MAR_4148 Y T I DG NISAGEKQ ITIARAFLA P LILDEATSS DTRTELLI RA EL DQ R SG S R Q A TA R
Rv1272c  Y T V DG ISVGEKQ ITIAR FLA P LILDEA SSVDTR ELLI RA EL DQ R SG G R Q Q MR RR
Mb 303 Y T V DG ISVGEKQ ITIARAFLA LLILDEATSSVDTR ELLI RA EL DQ R SG G R Q Q MR RR
530 540 550 560 570 580
sbA   RTS IAHRLSTI AD IVVV G IVE GTH DLL RGVY L ML EK E ED V R N EH AQ HK QFGQ.......
NCgl0925 RT FVIAHRLSTIRDA ILMM G IVE GNH ELM GAYW LA NL KD E Q R LE E YNSQFN P KEELQ
MSMEG_5009 ............................................................
L 11 RTSFIIAHHL TIRDAD ILVV G IVE GSH LL RGAYY M AP H A K Q AK R TQ ...........
MMAR_4148 RTSFIIAHRLSTIRDAD ILVV  G IVE GTH ELLA RGAYY M  A                            Q    QA Q   H   A    N     A TR ...........
Rv1272c   RTSFIIAHRLSTIRDAD ILVV  G IVE GNH ELLA RGVYY M  A                            H    QT Q   R   A    R     Q TR ...........
Mb1303c   RTSFIIAHRLSTIRDAD ILVV  G IVE GNH ELLA RGVYY M  A                            H    QT Q   R   A    R     Q TR ...........
                                                            
sbA   .....
NCgl0925 ADGDH        
MSMEG_5009 .....
L 11 .....
MMAR_4148 .....                                                       
Rv1272c   .....                                                       
Mb1303c   .....                                                       
 
360 370 380 390 400
sbA   G A G G K T L RFY G I D DA INL I V S IAS I D LM GRDVP LN K PA K R S DE ..... H RE
NCgl0925 G A VG G GK T RFY G I D DPLI L L V I PT A LVN IM DI S L V I TDR N D E R N S T GE AQ A R
SMEG_5009 G A VG G GK T RFY G I D DG PVI DLSL EP V PT LVN L DV S I GV I ST E D R T ..... A
ML 113 G T A VG G GK T RFY G I D DG PVI DLSMVVEP S V PT A LVN L DV S LI GV I TT D D Q .....
MAR_4148 G T A VG G GK T RFY G I D DG PVI DLSLVAEP S V PT A LVN L EV S LV GI I TH H D R .....
Rv1272c      G T A VG G GK T L  RFY G I D  DG PVI DLSLVAEP S V I PT A T LVN LM EI S  LI GV I ST R G R ..... A
Mb1303c                 G T A VG  G GK T   L  RFY    G I       D  D   G PVI DLSLVAEP S V I  PT A  T LVN LM   EI S  LI  GV I ST R G R ..... A
410 420 430 440 450 460
sbA   LR V Q T NI Y R FT N V L F V A E E I E ARM YA I MY S VH ND AN A YSR Q E MD K DN
NCgl0925 LR V Q L T NI Y R A A FM R SR GM L DTW F G D G PEA EEML KA Y DR LA ED T A R E. S R PE
SMEG_5009 LR V Q L T NI Y R A A FVSR IGM L D W F G D A G PDA DEVIE A A YVDR TE AS A Y DE. T H ....
ML 113 LR V Q L T NI Y R A A FVSR SRIGM L D W F G I A G P AS DEVME AKA YVDR TLHA A D A Q E. H SA
MAR_4148 LR V Q L T NI Y R A A FVSR S SHIGM L D W F G I A G PEAS DDII AKA YVDR LD S P. Q HM PA
Rv1272c L V Q T NI Y R A A FSR S SRIGM L D W Y G I E A G PEAT DEIV RA VD TLD A T H N PA
Mb13 3c LR V Q L T NI Y R A FVSR S SRIGM L DTW Y G I E G PEAT DEI E ARA VDR TL GQ D A T H N PA
470 480 490 500 510 520
sbA      T I G LS G RQ I IARA L ILILDEAT LDT SE AI A ELLD V EN VL G Q R A L RDSP A E R QA LD QKN
NCgl0925 Y T L E NLSVGERQLITIAR FLA P LLILDEATSSVDTRTELLI RA L DD V DD AM N R Q MSK RQ
SMEG_5009 ............................................................
ML 113 Y T V DG NISAGEKQLITIARAFLA P LLILDEAT SIDTRTEALI RA DL DR SG D R Q A TH Q
MAR_4148 Y T I DG NISAGEKQLITIARAFLA P LLILDEAT SVDTRTELLI RA EL DR SG S R Q A TA RR
Rv1272c   Y T V  DG SISVGEKQLITIARAFLA P LLILDEATSSVDTRTELLI RA  EL  D Q R SG  G                  R Q                   Q  MR  RR 
Mb1303c   Y T V  DG SISVGEKQLITIARAFLA P LLILDEATSSVDTRTELLI RA  EL  D Q R SG  G                  R Q                   Q  MR  RR 
530 540 550 560 570 580
sbA      RTS VIAHRL TI A IVVV G IVE GTH DLL RGVY L ML EK E D V N EH AQ HK Q GQ.......
NCgl0925 RT FVIAHRL TI DA ILMM G IVE GNH ELMA GAYW LA N KD E Q R LE E YNSQ NAPAKEELQ
SMEG_5009 ............................................................
ML 113 RTSFIIAHHL TI DA ILVV G IV GSH LLA RGAYY M AP H AA K Q AK R R TQ ...........
MAR_4148 RTSFIIAHRL TI DA ILVV G IV GTH ELLA RGAYY M AQ QA Q H A N A T ...........
Rv1272c   RTSFIIAHRLSTIRDAD ILVV  G IVE GNH ELLA RGVYY M  A                            H    QT Q   R   A    R     Q TR ...........
Mb1303c   RTSFIIAHRLSTIRDAD ILVV  G IVE GNH ELLA RGVYY M  A                            H    QT Q   R   A    R     Q TR ...........
                                                            
MsbA      .....                                                       
NCgl0925  ADGDH                                                       
MSMEG_5009 .....                                                       
ML1113c   .....                                                       
MMAR_4148 .....
Rv1272c   .....                                                       
Mb1303c   .....                                                       
 
36 37 38 39 40
sbA   G T A VG G GK T L RFY G I D DA INL I V S IAS I DI LM G LRDVP LN K PA K R S DE ..... H RE
NCgl0925 G A VG G GK T L RFY G I D DPLI L L V I I PT A T LVN IM DI S L V I TDR NN D E RS N S T GETAQ A R
MSMEG_5009 G A VG G GK T L RFY G I D DG PVI DLSL EP V I PT A T LVN LM DV S I GV I ST E D R T ..... A
L 11 G A VG G GK T L RFY G I D DG PVI DLSM VEP V I PT A T LVN LM DV S LI GV I TT D D Q ..... T
MAR_4148 G T VG G K T L R G D DG PV DL LVAEP V I PT A T LVN L EV S LV GI I TH H D R ..... T
Rv1272c G T A VG G GK T R Y G I D DG PVI DLSLVAEP S V I PT A LVN L EI S LI GV I ST R G R ..... A
b1303c   G T A VG G GK T RFY G I D DG PVI DLSLVAEP S V PT A LVN L EI S LI GV I ST R G R ..... A
410 420 430 440 450 460
sbA   LR V Q L T NI Y R A A FN V L F V A E E E ARM YA I MY LA Q S NVH ND N A QYSR Q E MD NK DN
NCgl0925 LR V Q L T NI Y R A A FM R SR GM L DTW F I D G PEAT EEML KA YVDR V L GA ED T A R E. S R PE
MSMEG_5009 LR V Q L T NI Y R A A FVSR IGM L D W F I D A G PDA D IE A A YVDR V TE A A Y DE. T H ....
L 11 LR V Q L T NI Y R A A FVSR SRIGM L D W F I E A G P AS D VME AKA YVDR V TLHA A D A Q E. H S
MAR_4148 L V Q L T NI Y R A A FSR S SHIGM L DTW F I E A G PEAS DD I AKA Y DR V L GR D S P. Q HM P
Rv1272c LR V Q L T NI Y R A A FSR S SRIGM L D W Y G I A G PEAT DEIVE ARA VDR TLQ D A T. H N PA
b1303c   LR V Q L T NI Y R FVSR S SRIGM L D W Y G I A G PEA DEIVE ARA VDR V TLQ D A T. H N PA
470       480       490       500       510       520        
sbA   T G LS RQ IARA L ILI ATS LDT SE AI A ELLD EN VL G Q R L RDSP A E QA LD QKN
NCgl 925 Y T E NLSV ERQ TIAR FLA P LI D A SVDT ELLI A DD D AM N R Q MSK RQ
SMEG_5009 .............................. ....................
L 11 Y T V DG NISAGEKQ ITIAR FLA LLILDEAT SIDTR E LI A D DR SG D R Q A TH LQ
MAR_4148 Y T I DG NISAGEKQ ITIAR FLA P LLILDEAT S DTRTELLI A E DR SG S R Q A TA RR
Rv 272 Y T V DG SISVGEKQLITIARAFLA P LLILDEAT SVDTRTELLI RA EL DR SG G R Q Q MR RR
Mb1303c   Y T V  DG SISVGEKQLITIARAFLA P LLILDEATSSVDTRTELLI RA  EL  D Q R SG  G                  R Q                   Q  MR  RR 
530       540       550       560       570       580        
sbA   RTS VIAH L TI A VVV G IV TH DLL RG Y L MEK E D V R N EH Q HK Q GQ
NCgl 925 RT F IAH L TI DA ILMM G IVE NH ELM G YW LA N KD Q R L E YNSQ N PAKEELQ
SMEG_5009 .................................... .....................
L 113 RTSFIIAHHL TI DAD ILVV G IVE GSH LL RG YY M AP H A K Q AK R TQ ...........
MAR_4148 RTSFIIAHRL TI DA ILVV G IV GTH ELL RGAYY M AQA Q H A N A T ...........
Rv 272 RTSFIIAHRL TI DA ILVV G IV GNH ELLA RGVYY M AH QT Q R A R Q T ...........
Mb1303c   RTSFIIAHRLSTIRDAD ILVV  G IVE GNH ELLA RGVYY M  A                            H    QT Q   R   A    R     Q TR ...........
                                                            





Rv1272c   .....
Mb1303c   .....                                                       
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Table 2.1: Heatmap of sequence identity of Mycobacterial and Corynebacterial protein sequences against 
MsbA and predicted Mtb MsbA homologs. Showing homology through all tested mycobacterial species and 
into C. glutamicum. Rv corresponds to gene expressed in Mtb, Mb corresponds to gene expressed in M. bovis, 
MMAR_ corresponds to gene expressed in M. marinum, MSMEG_ corresponds to gene expressed in M. 
smegmatis, and NCgl corresponds to gene expressed in C. glutamicum. Identity, residues conserved at each 
position compared to the reference sequence. Positive, residues with conserved physiological properties. Cells 
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Using BLAST analysis of the primary protein structure of E. coli K12 MsbA against the Mtb 
non-redundant protein database (Method 6.1), resulted in the selection of two proteins for 
further study (Rv1272c and Rv1273c), as they have high sequence identity to MsbA  and the 
likelihood that they comprise a single complete heterodimeric ABC-transporter, due to the 
genomic location (Braibant et al., 2000). Both selected genes were tested to determine the 
degree of conservation across slow and fast-growing mycobacterial species’ as well as both 
infectious and non-infectious species as well as C. glutamicum (Figures 2.2, 2.3). The genetic 
synteny across a selection of various mycobacterial species provides additional evidence to 
support a common function, as the surrounding genes are also generally conserved, particularly 
notable in M. leprae which is regarded as a minimal mycobacterial genome (Figures 2.2, 2.3, 
2.5) (Cole et al., 2001). Sequence identity of the identified ABC-transporters tabulated, 
compared to MsbA, or Mtb identified homologs is shown in Table 2.1. 
 
Sequences of predicted MsbA homologs were searched for conserved ABC-transporter motifs 
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Figure 2.4: Predicted membrane topology model of Rv1272c and Rv1273c. Residue numbers for first amino acid 
inserted into the membrane and first amino acid external to the membrane noted. First residues of the Walker 
A and B motifs annotated. Transmambrane predictions generated from TMHMM and Expasy TMPred, Appendix 
1. 
Chapter 2:                            Characterization of a PIM transporter system in C. glutamicum 
 67 
Markov model using both Transmembrane helix Hidden Markov Model (TMHMM), and 
EXpasy TMPred (Appendix 1) which predict the location of transmembrane helices from the 
primary protein structure. Leading to the prediction of six transmembrane helices, consistent 
with the four to eight transmembrane helices for a membrane spanning domain, required for 
the formation of a pore through the membrane upon formation of a dimer (Figure 2.4). The 
conservation of the ABC-transporter motifs, taken with the predicted conserved membrane 
topological structure lead to prediction that Rv1272c and Rv1273c form a functional 
transporter responsible for the translocation of PIMs across the cytoplasmic membrane.  
 
The identification of Rv1272c and Rv1273c as potential lipid transporters, contradicts the 
prediction of Braibant et al. in 2000, where Rv1272c and Rv1273c are predicted to function as 
Figure 2.5: Genetic synteny of mycobacterial genes predicted to be identified as putative PIM transporters. 
Conservation of the genes surrounding predicted PIM transporters through various mycobacterial species, 
including M. leprae, a mycobacterial genome regarded as the minimal mycobacterial genome (Cole et al., 2001), 
as well as conservation the neighbouring genes LprB and LprC suggest a conservation of this region of the 
genome, and potentially a conserved function.  
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a multidrug efflux pump. However, in the past 20 years since the publication of these 
predictions there has been no corroborating evidence for this prediction. Due to the limited 
functional dataset available to Braibant et al. 2000 at the time of prediction, it is likely that the 
most similar characterised transporter at the time was an antibiotic efflux pump.  
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Figure 2.6: Primary protein structure of predicted Mtb H37Rv MsbA homologs, Rv1272c and Rv1273c. Aligned 
sequences annotated with conserved consensus sequences present in nucleotide binding domains of ABC-
transporters Rv1272c, and Rv1273c. A-loop, Walker A, ABC signature, Walker B, H-loop motif sequences 
underlined. Showing that essential conserved regions are present in both Rv1272c and Rv1273c, alongside six 
transmembrane helices contained within the membrane spanning domain (MSD). 
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2.2.2: Generation of M. smegmatisDMSMEG_5008- 5009 double deletion mutant: 
 
Attempts to generate a M. smegmatisDMSMEG_5008- 5009 double deletion mutant were 
unsuccessful (Method 6. 3.1), with no mutants able to be generated with both MSMEG_5008 
and MSMEG_5009 deleted. The inability to generate this double deletion mutant suggests that 
these genes are either essential individually or become essential upon deletion of the other.  
 
2.2.3: Generation of C. glutamicum∆NCgl0925- 0926 double deletion mutant in C. 
glutamicum: 
 
Generation of a C. glutamicum∆NCgl0925- 0926 double deletion mutant from the parental C. 
glutamicum ATCC13032 strain was conducted by J. Marienhagen’s group in Julich (Method 
6.3.2). We hypothesised that the generation of a double deletion mutant of the C. glutamicum 
orthologs (NCgl0925 and NCgl0926) would not be lethal, due to the increased tolerance of cell 
wall mutations.  
 
Chapter 2:                            Characterization of a PIM transporter system in C. glutamicum 
 71 
The C. glutamicum∆NCgl0925- 0926 deletion mutant was generated using pk19mobsacB- 
∆NCgl0925- 0926 plasmid (Figure 2.7 A), with homologous recombination used to replace 
selected genes with non-coding DNA. The deletion of NCgl0925 and NCgl0926 confirmed 
using PCR (Figure 2.7 B). Analysis of the PCR product in the shows a reduction in the size of 
the product in the C. glutamicum∆NCgl0925- 0926 double deletion mutant, from ~4 kb to ~1 
kb, which corresponds to the deletion of NCgl0925 and NCgl0926.  
A B
Figure 2.7: Generation of C. glutamicum∆NCgl0925- 0926 double deletion mutant. A) Schematic of generation 
of C. glutamicum∆NCgl0925- 0926 double deletion mutant, B) Agarose gel electrophoresis of PCR of NCgl0925- 
0926 confirming the of deletion of NCgl0925-0926. Comparison of the PCR product between the WT C. 
glutamicum and the C. glutamicum∆NCgl0925- 0926 double deletion mutant shows a shift in the size of the PCR 
product, consistent with the deletion of NCgl0925 and NCgl0926. Figure made by J. Marienhagen’s group 
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2.2.4: Growth rate analysis in WT C. glutamicum and C. glutamicum∆NCgl0925- 0926 
double deletion mutant:  
Figure 2.8: Growth rate analysis of C. glutamicum strains in rich media as measured by OD600. Expression of 
complements induced with 1mM IPTG, n=3. Use of Bonferroni corrected ANOVA to analyse the OD600 readings 
throughout the experiment show no significant change (q > 0.05) between the deletion mutant and the WT C. 
glutamicum strain. Bonferroni corrected ANOVA of strains expressing the pEKEx3 plasmid does result in a 
reduced growth rate during throughout the experiment (q < 0.05), however there is no significant difference 
between the level of growth attained at 24 hours post inoculation, between any of the strains containing the 
pEKEx3 plasmid (pempty, pNCgl0925-6, and  pRv1272c-3c) and the WT C. glutamicum or C. glutamicum∆NCgl0925- 0926 
double deletion mutant strain, nor is there a significant difference between the strains restoring the native 
genes, or the homologous Mtb genes  and the strain containing only the unmodified vector (q > 0.05). Error 
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Initial testing of the deletion mutants to determine the effect of gene loss on growth rate 
phenotype was carried out (Figure 2.8, Method 6.10), as the deletion or disruption of genes 
involved in certain pathways often results in a growth defect (Alderwick et al., 2005). In order 
to induce the expression of the complementing genes on the pEKEx3 plasmid the growth media 
was supplemented with 0.5 mM IPTG. 
 
Analysis of the OD600 values, using Bonferroni corrected ANOVA, throughout all timepoints 
showed that the WT C. glutamicum and the C. glutamicum∆NCgl0925-0926 double mutant 
strain showed no significant change in the growth at any time point (q > 0.05), while C. 
glutamicum∆NCgl0925-0926 double mutant strains expressing pEKEx3 plasmids with or 
without gene inserts showed a statistically significant reduction in growth when compared to 
either the WT C. glutamicum or C. glutamicum∆NCgl0925-0926 double mutant strain at all 
time points from 4 hours post-inoculation, except for 24 hours post-inoculation, when using an 
Bonferroni-corrected ANOVA (q > 0.05) at each timepoint.  
 
There is no significant difference between any of the three strains containing the empty vector, 
or either of the plasmids recombinantly expressing either the deleted NCgl0925 and NCgl0926, 
or the Mtb homologs, Rv1272c and Rv1273c. This implies that the reduction in the growth rate 
is likely due to the fitness cost of either maintaining a plasmid or caused by the addition of 
antibiotic into the media to maintain the plasmid. This shows that in culture these genes are 
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2.2.5: Cell surface permeability characterization of WT C. glutamicum and C. 
glutamicum∆NCgl0925- 0926 double deletion mutant:  
Figure 2.9: Cell surface permeability of C. glutamicum strains to DPH. Data normalised to show fold change 
from WT C. glutamicum strain. Bonferroni corrected ANOVA of data showed significant increase in permeability 
from the WT C. glutamicum in both the C. glutamicum∆NCgl0925- 0926 double deletion mutant, and C. 
glutamicum∆NCgl0925- 0926 pEKEx3 strain (pempty), while the C. glutamicum∆NCgl0925- 0926 pEKEx3-
NCgl0925- 0926 (pNCgl0925-6), C. glutamicum∆NCgl0925- 6 pEKEx3-Rv1272c- 1273c (pRv1272c-3c) showed no 
significant change. Polymyxin B used as a positive control to increase permeability. Differences between strains 
that were statistically significant to the WT C. glutamicum (q< 0.01) marked by “*”.Error bars: Standard 
deviation, n= 4. 
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Cell surface permeability is affected by the lipid composition of the cell envelope, our 
prediction of the function of NCgl0925 and NCgl0926 as being involved in the transport of 
PIMs to the outer leaflet of the cytoplasmic membrane, lead to the prediction of a change in 
cell permeability in the deletion mutants.  
 
Using Bonferroni-corrected ANOVA to assess the change in permeability of the cell surface 
to 1, 6- diphenyl- hexa- 1, 3, 5- triene (DPH, Method 6.11), resulted in a statistically significant 
increase in permeability of the both the C. glutamicum∆NCgl0925- 0926, and the C. 
glutamicum∆NCgl0925-0926 pEKEx3 strains when compared to the WT (q > 0.01) (Figure 
2.9). The complementation of either the deleted NCgl0925 and NCgl0926, or Rv1272c and 
Rv1273c, restored the basal level (including at a reduced stringency of q > 0.05). The strains 
recombinantly expressing either NCgl0925 and NCgl0926 or Rv1272c and Rv1273c, both 
showed a significant difference to the ∆NCgl0925-0926 double mutant strain.  
 
The loss of NCgl0925 and NCgl0926 results in a significant increase in the permeability of the 
surface of the cell, in line with the hypothesis that these genes are involved in the maintenance 
of the cell surface, possibly through the transport of lipids across the cytoplasmic membrane. 
Complementation of the C. glutamicum∆NCgl0925- NCgl0926 strain with either: NCgl0925 
and NCgl0926 or Rv1272c and Rv1273c restored the wild type permeability phenotype, 
showing that the cause of the permeability change is due to the loss of NCgl0925 and NCgl0926 
rather than the result of an off target effect, as well as supporting the prediction of a shared 
function in both C. glutamicum and Mtb.  
 
 
Chapter 2:                            Characterization of a PIM transporter system in C. glutamicum 
 76 
2.2.6: Antibiotic susceptibility screening of WT C. glutamicum and C. 
glutamicum∆NCgl0925- 0926 double deletion mutant:  
 
As Rv1272c and Rv1273c are predicted to function as an antibiotic efflux pump, we tested the 
efficacy of various antibiotics against WT C. glutamicum, and the C. glutamicum∆NCgl0925-
0926 double deletion mutant (Method 6.19) to characterise the effect of loss of NCgl0925 and 
NCgl0926 on the bacterial survival in the presence of various antibiotics (Braibant et al., 2000; 
Wang et al., 2010).  
 
Of the antibiotics selected affecting both intra- and extra- cellular functions to determine if the 
change in the permeability of the cell is responsible for any changes in the tolerance of C. 
glutamicum strains to antibiotics.  
 
 
Determination of the MIC99 for WT C. glutamicum, C. glutamicum∆NCgl0925- 0926, C. 
glutamicum∆NCgl0925- 0926 pEKEx3, C. glutamicum∆NCgl0925- 0926 pEKEx3- 
NCgl0925- 0926, and C. glutamicum∆NCgl0925- 0926 pEKEx3- rv1272c-1273c, showed no 
detectable changes in MIC99 (Table 2.3). The lack of changes in tolerance to antibiotics 
Table 2.2: Antibiotic susceptibility screening of C. glutamicum strains to antibiotics. Showing the MIC99 values 
of various antibiotics against WT C. glutamicum, C. glutamicum∆NCgl0925- 0926, C. glutamicum∆NCgl0925- 0926 
pEKEx3, C. glutamicum∆NCgl0925- 0926 pEKEx3- NCgl0925- 0926, C. glutamicum∆NCgl0925- 0926 pEKEx3- Rv1272c- 
1273c.   
Chloramphenicol Amoxicillin Ampicillin Rifampicin Ethambutol Polymyxin B

















7.813 0.977 0.977 >0.488
3.906<500>0.4880.9770.9777.813
7.813 0.977
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between the WT C. glutamicum, and the C. glutamicum∆NCgl0925- 0926 double deletion 
mutant suggests that the function of these genes is not, as predicted by Braibant et al 2000, an 
antibiotic efflux pump. This, while not supporting the hypothesis that Rv1272c and Rv1273c 
function as the PIM transporter, does suggest that the annotation of these genes was incorrect.  
 
2.2.7: Characterization of the free lipid phenotype of WT C. glutamicum and C. 
glutamicum∆NCgl0925- 0926 double deletion mutant: 
Figure 2.10: TLC apolar outside lipid extraction from C. glutamicum strains. Showing the loss of a sugar 
containing lipid in the C. glutamicum∆NCgl0925- 0926 double deletion mutant, when compared to WT C. 
glutamicum. Solvent system- 65: 25: 0.5: 3.6 chloroform: methanol: 12 M ammonium hydroxide: water. TMcM- 
trehalose monocorynemycolate.  
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The increase in the cell surface permeability implied that the deletion of NCgl0925 and 
NCgl0926 results in a change in the lipid composition of the C. glutamicum cell surface. 
Therefore, characterisation of the overall lipid composition of the C. glutamicum∆NCgl0925-
0926 double deletion mutant using the standard polar-apolar lipid extraction procedure was 
used to analyse the lipid composition (Singh et al., 2016).  
  
Figure 2.11: TLC analysis of apolar inside lipid extraction fraction from C. glutamicum strains. Showing loss of 
unknown sugar containing lipid in the C. glutamicum∆NCgl0925- 0926 double deletion mutant when compared 
to the WT C. glutamicum strain. MPA staining for lipids, α-napthol staining for sugars. Solvent system- 30: 8: 1 
chloroform: methanol: water. FMA- free mycolic acid, TMcM-trehalose monocorynemycolate, CL- cardiolipin, 
PI- phosphatidylinositol. 
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TLC analysis of the apolar outside lipid fractions (Method 6.12.1) extracted from WT C. 
glutamium and the C. glutamicum∆NCgl0925-0926 double deletion mutant strain shows the 
depletion of a free lipid, staining positive for both fatty acids (TLC stained with MPA), and 
sugars (TLC stained with α-napthol, labelled unknown lipid in Figure 2.10).  
 
Similarly, TLC analysis of the apolar inside lipid fractions (Method 6.12.1) extracted from both 
the WT C. glutamium and the C. glutamicum∆NCgl0925- 0926 double deletion mutant showed 
the same phenotype, with the loss of a lipid staining positive for both fatty acids and sugars 
(Figure 2.11). 
Figure 2.12: TLC analysis of polar lipid extraction fraction from C. glutamicum strains. Showing slight depletion 
of an unknown sugar containing lipid. MPA staining for lipids, α-napthol staining for sugars. Solvent system- 30: 
8: 1 chloroform: methanol: water. TMcM-trehalose monocorynemycolate, CL- cardiolipin, PI- 
phosphatidylinositol. 
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TLC analysis of the remaining extractable lipids (Method 6.12.1) from C. glutamicum strains 
resulted in the determination of a similar phenotype to the apolar inside and apolar outside 
fractions, with a depletion, but crucially not loss, of the same sugar containing lipid in the C. 
glutamicum∆NCgl0925-0926 double deletion mutant, that was absent in the previously 
extracted fractions (Figure 2.12).  
 
Initial characterisation of the lipid characterisation of the WT C. glutamicum and the C. 
glutamicum∆NCgl0925-0926 mutant identified a loss of a sugar containing lipid. The most 
notable reductions were in the lipid fractions composed of mostly outer membrane lipids 
(Figures 2.10, 2.11), consistent with a PIM species. However, the nature of the extraction 
method does not lend itself to the determination of the precise location of the depleted lipid.  
 
2.2.8: Characterization of the cell wall bound lipid phenotype of WT C. glutamicum, and 
C. glutamicum∆NCgl0925- 0926:  
 
To determine if the loss of an extractable free lipid from the bacteria also resulted in an 
alteration of the cell wall bound lipids, lipids were extracted from C. glutamicum cells which 
had previously been treated to remove all non-covalently bound lipids and analysed by TLC.  
 
Cell wall bound lipid extractions (Method 6.12.4) show no significant changes in the cell wall 
bound lipids (Figure 2.13), suggesting that the depleted lipid does not serve as a source of fatty 
acids, or corynemycolic acids for attachment to the cell wall. We did not expect to see changes 
in the lipid composition of the cell wall core, as there is no published evidence suggesting that 
the PIM species act as a source of fatty acids for attachment to the cell wall. 
 










Figure 2.13: TLC analysis of C. glutamicum cell wall bound lipid extraction. No significant change in the cell wall 
bound lipids, detectable between the WT C. glutamicum and C. glutamicum∆NCgl0925- 0926 double deletion 
mutant. Solvent system: 95: 5 Petroleum ether 60-80: acetone, lipids visualised with MPA. 
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2.2.9: Characterization of the outer and inner membrane lipid phenotype of WT C. 
glutamicum, and C. glutamicum∆NCgl0925- 0926: 
Upon observation of a lipid depletion phenotype in the polar-apolar lipid extraction of the C. 
glutamicum∆NCgl0925- 0926 double deletion strain, determination of the location of the lipid 
was essential for the full characterisation of the effect of the loss of NCgl0925 and NCgl0926 
Figure 2.14: TLC analysis of outer membrane lipid extraction of C. glutamicum strains. Showing depletion in 
the level of unknown, sugar containing lipid present in the outer membrane in the WT C. glutamicum but 
substantially reduced in the C. glutamicum∆NCgl0925- 0926 double deletion mutant. MPA staining for lipids, α-
napthol staining for sugars. Solvent system: direction 1- 30: 8: 1 chloroform: methanol: water, direction 2- 70: 
30: 1 hexane: diethyl ether: acetic acid. FMA- free mycolic acid, FFA- free fatty acid, TMcM- trehalose 
monocorynemycolate, CL- cardiolipin, PI- phosphatidylinositol. 
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on the composition of the outer membrane. If NCgl0925 and NCgl0926 form the transporter 
for the PIMs (which are found in both the outer and inner membrane), a selective extraction of 
the C. glutamicum outer membrane is essential to fully characterise the effect of the gene loss. 
   
Figure 2.15: TLC analysis of inner membrane lipid extraction from C. glutamicum strains. No significant 
changes to the lipid composition were detectable between the inner membrane extraction of the WT and the 
C. glutamicum∆NCgl0925- 0926 double deletion mutant. MPA staining for lipids, α-napthol staining for sugars.  
Solvent system: direction 1- 30: 8: 1 chloroform: methanol: water, direction 2- 70: 30: 1 hexane: diethyl ether: 
acetic acid. FMA- free mycolic acid, FFA- free fatty acid, TMcM- trehalose monocorynemycolate, CL- cardiolipin, 
PI- phosphatidylinositol. 
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Analysis of the separated outer and inner membrane fractions (Method 6.12.2) by TLC showed 
loss of the same unknown sugar containing lipid in the outer membrane fraction (Figure2.14), 
while maintaining equivalent levels in the inner membrane fraction (Figure 2.15).  
 
This depletion of the unknown lipid in the outer membrane suggests that the loss of the lipid is 
in the outer, mycomembrane, where the loss of a transporter for a lipid found in both the inner 
and outer membrane is likely to be determined leads to further support of the hypothesis that 
NCgl0925 and NCgl0926 are responsible for the export of a sugar containing phospholipid in 
C. glutamicum. 
 
Some contamination of the outer membrane fraction was observed, through the detection of a 
carotenoid species in the outer membrane fraction, a lipid known to be only present in the inner 
membrane (Bansal-Mutalik and Nikaido, 2011). As there is detectable contamination of the 
outer membrane fraction with inner membrane lipids, the detection of some unknown lipid is 
likely to be caused by contamination of the inner membrane lipids in the outer membrane 
fraction.  
 
2.2.10: Surface lipid phenotype characterization of WT C. glutamicum, and C. 
glutamicum∆NCgl0925- 0926:  
 
To determine the location of the depleted lipid, reverse micellar extraction of cell surface lipids 
was used to selectively remove the surface lipids without disturbing the inner membrane. 
Reverse micelles are functionally distinct from micelles as the solvent system used for 
solubilising the detergent is an apolar one, such as heptane, rather than a polar solvent such as 
water, resulting in the hydrophobic regions of the molecule are exposed, rather than the polar 
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region. Sodium docusate (AOT) has been studied as a method for the selective extraction of 
the outer membrane lipids (Bansal-Mutalik and Nikaido, 2014, 2011). This extraction method 







Figure 2.16: Polar characteristics of standard and reverse micelles. A) Standard sodium docusate micelles, 
where the apolar regions of an amphipathic molecule are sequestered from the polar solvent. B) Reverse sodium 
docusate micelles, where the polar regions of an amphipathic molecule are sequestered from the apolar solvent. 
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Initial characterisation of the functionality of the lipid extraction method was used to separate 
the lipids extractable by solvent and those extractable by the action of the reverse micelles 
(Figure 2.17).  
   
 
Extraction of the surface lipids (Method 6.12.3) shows a depletion in the same sugar containing 
lipid identified in both the polar- apolar lipid extraction, and the inner membrane- outer 
membrane lipid extraction, confirming that the lipid lost is present on the surface of then cell.  
To confirm the restoration of functionality of the complementation vectors reverse micellar 
extraction was repeated on the complemented C. glutamicum∆NCgl0925- 0926 double 
deletion mutant strains (Figure 2.18).  
Figure 2.17:  TLC analysis of lipids extractable from C. glutamicum with heptane. TLCs showing partial 
extraction of the outer membrane by use of extraction method not containing AOT. A) lipids extracted from the 
WT C. glutamicum, B) lipids extracted from the C. glutamicum∆NCgl0925- 0926 double deletion mutant. Solvent 
system: direction 1- 30: 8: 1 chloroform: methanol: water, direction 2- 70: 30: 1 hexane: diethyl ether: acetic 
acid. FMA- free mycolic acid, FFA- free fatty acid, TMcM- trehalose monocorynemycolate.  
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Analysis surface lipid composition of the strains recombinantly expressing either the 
corynebacterial genes deleted, or the Mtb orthologs resulting in restoration of WT lipid 
composition (Figure 2.18). This confirms that the restoration of NCgl0925 and NCgl0926, or 
complementation with Rv1272c and Rv1273c, results in a reversion to the WT lipid phenotype. 
Further supporting the hypothesis that the function of NCgl0925 and NCgl0926 is conserved 
into mycobacterial species.  
 
The significant difference between the reverse micellar lipid extraction and the outer membrane 
lipid extract is that there is a carotinoid species that runs similarly to CL, in the outer membrane 
extraction method, which is not detectable in the reverse micellar extraction, which shows that 
the extraction method is less disruptive to the cell than the water saturated butanol extraction 
of the outer membrane extraction protocol.  
 
2.2.11: Purification of lipid depleted from surface lipid extractions in C. 
glutamicum∆NCgl0925- 0926 from WT C. glutamicum:  
 
While the extraction of surface lipids has shown that deletion of NCgl0925 and Ncgl0926 
results in the depletion of an unknown lipid on the C. glutamicum cell surface, determining the 
identity of the lipid is essential for assigning function to these proteins. In order to determine 
the identity of the lipid depleted on the cell surface of the C. glutamicum∆NCgl0925-0926 
mutant, purified lipid extracted from WT C. glutamicum was used. Purification of the depleted 
lipid by preparative TLC yielded an excess of contaminating AOT, due to the similar retention 
factors (Rf, the distance molecules move on a TLC plate when run in a solvent system system) 
values in previously defined systems, and relative abundance of the lipid to be purified from 
other extraction methods making analysis post extraction unreliable. The similar migration 
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patterns of the unknown lipid and AOT suggested that the lipid is, as predicted, a PIM as they 
have been seen to have similar migration patterns in the solvent system used (Figure 2.19, 
AOT) (Bansal-Mutalik and Nikaido, 2011). 
 
Therefore, use of a silica column (Method 6.13), washed with a stepwise chloroform: methanol 
gradient for gradual removal of lipid contaminants from large scale reverse micellar extraction 
was used for lipid purification from reverse micellar extracted lipids. Yielding 3 mg of pure 
lipid with no detectable contaminating AOT by TLC stained with α-napthol (Figure 2.19).  
Figure 2.19: TLC analysis of lipid purification by silica column. Showing gradual elution of lipids from the silica 
column, and the removal of the co-migrating contaminating AOT. Solvent system- 30:8:1 chloroform: methanol: 
water, visualized using α-napthol. TMcM- trehalose corynemycolate. 
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2.2.12: Analysis of surface lipid extracts and purified lipid from extractions from WT C. 
glutamicum, and C. glutamicum∆NCgl0925- 0926:  
 
Crude and purified lipid samples were analysed by direct infusion electrospray mass 
spectrometry (Method 6.15), in both positive and negative flight modes to determine changes 
in the lipid composition of the crude extracts and the identity of the purified lipid, with minimal 
fragmentation. Data obtained from the crude and purified lipid samples compared within a 
single experimental setup between samples compared in Figure 2.20.  
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Comparison of the crude reverse micellar extractions from reverse micellar lipid extractions 
from WT C. glutamicum, C. glutamicum∆NCgl0925- 0926 double deletion mutant, and 
purified lipid seen to be depleted in the C. glutamicum∆NCgl0925- 0926 double deletion 
Figure 2.20: Direct infusion electrospray mass spectrometry of lipid samples. Lipid samples diluted in 2: 1 7.5 
mM ammonium acetate: chloroform, in positive mode. i) WT C. glutamicum reverse micellar extracted lipid 
sample, ii) reverse micellar lipid extraction from C. glutamicum∆NCgl0925- 0926 double deletion mutant, iii) 
purified depleted lipid extracted from WT C. glutamicum. 
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mutant strain (Figure 2.20). Figure 2.20ii shows the C. glutamicum∆NCgl0925- 0926 double 
deletion mutant having a loss of peaks at m/z: 1659.2340 and 1685.2640. Masses obtained 
from mass spectrometry were compared to structural models of various PIM species, such as 
PIM1 PIM2, Ac1PIM2 and Ac2PIM2 (Figure 2.21), and found to correspond to sodium adducts 
of Ac2PIM2 species with the difference in mass corresponding to changes in the fatty acid 
Figure 2.21: Structural model of C. glutamicum Ac2PIM2. Ac2PIM2 structure used to determine the identity of 
the lipid purified from WT C. glutamicim, and reverse micellar lipid extraction fractions from WT C. glutamcicum 
and C. glutamicum∆NCgl0925- 0926 double deletion mutant.  R1-4 denote attachment of fatty acyl chains, where 
in the case of PIM2 and Ac1PIM2 R3 and R4 are H. Fatty acid chains present in the identified lipid modelled in un-
esterified form i) C16:0, ii) C18:1 
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composition of the lipid, either C16:0 or C18:1 (Figure 2.21i and 2.21ii respectively). Data 
collected from the purified lipid showed peaks at m/z: 1659.2168 and 1685.2364, supporting 
the hypothesis that the change in the spectra is due to the loss of Ac2PIM2 from the mutant. 
 
2.2.13: SDS-PAGE analysis of lipoglycan extractions from WT C. glutamicum, and C. 
glutamicum∆NCgl0925- 0926: 
 
As both Cg-LM and Cg-LAM can be generated from a PIM anchor and the identification of 
the depleted lipid to be Ac2PIM2, the cell lipoglycan composition was analysed, with the 
expectation that there would be a change in the composition due to the loss of one of the 
anchors. Howeverm due to the presence of an alternative Gl-A anchored unit, the change was 
not expected to be as significant as it would be in mycobacterial species.  
 
Extraction and analysis of the lipoglycan fraction (Methods 6.16.1, 6.17.1, 6.17.2) of the C. 
glutamicum lipoglycans in both the WT C. glutamicum and C. glutamicum∆NCgl0925- 0926 
double deletion mutant strain show that there is a slight change in the overall size of the 
lipoglycans, with both the Cg-LAM being slightly smaller than the in the WT C. glutamicum 
strain. However, complementation with either the C. glutamicum or the Mtb genes does not 
fully restore the WT C. glutamicum phenotype (Figure 2.22).  
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The alteration of the lipoglycan profile is expected as the loss of NCgl0925 and NCgl0926 
leads to the depletion of PIMs on the external face of the cell, and PIM species act as an 
anchoring lipid for Cg-LM and Cg-LAM the alteration of the ratio of anchors will likely affect 







1 2 3 4 5
Figure 2.22: SDS-PAGE analysis of lipoglycan extractions from C. glutamicum, visualised using silver staining. 
1) WT C. glutamicum, 2) C. glutamicumDNCgl0925-NCgl0926, 3) C. glutamicumDNCgl0925- 0926 pEKEx3, 4) C. 
glutamicumDNCgl0925- 0926 pEKEx3- NCgl0925- 0926, 5) C. glutamicumDNCgl0925- 0926 pEKEx3-Rv1272c- 
1273c. Showing a slight decrease in the upper end of the size of LAM, with minimal impact on the LM. This 
reduced change is likely due to the presence of the an alternate lipoglycan anchor.  
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2.2.14: Monosaccharide composition analysis of lipoglycan extractions from WT C. 
glutamicum, and C. glutamicum∆NCgl0925- 0926:  
 
As the profiles of the lipoglycan extractions showed potential differences, the overall sugar 
composition was predicted to be altered. To determine the sugar composition of the 
lipoglycans, extracted lipoglycan mixture was hydrolysed, and derivatized to form aditol 
acetates in order to improve the separation when using gas chromatography (GC Methods 
6.18.1, 6.18.2, Appendix 3). Derivatized monosaccharides were analysed using GC to quantify 
the ratio of arabinose to mannose and inositol in the overall extraction. 
 
Composition determination of aditol acetate derivatised Cg-LM and Cg-LAM (Appendix 3) 
resulted in two peaks corresponding to arabinose (retention time ~ 9.1- 9.5 min), mannose 
(retention time ~ 12.4-12.6 min), and inositol (retention time ~ 14.6- 15 min). The analysis of 
the resulting spectra (Table 2.3), lead to the determination that the arabinose: mannose: inositol 
ratio changes from 1:33.4: 1.0 in the WT C. glutamicum strain, to 1:6.2: 0.6 in the C. 
glutamicum∆NCgl0925-0926 mutant. Analysis of the lipoglycan composition of the C. 
glutamicum∆NCgl0925-0926 pEKEx3 strain gave a ratio of 1: 11.7: 0.6 arabinose: mannose: 
inositol, while the C. glutamicum∆NCgl0925-0926 pEKEx3-NCgl0925-0926, and C. 
Table 2.3: Arabinose: Mannose: inositol ratios of aditol acetate derivatised lipoglycan extractions from C. 
glutamicum strains. 
Ara:Man:Ino
WT C. glutamicum 1:33.4:1.3
C. glutamicumNCGL0925-0926 1:6.2:0.6
C. glutamicumNCGL0925-0926 pEKEx3 1:11.7:0.6
C. glutamicumNCGL0925-0926 pEKEx3-NCgl0925-0926 1:11.2:0.6
C. glutamicumNCGL0925-0926 pEKEx3-Rv1272c-1273c 1:14.2:0.5
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glutamicum∆NCgl0925-0926 pEKEx3-Rv1272c-1273c strains gave mannose: arabinose ratios 
of: 1:11.2: 0.6, and 1:14.2: 0.5 respectively.  
 
While the change in the ratio of arabinose to mannose and inositol is expected to be different 
to the WT C. glutamicum in both the C. glutamicum∆NCgl0925- 0926 double deletion mutant 
and the C. glutamicum∆NCgl0925- 0926 pEKEx3 strain, the recombinant expression of both 
the corynebacterial and Mtb genes do not restore the WT C. glutamicum ratio, instead 
maintaining the ratio found in the C. glutamicum∆NCgl0925- 0926 pEKEx3 strain. This 
indicates that while the recombinant expression leads to a restoration of the WT strain lipid 
and lipoglycan size profile, there is an impact on the sugar composition of the lipoglycans 
which remains as yet unexplained. 
 
Additionally, the maintained presence of inositol in the extracted Cg-LM and Cg-LAM in the 
C. glutamicum∆NCgl0925- 0926 double deletion mutant, and the C. glutamicum∆NCgl0925- 
0926 pEKEx3 strain does not necessitate the presence of inositol anchored Cg-LM and Cg-
LAM. This is due to the disruptive nature of the extraction procedure, which does not extract 
only the surface layers of the, resulting in contaminating PIM species in the extraction. These 
PIM species can come from either the outer membrane, or the cytoplasmic membrane, and 
therefore it is probable that the presence of inositol in the extractions, is due to these 
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2.3: Discussion:  
 
PIMs, LM, and LAM are vital for the integrity of the cell wall. With the PIM species forming 
a significant portion of the membranes, and LM and LAM involved in the evasion of the 
immune response, as such understanding of how these molecules are synthesised is important 
in understanding how mycobacteria interact with their environment. While much of the 
biosynthetic processes have previously been determined, the transport mechanism has, until 
now, remained unknown (Abrahams and Besra, 2016; Alderwick et al., 2007). 
 
Our data supports our initial hypothesis that the Mtb homologs of MsbA, Rv1272c and 
Rv1273c, are involved in the transport of PIMs across the inner membrane of Mtb. As a clear 
loss of a lipid on the C. glutamicum∆NCgl0925- 0926 cell surface was detected and the 
depleted lipid characterised as Ac2PIM2. The complementation of the C. 
glutamicum∆NCgl0925- 0926 strain with either NCgl0925 and NCgl0926 or Rv1272c and 
Rv1273c resulted in a restoration of the WT C. glutamicum phenotype in all conditions, with 
the exception of the arabinose: mannose: inositol ratio in the Cg-LM and Cg-LAM, implies 
that the function of these genes is conserved across all mycobacteria (Alderwick et al., 2005). 
The generation of a conditional knockout in a mycobacterial species such as M. bovis BCG 
would allow for the confirmation of this hypothesis. 
 
The presence of Ac2PIM2 in the inner membrane lipid extraction fraction supports our 
hypothesis that the cause of the loss of the surface lipid is due to an export defect, rather than 
a biosynthetic defect. As Ac2PIM2 is present in the inner membrane, we predict that it is present 
as part of the inner leaflet, with attempts to yield an outer leaflet extraction of the inner 
membrane unsuccessful. The development of a selective lipid extraction method for extracting 
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the outer leaflet of an exposed cytoplasmic membrane would allow for further testing of this 
hypothesis.  
 
Further, the data presented supports that both Rv1272c and Rv1273c are functional transporters 
within the ABC-transporter superfamily, as while they are predicted to contain the correct 
elements and consensus sequences, no available literature has confirmed their function 
(Braibant et al., 2000; Martin and Daniel, 2018). 
 
The determination of the function of NCgl0925 and NCgl0926 fills a gap in the knowledge of 
the biosynthesis of both the mycobacterial and corynebacterial cell surface and the synthesis 
of LM and LAM in both mycobacteria, and corynebacteria. This allows for an updated 
schematic of the biosynthetic pathways of LM and LAM (Figure 2.23), with the addition of 
NCgl0925 and NCgl0926 as the ABC-transporter responsible for the translocation of Ac2PIM2 
in C. glutamicum.  
  
The maintained presence of Cg-LM and Cg-LAM in the C. glutamicum∆NCgl0925- 0926 
double deletion mutant, is likely formed from the alternative Gl-A anchor. This raises the 
question of the presence of an additional, as yet uncharacterised, ABC-transporter in C. 
glutamicum responsible for the translocation of Gl-A (Mishra et al., 2008b). With further 
bioinformatic analysis of the C. glutamicum genome required to determine putative 
transporters, and 
Chapter 2:                            Characterization of a PIM transporter system in C. glutamicum 
 99 


















































Figure 2.23: Updated biosynthetic pathways for the synthesis of PIMs, LM, and LAM. Updated processes 
highlighted in red. A) PIM, LM, and LAM synthetic pathway in Mtb. B) PIM anchored Cg-LM and Cg-LAM synthetic 
pathway in C. glutamicum. C) GL-A anchored pathway for the Cg-LM and Cg-LAM synthesis in C. glutamicum.  
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characterisation of the identified genes to determine the C. glutamicum genes responsible for 
the translocation of this alternative lipoglycan anchoring lipid.  
 
The inability to generate a double deletion mutant in M. smegmatis indicates that the deletion 
of both MSMEG_5008 and MSMEG_5009 is lethal (Cox et al., 2016), therefore at least one 
of these genes must be present for cell viability. The generation of a conditional deletion mutant 
with complementation with MSMEG_5008 and MSMEG_5009 expression under separate 
control would either confirm or disprove this hypothesis. Additionally, due to the use of a 
double deletion mutant in C. glutamicum to determine this phenotype further research into the 
level of redundancy of these genes would be required, with characterisation of the effect of 
complementation of a double deletion mutant with individual genes, and investigation of the 
phenotype of single deletions of both NCgl0925 and NCgl0925. 
 
Investigation into the in vivo conformation of these proteins is necessary, as predictions into 
the formation of a heterodimer remain predictions (Braibant et al., 2000). This requires in 
vivo or in vitro confirmation, either by bacterial two-hybrid, or far Western blotting (Lim et 
al., 2019; Martin and Daniel, 2018). If positive these results would suggest either the 
formation of a single heterodimeric transporter, or an equilibrium between the formation of 
hetero- and homo- dimeric isoforms. A negative result would suggest the formation of two 
distinct homodimeric transporters, likely with differing affinities to PIM species. 
 
In addition to the characterisation of the conformation of these proteins, determination of where 
they localise within the cell of the bacteria and how this changes during the replication cycle 
of the bacteria would provide insight into the maintenance of the cytoplasmic membrane 
(Heinkel et al., 2019). As it is possible that the transporter could disperse across the entirety of 
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the bacteria, or remain localised to a particular region if they reside within a functional 
membrane microdomain (Wagner et al., 2017). Determination of localisation within the cell 
would enable a more nuanced understanding of synthesis of the external membrane as proteins 
required for the transport of PIMs to the outer membrane would likely interact with the 
transport mechanism to the external face of the membrane, as the transporters would be likely 
to have an increased PIM presence and therefore would increase the efficiency of transport to 
the outer membrane.   
 
Investigation of the physical structure of these proteins would provide insight into the 
mechanism by which the PIMs are transported across the membrane, and would allow for 
structure-based drug design targeting this protein (Méndez et al., 2019; Skalic et al., 2019). 
Which due to the inability to generate a double deletion mutant in M. smegmatis is likely 
essential could lead to the development of a novel therapeutic agent for the treatment of TB 
(Cox et al., 2016). 
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3.1: Introduction:  
 
The Mtb genome includes three arabinofuranosyl transferases (AraTs) (EmbA, EmbB and 
EmbC) within a single operon located in the genome at Rv3793-Rv3795, embCAB. 
Individually, these AraT genes are non-essential, however when either embA or embB are 
disrupted the other is predicted to become essential due to a redundancy in their function 
(Alderwick et al., 2005). Both EmbA and EmbB are involved in the synthesis of the arabinian 
domains in AG, which is serves to connect the outer myco-membrane to peptidoglycan via the 
galactan core. Conversely, EmbC is involved only in the synthesis of the arabinian domains of 
LAM (Escuyer et al., 2001; Zhang et al., 2003).  
 
The EmbCAB proteins have been the subject of research due to the high frequency of mutations 
found in Mtb strains resistant to EMB, which led to the naming of these proteins (Abrahams 
and Besra, 2016; Belanger et al., 1996; Takayama and Kilburn, 1989; Tsukamura, 1965). 
 
While mycobacteria are able to tolerate the deletion of either EmbA or EmbB with minor 
changes to the terminal domain of the AG, the deletion of both EmbA and EmbB together is 
lethal, which has made characterising the function of these proteins challenging. In order to 
better characterise the effect of the loss of both these genes, the Mtb model organism C. 
glutamicum has been used (Alderwick et al., 2005; Batt et al., 2010). The C. glutamicum 
genome inclused a single Emb protein, Cg-Emb, which functions as a model for the 
mycobacterial EmbA and EmbB. The major reason for the use of C. glutamicum for the study 
of AG biosynthesis is due to the ability of C. glutamicum to tolerate the deletion of Cg-Emb in 
media supplemented with sorbitol (which acts as an osmoprotectant), preventing the bacteria 
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from lysing due to the inability to maintain a structurally sound cell wall (Alderwick et al., 
2005; Jankute et al., 2018).  
 
The deletion of Cg-emb results in an almost complete loss of arabinose from the AG, with only 
the priming arabinose residues remaining. The deletion of Cg-emb also results in the total loss 
of the cell wall bound corynemycolic acid methyl esters (cMAMEs), due to the inability to 
extend the primed branching points of the arabinan domains, and the resulting loss in the 
attachment site of the cMAMEs, which anchor the mycobacterial outer membrane (Figure 1.10, 
Figure 1.16) (Alderwick et al., 2005).  
 
The function of the Emb proteins is conserved between the Mtb and C. glutamicum, with all 
Emb proteins acting as arabinosyl transferases, formed of two domains, a domain comprised 
of transmembrane helices, and a binding domain exposed on the periplasm (Figure 3.1). The 
function of Mtb EmbA and EmbB, is the extension of the arabinose branches after the initial 
priming of the branch point by the attachment of the single Araf catalysed by AftA. The Emb 
proteins then extend the branch through the synthesis of a(1à5) glycosidic linkages, with 
DPA acting as the source of arabinose (Alderwick et al., 2005).  
 
Comparison of the predicted tertiary structures of mycobacterial and corynebacterial Emb 
proteins shows significant similarities between the Mtb EmbA and EmbB, and Cg-Emb (Seidel 
et al., 2007b). Prediction of the numbers of transmembrane helices of Mtb EmbA and EmbB 
results in the prediction of an N-terminal domain composed of 11- 13 transmembrane helices 
(Escuyer et al., 2001), while the N-terminal domain of Cg-Emb in C. glutamicum is predicted 
to contain 15 transmembrane helices (Seidel et al., 2007b).  
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The C-terminal domains of all the Emb proteins is a type C lectin, and is strongly conserved 
within the Corynebacteriales, a diverse group of proteins bound to the membrane which 
catalyse the transfer of lipid bound sugars onto their substrate rather than nucleotide bound 
sugars which are only found in the cytoplasm of the bacteria (Alderwick et al., 2011).  
 
The front line drug EMB was discovered in 1961, however the mechanism of action was not 
determined until significantly later, upon the generation of EMB resistant mutants, and 
phenotypic analysis of the effects on EMB on whole cells (Belanger et al., 1996; Takayama 
and Kilburn, 1989; Zumla et al., 2013). However, while the target of EMB has been determined 
through generation of spontaneous resistant mutations, there has not yet been conclusive 
mechanistic evidence on how EMB inhibits the Emb protein targets. EMB is specific in 
inhibiting the Emb proteins, and does not have an impact on other arabinosyl transferases such 
meaning that it is unlikely to inhibit the active site of Emb as this would likely also result in 
inhibition of other mycobacterial AraTs. As the active site is likely to share significant 
similarity as they all rely on the same DPA pool as a source of arabinose and therefore are 
likely to have similar recognition methods (Alderwick et al., 2006; Birch et al., 2008; Seidel et 
al., 2007a).  
 
Mtb EmbB has been studied as the site of many point mutations associated with EMB 
resistance. The mutation of the methionine at position 306, to a hydrophobic residue such as 
valine, isoleucine, or leucine is associated with both EMB and multidrug resistance (D. Shi et 
al., 2011; Srivastava et al., 2009). However other mutations in EmbB, in locations such as: 
codon 406 and 497 (glycine and glutamine respectively in WT EmbB) are frequently seen in 
EMB resistant strains where no mutation is seen at EmbB306 (D. Shi et al., 2011). 
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A C. glutamicum strain with significantly reduced tolerance to EMB was generated through 
the deletion of steA and ripA (Lim et al., 2019). RipA is an endopeptidase which is involved in 
degrading and recycling peptidoglycan and has been shown to localise to the poles and septa 
of mycobacterial cells (Chao et al., 2013). As such, a  ripA deletion mutant affects cell division 
and leads to increased antibiotic susceptibility due to disrupted daughter cell separation (Hett 
et al., 2008, 2007). SteA is less well characterized, but has been shown to function as a 
component of the cytokinetic ring (Lim et al., 2019). 
 
As the C. glutamicum∆steA∆ripA strain was generated C. glutamicum a strain that shows a loss 
of three prophage regions when compared to the reference strain (C. glutamicum ATCC13032), 
with unknown functionality. Phenotypic analysis of the strain in comparison to ATCC13032 
shows no fitness cost for the bacteria, with an improved tolerance to DNA damage inducing 
the SOS-response (Baumgart et al., 2013).  
 
Here we aim to characterise the effect of the combined of steA and ripA double deletion on the 
cell envelope of C. glutamicum that causes susceptibility to EMB, and to characterise any 
additional effects caused by spontaneously generated point mutations restoring resistance to 
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3.2: Results:  
 
3.2.1: Generation, and mutation mapping of EMB resistant strains of C. 
glutamicum∆steA∆ripA:  
C. glutamicum∆steA∆ripA and C. glutamicum∆steA∆ripA Cg-Emb point mutations generated 
by T. Bernhardt’s group (Methods 6.3.3, 6.4.1, and 6.4.2). Strains generated from the C. 
glutamicum∆steA∆ripA mutant by the exposure to EMB to produce resistant mutants resulted 
in various point mutations within the Cg-emb gene, producing six strains with restored 
resistance to EMB, all of which are within the transmembrane domain of the Cg-Emb protein. 
Genome sequencing of the resistant strains showed no mutations other than the documented 
Cg-emb mutations. The six different point mutations provided for testing are: Cg-EmbG411S, 























Figure 3.1: Membrane topology and point mutation locations of C. glutamicum Emb. Transmembrane helix 
predicted first and last residue marked. Stars marking position of mutations in the Emb protein resulting in 
increased tolerance to EMB. 
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3.2.2: Growth rate analysis of WT C. glutamicum, C. glutamicum∆steA∆ripA, and C. 
glutamicum∆steA∆ripA Cg-Emb point mutant strains: 
Figure 3.2: Growth curves of C. glutamicum strains in rich media, measured by OD600. Biological replicates, 
n=3. The C. glutamicum∆steA∆ripA strain which forms the basis of the Cg-Emb point mutants, shows a slow 
growth phenotype when compared to the WT C. glutamicum up until 24 hours post-inoculation. Of the point 
mutations in C-gEmb, the Cg-EmbP414T, Cg-EmbA453E mutant strains show no significant difference to the C. 
glutamicum∆steA∆ripA strain at any point. The Cg-EmbG411S mutant strain shows a significant different in growth 
rate at all time points. The Cg-EmbA453V, Cg-EmbP505L, and Cg-EmbS528A mutant strains show significant differences 
growth in at least one timepoint when compared to the C. glutjamicum∆steA∆ripA strain. All differences 
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To determine the overall fitness cost the deletion of steA and ripA, required to generate the 
EMB hypersensitive strain of C. glutamicum, and the effect of the point mutations in Cg-Emb 
which restore resistance to EMB, growth rate analysis was conducted (Method 6.10), with 
assistance from S. Benedict (Figure 3.2).  
 
Analysis of the growth rate of the WT C. glutamicum, C. glutamicum∆steA∆ripA strain, and 
C. glutamicum∆steA∆ripA strains with point mutations in Cg-Emb, showed that the loss of 
steA and ripA results in a significant increase in the lag phase of growth in all strains, with all 
strains sharing a slowed growth phenotype when compared to the WT C. glutamicum until 24 
hours post inoculation, where only the C. glutamicum∆steA∆ripA Cg-EmbG411S strain has a 
significant difference in growth to the WT strain (q > 0.01) (Figure 3.2).  
 
Comparison of the OD600 readings of the C. glutamicum∆steA∆ripA strain and the Cg-Emb 
point mutant strains shows that similar to the comparison of the Cg-EmbG411S strain to the WT 
C. glutamicum strain, there is a significant difference between the OD600 at all timepoints, with 
Cg-EmbG411S showing a significantly slowed growth. The Cg-EmbP505L strain shows significant 
differences to the C. glutamicum∆steA∆ripA strain at 4-, 5-, and 6- hours post-inoculation, with 
all other differences not significant to q > 0.01. Measurement of the Cg-EmbA453V strain at four 
hours post-inoculation lead to a significant difference when compared to the C. 
glutamicum∆steA∆ripA strain.  
 
This data shows that the deletion of steA and ripA results in a significant increase in the lag 
phase of the bacteria, with further some mutations in the Cg-Emb protein leading to a further 
growth perturbation, while others result in no overall change to the growth phenotype 
compared to the C. glutamicum∆steA∆ripA strain.   
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3.2.3: Growth rate analysis in media supplemented with sorbitol of WT C. glutamicum, 
C. glutamicum∆steA∆ripA, and C. glutamicum∆steA∆ripA Cg-Emb point mutant strains: 
Figure 3.3: Growth curve of C. glutamicum strains in rich media supplemented with 0.5 M sorbitol, measured 
using OD600. Biological replicates, n=3. Similar to growth in un-supplemented media, the C. 
glutamicum∆steA∆ripA strain shows significantly reduced growth at all time points when compared to the WT 
strain. Both the EmbP414T and EmbA453V straisn show no difference to the ∆steA∆ripA strain at any time point. The 
EmbG411S strain shows a significant difference in all time points until 24 hours post-inoculation. The EmbP505L 
strain shows a significant difference to the ∆steA∆ripA strain at 4-, 5-, and 6- hours post-inoculation, but no 
significant difference at 24 hours post-inoculation. The EmbS528A strain shows a significant difference to the 
∆steA∆ripA strain at all point until 24 hours post-inoculation. All differences calculated using Bonferroni 
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To determine if the change in the growth rate of the C. glutamicum∆steA∆ripA strain relative 
to the WT C. glutamicum strain, and the change in the growth rate of the Cg-EmbG411S strain 
relative the C. glutamicum∆steA∆ripA, is due to a reduction in the structural integrity of the 
cell wall core, growth rate analysis of the C. glutamicum strains was conducted in media 
supplemented with 0.5 M sorbitol (Method 6.10), with assistance from S. Benedict (Figure 
3.3). Sorbitol acts as an osmoprotectant, and has been used to rescue mutants unable to maintain 
the cell wall in standard media, of particular relevance is the use of sorbitol for growth of the 
C. glutamiucm∆emb strain (Alderwick et al., 2005).  
 
The addition of sorbitol to the media did not result in the restoration of the WT C. glutamicum 
growth rate in the C. glutamicum∆steA∆ripA strain, and did result in there being a significant 
difference in the cell density 24 hours post-inoculation (q > 0.01), where in media not 
containing sorbitol there was no significant difference. Both the Cg-EmbP414T and the Cg-
EmbA453V strains showed no significant difference at any timepoint (q > 0.01). The Cg-
EmbA453E and the Cg-EmbP505L strains show a significant difference at 4-, 5- and 6- hours post-
inoculation (q > 0.01). Cg-EmbS528A showed a significant difference at all time points expect 
for 24 hours post-inoculation (q > 0.01).  
 
The cause of the drop in OD600 at 3 hours post-inoculation is unknown, I hypothesise that this 
is likely due to an error in the readings at 1- and 2-hours post-inoculation, as the readings from 
3-hours are consistent beyond this point. 
 
Analysis of the data generated showed a significant difference between the Cg-EmbG411S strain 
and the C. glutamicum∆steA∆ripA strain at all time points except for 24 hours post-inoculation 
(q > 0.01), while there is still a statistical difference between many of the timepoints, the 
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difference between the strains growth rates is substantially reduced, with comparison of the 
timepoints from media containing and not containing sorbitol showing significant differences 
at all points. This shows that the supplementation of the growth media with sorbitol, while not 
fully restoring the C. glutamicum∆steA∆ripA strain growth phenotype, does significantly 
improve the ability of the Cg-EmbG411S strain to grow.  
 
As the use of osmoprotectants in bacterial growth media is used to allow for the growth of 
strains less able to synthesise and maintain a fully functional cell wall. The effect it has on the 
Cg-EmbG411S mutant strain implies that, while this mutation does not cause the cell wall to 
become completely non-functional, as the strain is able to grow in un-supplemented media, the 
change in the Cg-Emb protein likely leads to a reduction in the functionality of Cg-Emb, 
potentially leading to a hybrid phenotype between the C. glutamicum∆steA∆ripA strain and the 
C. glutamicum∆Emb strain characterised by Alderwick et al. 2005.  
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3.2.4: Cell surface permeability analysis of WT C. glutamicum, C. glutamicum∆steA∆ripA, 























































Figure 3.4:  Cell surface permeability of C. glutmicum strains. Mutations listed are point mutations in Cg-Emb 
generated from the C. glutamicum∆steA∆ripA strain, with only location of the point mutation in Cg-Emb given. 
The C glutamicum∆steA∆ripA mutant shows a significant reduction in permeability, with all mutants except the 
Cg-EmbA453E mutant resulting in a further reduction in permeability. Polymyxin B used as a positive control to 
increase permeability. All differences calculated using Bonferroni corrected ANOVA, q > 0.01, significantly 
different values indicated in Table 3.1. Error bars: Std. deviation, n=4 
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Due to the changes in the growth phenotype of the C. glutamicum∆steA∆ripA strain the and 
Emb point mutant strains, analysis of the permeability of the C. glutamicum cell surface was 
undertaken (Method 6.11) to investigate if there is a change in the permeability of the cells 
(Figure 3.4, Table 3.1).  
 
Figure 3.4, shows that the C. glutamicum∆steA∆ripA strains shows a statistically significant 
reduction in the permeability of the cell to DPH compared to the WT C. glutamicum strain. 
Furthermore, all mutant strains, with the exception of the Cg-EmbA453E strain show an 
additional statistically significant reduction in surface permeability (Table 3.1). This shows 
that there is a significant impact on the permeability of the cell surface to DPH, both in the C. 
glutamicm∆steA∆ripA strain and the Cg-Emb point mutant strains, as well as showing that the 
degree to which the mutations affect the cell surface is not uniform, potentially due to different 





Table 3.1: Bonferroni corrected ANOVA analysis of cell surface permeability testing. Significance level tested to 
q > 0.01. Green indicates significant difference between strains, red indicates no significant difference between 
strains. 
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3.2.5: Assessing Antibiotic susceptibility of WT C. glutamicum, C. glutamicum∆steA∆ripA, 
and C. glutamicum∆steA∆ripA Cg-Emb point mutant strains: 
 
The reduction in the permeability of the cell is likely to have an impact on the ability of 
antibiotics to reach their target. Therefore, the effects of the Cg-Emb mutations on the 
sensitivity to other antibiotics was measured (Table 3.2, Method 6.19). Using antibiotics that 
target either intra- or extra- cellular enzymes. Amoxicillin is a beta-lactam inhibiting 
transpeptidation, while chloramphenicol, kanamycin, and streptomycin all inhibit protein 
synthesis. Rifampicin inhibits transcription, and vancomycin binds to the pentapeptide stem of 
peptidoglycan to prevent polymerisation (Abrahams and Besra, 2016; Alifano et al., 2015; 
Bartlett, 1982; Reynolds, 1989; Rolinson, 1994; Zumla et al., 2013). Experiments conducted 
by S. Benedict. 
 
We found that the C. glutamicum∆steA∆ripA strain had MIC99 changes when compared to WT 
C. glutamicum, with the point mutations in Cg-Emb resulting in further changes from the C. 
glutamicum∆steA∆ripA strain across a range of antibiotics. Multiple strains expressing Cg-
Emb point mutations showed increased resistance to both antibiotics with intracellular and 
extracellular targets (Table 3.2). However, due to the increased tolerance to stress causing DNA 
damage, it is possible that some of the changes seen are due to the differences between the 
ATCC13032 and MB001 strains (Baumgart et al., 2013). 
 
The C. glutamicum∆steA∆ripA strain, showed an increase in the MIC99 against Kanamycin, 
Amoxicillin, Chloramphenicol, and Streptomycin, ranging from a 4 to 16-fold increase. 
However, the change in the resistance was not universal, nor specific to a single target location, 
with both Rifampicin and Vancomycin both showing no change in MIC99.  
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The various point mutations in the Cg-Emb protein resulted in further changes in the 
antibiotic sensitivity from the C. glutamicum∆steA∆ripA strain. All mutations tested resulted 
in resistance to Amoxicillin to over 500 μM, except for the Cg-EmbA453V mutant where the 
strain shows a 2-fold reduction in MIC. However, this decrease compared to the C. 
glutamicum∆steA∆ripA strain MIC99 still maintains a 2-fold increase when compared to the 
WT C. glutamicum strain.  
 
Only two of the point mutations in Cg-Emb had an effect on the MIC99 of vancomycin, EmbP414T 
and EmbA453A, resulting in a 184-fold increase, and a 2-fold increase in MIC99 respectively. All 
mutants, except for the EmbS528A, showed an altered MIC99 to chloramphenicol. The Cg-
EmbA453V, and Cg-EmbP505L strains showing a 2-fold increase, and Cg-EmbP414T, Cg-EmbA453E, 
and Cg-EmbG411S strains showing a 4-fold increase in MIC99. Streptomycin showed a similar 
effect, with all strains apart from Cg-EmbA453V showing a change in the MIC99. The Cg-EmbP505L, 
Cg-EmbS528A, and Cg-EmbG411S strains show a 2-fold increase in MIC, while the Cg-EmbA453E 
strain shows a 4-fold increase and Cg-EmbP414T strain shows an 8-fold increase.  
 
No strain showed a detectable increased resistance to Rifampicin. The Cg-EmbA453V and Cg-
EmbS528A strains showed no change in Kanamycin MIC99 compared to the C. 
glutamicum∆steA∆ripA strain, the Cg-EmbP505L strain showed a 2-fold increase in MIC99, the 
Cg-EmbP414T strain showed a 3-fold increase in MIC99, and the Cg-EmbG411S strain showed a 4-
fold increase in MIC99. While Cg-EmbA453E reverted back to WT C. glutamicum with a 16-fold 
decrease in MIC99.  
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3.2.6: Characterization of the free lipid phenotype of WT C. glutamicum, C. 









Figure 3.5: TLC analysis of apolar outside lipid extraction from C. glutamicum strains. Solvent system: 
direction 1- 30: 8: 1 chloroform: methanol: water, direction 2- 70: 30: 1 hexane: diethyl-ether: acetic acid. 
FMA: free mycolic acid, FFA: free fatty acid, TMcM: trehalose corynemycolate.  
Chapter 3: Investigation of SNPs involved in corynebacterial EMB resistance on the 
corynebacterial cell envelope 
 119 
All strains tested showed significant changes in the permeability of the cell surface (Figure 
3.4), as well as antibiotic resistance (Table 3.2). Due to these changes we hypothesised that the 
free lipid composition of the strains was likely to be altered, and potentially contributed 
towards these changes. As the lipid composition of the outer membrane forms the key barrier 
in mycobacterial antibiotic resistance (Abrahams and Besra, 2016).  
 
Characterisation of the lipid composition of the C. glutamicum∆steA∆ripA strain and the Cg-
emb point mutants generated from it (Method 6.12.1), resulted in the identification of subtle 
changes in the lipid composition, with the C. glutamicum∆steA∆ripA strain, and all 
subsequently generated mutants, showing a slight increase in the relative amount of free fatty 
acids, present in the apolar outside,  compared to the WT C. glutamicum strain (Figure 3.5, 
Table 3.3).  
 
Characterisation of the lipid composition of this fraction in the Cg-Emb mutant strains resulted 
in further changes to the lipid composition, with the Cg-EmbG411S strain (Figure 3.5, Table 3.3) 
showing a reduction in the free mycolic acids compared to both the WT C. glutamicum and C. 
glutamicum∆steA∆ripA strains, while showing an increase in production of TMcM. The Cg-
EmbP414T, Cg-EmbA453V, Cg-EmbA453E, and Cg-EmbP505L strains (Figure 3.5) showed a similar 
increase in TMcM, however there was no change in the production of free mycolic acids, 
relative to the C. glutamicum∆steA∆ripA strain. While the Cg-EmbS528A strain (Figure 3.5) also 
showed a similar reduction in the free mycolic acid production to the Cg-EmbG411S strain.  
 
Characterisation of the remaining extractable apolar lipids, results in the reduction of free 
mycolic acids, in the C. glutamicum∆steA∆ripA strain, compared to the WT C. glutamicum 
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strain, with no significant changes in the levels of diacyl-glycerol (DAG), TMcM, free fatty 








Figure 3.6: TLC analysis of apolar inside lipid extraction fraction from C. glutamicum strains. Solvent system: 
direction 1- 30: 8: 1 chloroform: methanol: water, direction 2- . DAG: diacyl glycerol, FMA: free mycolic acid, 
FFA: free fatty acid, TMcM: trehalose corynemycolate, CL: cardiolipin.  
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Figure 3.7: TLC analysis of polar lipid extraction fraction from C. glutamicum strains. Solvent system: direction 
1- 30: 8: 1 chloroform: methanol: water, direction 2- 70: 30: 1 hexane: diethyl ether: acetic acid. DAG: 
diacylglycerol, FMA: free mycolic acid, FFA: free fatty acid, TMcM: trehalose corynemycolate, PIM: phosphotidyl-
myo-inositol mannoside, CL: cardiolipin, PI: phosphotidyl inositol.  
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inside fraction than the Apolar outside when compared to the WT C. glutamicum strain (Figure 
3.6, Table 3.3). All Emb mutant strains showed an increase in free mycolic acids relative to the 
C. glutamicum∆steA∆ripA strain. However, there is no change relative to the WT C. 
glutamicum strain, with the remaining profile being unchanged, with the exception of CL. With 
the Cg-EmbA453V, Cg-EmbA453E, and Cg-EmbP505L strains all showing an increase in the level 
of CL.  
Table 3.3: Changes in lipid composition of C. glutamicum strains. Changes are shown relative to either WT C. 
glutamicum, or C. glutamicum∆steA∆ripA. “+” Increase in lipid in respect to reference strain, “-” decrease in 
lipid in respect to reference strain, “ND” no difference in lipid  
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Analysis of the remaining polar lipid fraction (Figure 3.7, Table 3.3), showed a reduction in 
remaining free mycolic acids, DAG, and CL in the C. glutamicum∆steA∆ripA strain. The Emb 
mutant strains show a restoration of these lipids, with the Cg-EmbG411S, Cg-EmbP414T, Cg-
EmbA453V, and Cg-EmbA453E strains resulting in an increase in CL relative to WT C. 
glutamicum. The Cg-EmbG411S strain also shows an increase in PI relative to WT C. 
glutamicum.  
 
3.2.7: Characterization of the cell wall bound lipid phenotype of WT C. glutamicum, C. 
glutamicum∆steA∆ripA, and C. glutamicum∆steA∆ripA Cg-Emb point mutant strains: 
 
As there were alterations to the free lipid composition, the cell wall bound lipids were also 
analysed by hydrolysis from the cell wall core and conversion to fatty acid methyl esters 
(FAMEs), or corynemycolic acid methyl esters (cMAMEs), to determine if there was an effect 
on the attachment of lipids to the arabinogalactan in these strains (Method 6.12.4), if the 
mutations result in a significant decrease in the arabinosyltransferase activity of the Cg-Emb 
protein the effect this would have the AG would likely lead to an altered AG structure, and 
potentially from there result in a change to the attachment of lipids to the cell wall core.  
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Figure 3.8, shows that in the C. glutamicum∆steA∆ripA strain there is an increase in the level 
of corynemycolation of the cell wall core, compared to the WT C. glutamicum strain, with not 
significant changes in the attachment rate of the fatty acids. However, in the Cg-EmbG411S strain 
there is an almost complete loss of fatty acid attachment and a reversion to the WT C. 
glutamicum strain level of corynemycolation, suggested that there is an impairment of the 
activity of either antigen 85 transferring the corynemycolates onto the cell wall core, or in the 
synthesis of the attachment site for corynemycolation, or fatty acid esterification. This altered 
phenotype in the cell wall core additionally potentially explains the relative increase in the 
Figure 3.8: TLC analysis of cell wall bound lipid extraction from C. glutamicum strains. Effect of loss of steA and 
ripA results in a slight reduction in the higher Rf FAMEs in the cell wall bound lipid profile. Mutations in Cg-emb 
result in no change in the overall cell wall bound lipid profile, except for Cg-EmbG411S results in a decrease in the 
cell wall bound fatty acids, while other mutations lead to no overall change to the lipid composition of the cell 
wall core. Solvent system- 95: 5 Petroleum ether 60-80: acetone, visualised with MPA.  
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levels of TMcM in the free lipid extraction, as TMcM acts as the substrate for the transfer of 
corynemycolates, due to the nature of the mutations present in the bacteria it is likely that the 
change is due to an alteration in the activity of the Cg-Emb protein. 
 
The alteration of the level of fatty acid esterification to the cell wall core in the Cg-EmbG411S 
strain provides further support for the change in the structure of the AG as it has been seen that 
the AG can have either fatty acids, or mycolic acids attached to terminal domain of the AG, 
although a significant amount of the cell wall attached lipids in C. glutamicum are attributed to 
the attachment of cardiolipin to the peptidoglycan (Bansal-Mutalik and Nikaido, 2011). 
 
3.2.8: SDS-PAGE lipoglycan characterization from WT C. glutamicum, C. 
glutamicum∆steA∆ripA, and C. glutamicum∆steA∆ripA Cg-Emb point mutant strains: 
 
Further to the effect on the lipid composition, we predicted that there would be changes in the 
lipoglycan composition. This is due to the mutations in the Cg-Emb protein, which potentially 
changes the levels of DPA through changes in the activity of Cg-Emb. With the changes in 
AraT impacting on the arabinan domain of lipoarabinomannan.  
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Analysis of the lipoglycan extraction (Methods 6.16, 6,17.1, 6.17.3), shown in Figure 3.9 
shows some changes to the relative levels of Cg-LM and Cg-LAM when the WT C. 
glutamicum, C. glutamicum∆steA∆ripA and mutant strains are compared. The C. 
glutamicm∆steA∆ripA strain shows a subtle change in the Cg-LM and Cg-LAM size profile, 
with the distribution altering to a point where the bands are not separated as they are in the WT 
C. glutamicum.  
 
Figure 3.9: SDS-PAGE analysis of lipoglycan extraction from C. glutamicum strains visualised using Pro-Q 
Emerald 300. Loss of steA and ripA results in the Cg-LM and Cg-LAM bands merging, implying a change in the 
composition of the lipoglycans. Mutations in the Cg-Emb protein result in either further changes from the C. 
glutamicum∆steA∆ripA strain, or a restoration towards the WT C. glutamicum phenotype. Cg-EmbG411S and Cg-
EmbS538A show a reduction in the relative amount of Cg-LM compared to Cg-LAM. Cg-EmbA453V and Cg-EmbA453E 
show an unchanged phenotype to the C. glutamicum∆steA∆ripA strain. The Cg-EmbP414T and Cg-EmbP505L strains 
show a relative return to the WT C. glutamicum strain.  
Chapter 3: Investigation of SNPs involved in corynebacterial EMB resistance on the 
corynebacterial cell envelope 
 127 
The effect of the mutations on the lipoglycan profile vary depending on the strain. The Cg-
EmbA453V and Cg-EmbA453E strains both show no significant noticeable effect on the lipoglycan 
profile. The Cg-EmbP414T, Cg-EmbP505L, and Cg-EmbS528A, mutations show a restoration of the 
separation between these bands, however the relative levels of the Cg-LM and Cg-LAM vary. 
Most notable in the Cg-EmbS528A strain, where the relative abundance on Cg-LM is 
significantly reduced compared to the Cg-LAM. Finally, the EmbG411S mutation results in a 
similar phenotype to the Cg-EmbS528A strain, however the level of Cg-LM is reduced further.  
 
3.2.9: Aditol acetate derivatized monosaccharide composition analysis of extracted 
lipoglycans from WT C. glutamicum, C. glutamicum∆steA∆ripA, and C. 
glutamicum∆steA∆ripA Cg-Emb point mutant strains: 
 
In order to further understand the effect on the changes in the lipoglycan profile the 
composition of the whole extract was determined by generation of hydrolysed aditol acetate 
derivatives and analysis by gas chromatography to determine the sugar composition of the 
lipoglycans (Methods 6.18.1, 6.18.2, Appendix 3). 
 
Composition determination of derivatised of the lipoglycans resulted in two peaks 
corresponding to arabinose, retention time ~ 9.1- 9.5 min, and mannose, retention time ~ 12.4-
12.6 min. The analysis of the resulting spectra (Table 3.3, Appendix 3), lead to the 
determination that the mannose: arabinose ratio changes from 33.4: 1 in the WT C. glutamicum 
WT SteARipA EmbA453V EmbP414T EmbA453E EmbP505L EmbS528A EmbG411S
Man: Ara 33.4:1 7.9:1 2.0:1 24.0:1 14.6:1 3.5:1 3.7:1 1.0:1
Table 3.4: Mannose: arabinose ratio of aditol acetate derivatized lipoglycan extractions from C. glutamicum 
strains. 
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strain, to 7.9: 1 in the C. glutamicum∆steA∆ripA strain, showing that the change in these genes, 
increased the arabinose content of the Cg-LM and Cg-LAM profile.  
 
The point mutations in the Cg-Emb gene all altered the relative abundance of arabinose in 
lipoglycan profile. The Cg-EmbG411S strain resulted in the largest increase in the relative 
arabinose composition, with a ratio of: 1:1, implying that the mutation is reducing the activity 
of Cg-Emb, and in order to allow for the use of the decaprenyl phosphate anchor for other 
purposes a higher ratio of LM is being arabinosylated.  
 
Contrary to the Cg-EmbG411S strain, the both the Cg-EmbP414T, and Cg-EmbA453E strains 
reverted closer to the WT C. glutamicum, with a mannose: arabinose ratio of 24: 1, and 14.6:1 
respectively. While these changes do not fully restore the WT ratio, there is a reversion towards 
the WT C. glutamicum from the C. glutamicum∆steA∆ripA strain. The remaining Cg-Emb 
mutants all resulted in a similar, if reduced, phenotype to the Cg-EmbG411S mutant strain, with 
Cg-EmbP505L, Cg-EmbA453V, and Cg-EmbS528A, resulting in mannose: arabinose ratios of: 3.5: 
1, 2: 1, and 3.6: 1 respectively. Suggesting that they have a similar impact on the activity of 
Emb, though of reduced severity the EmbG411S mutant.  
 
3.2.10: Cell free Cg-Emb glycosyl transferase activity of WT C. glutamicum, C. 
glutamicum∆steA∆ripA, and C. glutamicum∆steA∆ripA Cg-Emb point mutant strains: 
 
In order to determine the effect of the mutations on the rate of Emb activity cell free 
arabinosyltranferase activity was tested (Methods 6.20.1, 6.20.2). This allowed for the testing 
of both the in vitro activity of both the WT and mutant Cg-Emb proteins, as well as the 
sensitivity of the respective proteins to EMB, using a C8-Araf-Araf (YHF-1) acceptor as a 
Chapter 3: Investigation of SNPs involved in corynebacterial EMB resistance on the 
corynebacterial cell envelope 
 129 
standard, purifiable anchor, and 14C labelled pRpp for detection of incorporation by AraT 
activity (Figure 3.10).  
 
As expected the WT C. glutamicum and C. glutamicum∆steA∆ripA strain, show sensitivity to 
of EMB (Figure 3.11), as the C. glutamicum∆steA∆ripA strain produces the WT Cg-Emb and 
such the WT C. glutamicum and C. glutamicum∆steA∆ripA strain phenotypes should be 
identical, therefore upon supply of an excess of substrate in the form of pRpp, the synthesis 
should occur at a similar rate. The addition of EMB to the reaction mixture resulted in an almost 
complete reduction in the activity of Cg-Emb in both strains.  
Figure 3.10: Cell free Emb glycosyl transferase activity assay schematic. 14C labelled pRpp is converted 
into DPA by DPRE1 and DPRE2, the 14C labelled DPA is then transferred onto the acceptor by either Emb or 
AftB. The resulting products are purified from the 14C donor and separated by TLC. 
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The C. glutamicum strains with point mutations in the Cg-Emb protein, with the exception of 
the Cg-EmbA453V mutant strain, showed an altered response in the absence of EMB to the 
reaction mixture when compared to either the WT C. glutamicum strain or the C. 
glutamicum∆steA∆ripA strain. Where the absence of EMB in the reaction mixture of the WT 
C. glutamicum and C. glutamicum∆steA∆ripA strains, resulted in the loss of multiple bands of 
higher Rf, when compared to the reaction containing EMB, the mutant strains showed no 
significant change in overall product formation. The only Cg-Emb mutant strain to not show 
this response was the Cg-EmbA453V mutant which showed the same phenotype as the WT strain 
upon addition of EMB.  
 
While the majority of the mutant showed no alteration in the reaction profile in the absence of 
EMB, the Cg-EmbP505L strain showed a reduction in the higher Rf bands upon addition of EMB, 
however not the complete loss of these bands seen in the WT C. glutamicum and C. 
glutamicum∆steA∆ripA strains.  
 
In addition to the lack of any change in the reaction profile based on the presence or lack of 
EMB in the reaction mixture, of the Cg-EmbG411S and Cg-EmbS528A strains, the overall profile 
in the absence of EMB was altered slightly compared to the strains expressing the WT Cg-
Emb. With the band produced by the action of AftB, and the initial band lost in the presence 
of EMB in the WT C. glutamicum strain, appearing as multiple overlapping bands with similar 
Rfs, where in both the WT C. glutamicum, and the various mutant strains this band appeared 
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3.3: Discussion:  
 
Here we show that point mutations in the Cg-Emb protein in C. glutamicum results in 
significant changes in the cell surface, and antibiotic resistance profile of C. glutamicum. While 
this provides advantages in some situations, there is a reduction in the growth rate associated 
with the tested mutations in Cg-Emb when not under antibiotic stress compared to WT C. 
glutamicum, as well as a significant decrease in the permeability of the cell surface to DPH 
(Freihofer et al., 2016; Wang et al., 2019). These phenomena are likely to be linked as a change 
in the permeability of the cell is likely to affect the ability of some antibiotics to be able to 
reach the target required for efficacy (Lanéelle et al., 2001). However, due to the hydrophobic 
nature of the method for testing permeability, further testing into the permeability of the cell 
surface to hydrophilic compounds would also be required, as the decrease in permeability of 
the cell surface does not result in a universal increase in the ability of the bacteria to withstand 
antibiotics.  
 
Antibiotic sensitivity screening of the Cg-Emb point mutations in the C. 
glutamicum∆steA∆ripA strain significantly alters the sensitivity of C. glutamicum to 
antibiotics, further confirmation of the effect of these mutations by the generation of 
complements of the C. glutamicum∆emb strain recombinantly expressing Cg-Emb containing 
the studied point mutations to confirm that these mutations affect the WT C. glutamicum strain 
in the same way as they do the C. glutamicum∆steA∆ripA strain. This would confirm that these 
changes in sensitivity are not due confounding factors caused by changes in the physiology of 
the cell resulting from the deletion of multiple genes.  
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Further study into the effect of the mutations on the composition of the cell wall core in the 
Cg-Emb point mutation strains is required to understand how the surface of the cell is affected 
by these mutations. One method of this would be to purify the mAGP  (Moynihan et al., 2019), 
the composition could then be determined by use of gas chromatography of aditol acetate 
derivatized material (Methods 6.18.1 and 6.18.2). With investigation of the composition of the 
AG attached to the cell wall required to determine the effect on the AG in addition to the effect 
on the LM and LAM (Alderwick et al., 2005). The effect is likely to be minimal in the mutants, 
as only the Cg-EmbG411S strain showed a clear alteration in the cell wall bound lipids to provide 
a potential explanation as to the change in the permeability of the cell.  
 
The changes in the lipoglycan composition is likely due to the changes in the availability of 
the polyprenyl anchor which is required for both DPA and for DPM, with DPA acting as the 
source of arabinose for Cg-Emb alterations to the activity of Cg-Emb will have an impact on 
the pool of lipid anchored sugars available and as such will have a knock-on effect on the LM 
and LAM (Kolly et al., 2014). In addition to the changes in the ratio of Cg-LM to Cg-LAM 
which result in changes to the ratio of mannose to arabinose in the Cg-LM and Cg-LAM 
extraction from both the C. glutamicum∆steA∆ripA in comparison to the WT C. glutamicum 
strain and the relative change compared to the composition of the Cg-Emb point mutant strains 
suggests that, while Cg-Emb is not involved in the synthesis of these lipoglycans, the change 
in the activity of the enzyme results in large scale changes to the composition of the entire cell, 
with further work to characterise these changes required to fully understand the effect of 
mutations in Cg-Emb on the cell as a whole (Alderwick et al., 2006, 2005).  
 
Due to the location of the mutations in the Cg-Emb proteins will all of the mutations in this 
study occurring in the transmembrane domain of Cg-Emb, further study of both the full-length 
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Cg-Emb and Mtb-Emb protein is required in vitro (Alderwick et al., 2011; Goude et al., 2009). 
Due to the difficulty in the expression and purification of membrane proteins the majority of 
the research in to the function of Cg-Emb, both in C. glutamicum and Mtb has been focussed 
on the soluble C-terminal domain removed from the transmembrane domain (Alderwick et al., 
2011; Shi et al., 2006). This is likely to have impeded understanding of the mechanism by 
which EMB acts, as the conservation of a large membrane spanning domain of all Emb proteins 
implies that the domain is vital for the function of the protein beyond ensuring that it remains 
close to the membrane where the substrates are bound, with it being identified as the 
recognition domain (Anandan and Vrielink, 2016; Goude et al., 2009; Jeffery, 2016).  
 
Further analysis on the effect the deletion of either steA or ripA on the cell surface of C. 
glutamicum, would provide insight into the mechanism by which the deletion of these genes 
results in increased sensitivity to EMB. Further characterising the functions of SteA and SteB 
through the purification of recombinantly expressed protein determination of their in vitro 
functionality, would also provide insight into why the deletion of proteins is linked to an 
increased sensitivity to EMB. RipA acts as an endopeptidase, degrading the peptidoglycan, and 
has been shown to localise to the septa of dividing cells, and as such deletions in this gene are 
likely to affect the integrity, and potentially the composition of, the peptidoglycan (Böth et al., 
2011; Chao et al., 2013; Lim et al., 2019; Nikitushkin et al., 2015). 
 






Biochemical investigation of a mycobacterial 













AG provides a scaffold for multiple components of the mycobacterial cell envelope and its 
structure and biosynthesis has been extensively studied (Abrahams and Besra, 2016; Alderwick 
et al., 2008, 2005; Birch et al., 2008). The transport mechanism responsible for the 
translocation of galactan from the inner leaflet of the cytoplasmic membrane to the external 
leaflet, has yet to be precisely determined, although the transporter responsible has been 
predicted (Abrahams and Besra, 2016; Dianišková et al., 2011).  
 
AG synthesis occurs in two stages: the cytoplasmic synthesis of galactan attached to decaprenyl 
pyrophosphate, and the periplasmic decoration of the galactan with arabinan domains. Galactan 
is built on a linker unit formed of a GlcNAc (1à3) L-rhamnose (Rha) attached to a decaprenyl 
pyrophosphate. The formation of this linker unit is catalysed by the action of WecA and WbbL 
(Jin et al., 2010; McNeil et al., 1990; Mills et al., 2004). With WecA responsible for the 
addition of the GlcNAc-1-phosphate onto the decaprenyl phosphate from a UDP-GlcNAc 
carrier. The addition of Rha to form the linking unit is catalysed by Wbbl, from a TDP-Rha 
carrier. 
 
 The galactan core is then built upon the linker unit (C50-P-GlcNAc-Rha) with the addition of 
the first two galactofuranose residues catalysed by the action of GlfT1, using UDP-Galf as a 
substrate (Alderwick et al., 2008; Mikusova et al., 2006). The nascent galactan chain is then 
elongated by the addition of GlfT2, introducing alternating α(1à5) α(1à6) glycosidic bonds, 
with the mature galactan comprising ~30 Galf residues (Kremer et al., 2001a; Rose et al., 2006). 
While the enzymes responsible for the synthesis of the galactan are known (Table 1.2, Figure 
4.1), the mechanism by which the process is terminated, and the process by which the galactan 
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is flipped across the cytoplasmic membrane remains unclear (Abrahams and Besra, 2016; 
Daffe et al., 1990).  
 
Upon flipping of the mature galactan to the external leaflet of the cytoplasmic membrane, the 
galactan is decorated with three Araf chains (Figure 4.1). The three branch points are located 
at residues: 8, 10, and 12 of the galactan chain. The addition of the initial, priming, arabinose 
Figure 4.1: Synthesis, and translocation of arabinogalactan in mycobacterial species. Showing the process by 
which galactan is synthesised in the cytoplasm of mycobacterial cells, and how the translocated galactan is 
decorated with arabinan domains after translocation. 
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is catalysed by the action of AftA. AftA catalyses the transfer of arabinfuranose onto the 
galactan chain through the formation of an α(1à5) glycosidic bonds, using DPA as a source 
of arabinose (Alderwick et al., 2005). Once the branches are primed they are extended by the 
action of EmbA and EmbB, which extend the arabinan domain through a series of α(1à5) 
glycosidic bonds, using DPA as a source of arabinose (Escuyer et al., 2001). Branching points 
are introduced into the arabinan domain by the action of AftC, and AftD, through the formation 
of α(1à3) glycosidic bonds, using DPA as a source of arabinose (Birch et al., 2008; Škovierová 
et al., 2009). 
 
The terminal region of the arabinan domain is a branched hexarabinofuranose motif, and is 
produced by AftB, AftC, AftD, EmbA, and EmbB. With the terminal b(1à2) linked araf 
residues added by the action of AftB, using DPA as the source of arabinose (Alderwick et al., 
2006, 2005; Birch et al., 2008; Escuyer et al., 2001; Jankute et al., 2017; Škovierová et al., 
2009, 2009). The mature arabinogalactan is cleaved from the decaprenyl phosphate, and 
attached to the muramic acid of the PG, by Lcp1 (Harrison et al., 2016). The terminal arabinose 
residues act as the attachment site for mycolic acids, catalysed by Antigen 85, with the 5’ 
carbon of the terminal arabinose residues being esterified to the mycolic acids (Backus et al., 
2014).  
 
While there has been a comprehensive study predicting the ABC-transporters in Mtb, 
identifying at least 26 complete and 11 incomplete ABC-transporters. Of these transporters 
predicted to function as a polysaccharide transporter is Rv3781, and Rv3783, which have been 
predicted to form a tetrameric ABC-transporter (Braibant et al., 2000). Rv3781 is predicted to 
function as the nucleotide binding domain responsible for the hydrolysis of ATP providing the 
energy required for the substrate transport, and Rv3783 is predicted to form the transmembrane 
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pore across the cytoplasmic membrane (Beis, 2015; Braibant et al., 2000; Dianišková et al., 
2011). 
 
The location of these genes in the Mtb genome among various genes involved in the 
biosynthesis of arabinogalactan (Table 1.2). The importance of these predicted ABC 
transporters have been confirmed, as the Rv3781 ortholog in M. smegmatis, MSMEG_6366 
has been shown to essential for bacterial survival. However, the predicted membrane spanning 
domain for galactan transport, MSMEG_6369, was found to be non-essential  (Dianišková et 
al., 2011).  
 
Here we aim to over-express, purify and characterise recombinant proteins from the 
mycobacterial galactan transporter system. Making use of chemically synthesised galactan 
oligomers, we investigated the precise biochemical interactions between the NBD 
component of the M. smegmatis orthologs of Rv3781/Rv3783 ABC transporter system and 














4.2.1: Bioinformatic analysis of Rv3781, Rv3783, and M. smegmatis orthologs:  
 
While the conservation of the mycobacterial proteins predicted to be involved in galactan 
export have been shown (Dianišková et al., 2011), a basic bioinformatic analysis (Method 6.1.2) 
of Rv3781 and Rv3783 alongside predicted M. smegmatis and M. leprae orthologs was 
conducted to ensure the accuracy of previous predictions. M. smegmatis was selected due to 
the previously available information on the deletion of the predicted orthologs, while M. leprae 
was selected due to the level of genomic depletion of the bacteria, which ensures that if the 
gene is conserved between Mtb and M. leprae the gene is likely to be required for survival 
(Cole et al., 2001; Dianišková et al., 2011).  
 
Sequence analysis of the Mtb proteins (Rv3781 and Rv3783) against the M. smegmatis 
orthologs (MSMEG_6366 and MSMEG_6369) showed significant levels of homology to both 
the NBD and the MSD (Table 4.1). There is 90 % and 91 % amino acid sequence identity 
between Rv3781 against the M. smegmatis and M. leprae orthologs respectively, this high level 
of sequence conservation supports the prediction that the functions of these genes are 
conserved between the three species.  
 
Table 4.1: BLASTp analysed primary structure of Rv3781 and Rv3783 against M. smegmatis and M. leprae 
orthologs. Showing high levels of conservation in both the NBDs, and in the MSDs. 
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The MSDs are more sequentially diverse, with M smegmatis and M. leprae orthologs having 
identity of 80 % and 84 % to Rv3783. However, as increased structural variability across all 
MSDs is observed, due one of their primary functions being the formation of a pore rather than 
providing enzymatic function, this increase in the sequence divergence can be accounted for. 
 
Analysis of the number and location of transmembrane helices in both the predicted membrane 
spanning domain and the predicted nucleotide binding domain predict that the membrane 
spanning domains all form six transmembrane helices (Figure 4.1, Appendix 1). Membrane 
spanning domains contain 4- 8 transmembrane helices and require the formation of a dimer in 
order to be able to function (Braibant et al., 2000, Higgins and Linton, 2004). Prediction of the 
membrane topology of Rv3783 and MSMEG_6369 predicts that the sequence similarity of 



























Figure 4.2: Transmembrane prediction of mycobacterial MSDs. A) Rv3783, B) MSMEG_6369. Predictions 
generated using TMHMM, and TMPred, amino acids predicted to be the first and final residue of the 
transmembrane helix given, final residue noted. Both the Mtb and the M. smegmatis ortholog show six 
transmembrane helices, with similar start and end points, as expected by the sequence comparison. 
Transmembrane predictions listed in Appendix 2. 
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As expected, the nucleotide binding domains are not predicted to contain any transmembrane 
helices. Further analysis of the sequence of these proteins was used to confirm the presence of 
the conserved NBD motifs that are essential for functionality; Walker A, Walker B, ABC-
signature (Figure 4.3).  
 
Both Rv3781 and MSMEG_6366 contain Walker A, Walker B, H-loop, and ABC signature 
motifs (Figure 4.3). Additionally, both Rv3781, and MSMEG_6366, do not contain the A-loop, 
composed of an aromatic amino acid residue, most commonly a phenylalanine, 23- 27 residues 
upstream of the Walker A motif. The A-loop forms an interaction with the adenosine ring of 
ATP (Ambudkar et al., 2006). However, while this residue is seen in many ABC-transporters, 
it is not conserved in all ABC-transporters. Therefore, the lack of this residue in both proteins 
Figure 4.3: Sequence alignment of Rv3781, and MSMEG_6366. Predicted nucleotide binding domains analysed 
for conserved motifs found throughout ABC-transporters. Walker A, ABC-signature, Walker B, and H-loop motifs 
annotated. Notably absent is the A-loop, upstream of the Walker A motif, however this motif is not conserved 
in all NBDs of ABC-transporters, but is seen in the majority.  
1       10        20        30        40        50        60
Rv3781          P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LVS  H  H            S                N               DPHH Q N V T E
MSMEG_6366       P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LMT  R  R            T                Q               SSSA E D F A S
        70        80        90       100       110       120
Rv3781      GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIL                                T          I        Y   N W K
MSMEG_6366   GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIM                                S          V        F   E S T
       130       140       150       160       170       180
Rv3781    IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              Q                                             
MSMEG_6366 IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              L                                             
       190       200       210       220       230       240
Rv3781    LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          D  R                                I       L   N V A
MSMEG_6366 LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          E  K                                M       M   D T T
       250       260       270                              
Rv3781    IEEVVRAYEGEDAARHVREVL ET  D                                                      A  QA RQNVQG
MSMEG_6366 IEEVVRAYEGEDAARHVREVL ET  D                                                      E  AR AH....
 
1       10        20        30        40        50        60
Rv3781          P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LVS  H  H            S                N               DPHH Q N V T E
MSMEG_6366       P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LMT  R  R            T                Q               SSSA E D F A S
        70        80        90       100       110       120
Rv3781      GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIL                                T          I        Y   N W K
MSMEG_6366   GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIM                                S          V        F   E S T
       130       140       150       160       170       180
Rv3781    IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              Q                                             
MSMEG_6366 IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              L                                             
       190       200       210       220       230       240
Rv3781    LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          D  R                                I       L   N V A
MSMEG_6366 LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          E  K                                M       M   D T T
       250       260       270                              
Rv3781    IEEVVRAYEGEDAARHVREVL ET  D                                                      A  QA RQNVQG
MSMEG_6366 IEEVVRAYEGEDAARHVREVL ET  D                                                      E  AR AH....
 
1       10        20        30        40        50        60
Rv3781          P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LVS  H  H            S                N               DPHH Q N V T E
MSMEG_6366  P I T AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LMT R R   T    Q    SSSA E D F A S
        70        80        90       100       110       120
Rv3781      GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIL                                T          I        Y   N W K
MSMEG_6366 GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIM       S   V  F   E S T
       130       140       150       160       170       180
Rv3781    IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              Q                                             
MSMEG_6366 IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL   L                
       190       200       210       220       230       240
Rv3781    LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          D  R                                I       L   N V A
MSMEG_6366 LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG   E K          M  M   D T T
       250       260       270                              
Rv3781    IEEVVRAYEGEDAARHVREVL ET  D                                                      A  QA RQNVQG
MSMEG_6366 IEEVVRAYEGEDAARHVREVL ET D         E AR AH....
 
1       10        20        30        40        50        60
Rv3781          P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LVS  H  H            S                N               DPHH Q N V T E
MSMEG_6366       P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LMT  R  R            T                Q               SSSA E D F A S
        70        80        90       100       110       120
Rv3781      GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIL                                T          I        Y   N W K
MSMEG_6366   GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIM                                S          V        F   E S T
       130       140       150       160       170       180
Rv3781    IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              Q                                             
MSMEG_6366 IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              L                                             
       190       200       210       220       230       240
Rv3781    LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          D  R                                I       L   N V A
MSMEG_6366 LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          E  K                                M       M   D T T
       250       260       270                              
Rv3781    IEEVVRAYEGEDAARHVREVL ET  D                                                      A  QA RQNVQG
MSMEG_6366 IEEVVRAYEGEDAARHVREVL ET  D                                                      E  AR AH....
 
1       10        20        30        40        50        60
Rv3781          P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LVS  H  H            S                N               DPHH Q N V T E
MSMEG_6366      P I T  AWVEFPIFDAK RSLKKA LGKAGG IGRN SNVVVIEALRDITM LMT R  R          T               Q             SSSA E D F A S
        70        80        90       100       110       120
Rv3781      GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIL                                T          I        Y   N W K
MSMEG_6366  GDRVGLVGHNGAGKSTLLRLLSGIYEPTRG A V GRVAPVFDLG GMDPEISG ENIM       S   V  F   E S T
       130       140       150       160       170       180
Rv3781    IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL              Q                                             
MSMEG_6366 IIRGLFLGQTRKQM AKVDEIAEFTELGEYLSMPLRTYSTGMRVRLAMGVVTSIDPEILL  L              
       190       200       210       220       230       240
Rv3781    LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG          D  R                                I       L   N V A
MSMEG_6366 LDEGIGAVDA FL KAQSRLQ LVERSGILVFASHSNEFLARLCKTA WIDHG IR  GG   E K          M  M   D T T
       250       260       270                              
Rv3781    IEEVVRAYEGEDAARHVREVL ET  D                                                      A  QA RQNVQG
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is unlikely to indicate that they are non-functional, although there may be an impact on the 
binding affinity of ATP, and therefore the maximal rate of ATP turnover.  
 
Due to the presence of individually transcribed domains, and the predicted number of 
transmembrane helices in the MSD, the fully functional ABC-transporter is predicted to form 
a tetramer comprised of two copies of both the NBD and the MSD. 
 
4.2.2: Expression and purification of maltose binding protein (MBP) tagged 
MSMEG_6366: 
 
Purification of MSMEG_6366 from E. coli BL21 (DE3) expressing pMAL-c2x-
MSMEG_6366, and purified using an amylose resin MBP-trap column (Methods 6.21.1, 
6.21.3). Resulting in the purification of a protein corresponding to the molecular weight of 
MSMEG_6366, tagged with MBP (72 kDa), with minimal contaminating proteins (Figure 4.4).  
Chapter 4:                   Biochemical investigation of a mycobacterial galactan transport system 
 144 
 
The effect of the presence of low-level contaminating proteins on assays is likely to be 
negligible as the abundance of MSMEG_6366 outweighs any contaminating proteins.  
 
 












Figure 4.4: SDS-PAGE analysis of purification of MBP-tagged MSMEG_6366. 1) 
Protein standard ladder, 2) clarified E. coli cell lysate, 3) cell lysate flowthrough, 4) 
protein column wash, 5) protein elution. Showing purification of MBP-tagged 
MSMEG_6366 from E. coli. 
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4.2.3: Intrinsic tryptophan fluorescence ligand binding assay of MSMEG_6366 to 
chemically synthesised galactan analogues:  
 
To determine if MSMEG_6366 is able to interact with the galactan molecule either during or 
before the initiation of translocation across the membrane, purified MSMEG_6366 intrinsic 
tryptophan fluorescence (ITF, Methods 6.21.4, 6.21.5) measuring fluorescence change at 350 
nm was used to measure ligand binding. The change in fluorescence, beyond the effect of 
dilution, of the protein when galactan analogues (Figure 4.5) were titrated was used to calculate 
the binding affinity.  
Figure 4.5: Schematic representation of galactan analogues. Showing the linker unit attached to the variable 
length galactofuranose chain (chain length of ligands used noted as Galfn).  formed of an N-acetyl glucosamine 
rhamnose linking unit extended by 1à 4 glycosidic linkage to the galactofuranose chain, followed by alternating 
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To determine that interactions were specific to galactan analogues, and that changes in 
fluorescence were not the result of non-specific interactions to MSMEG_6366 ITF was 
conducted using maltose as a control ligand (Figure 4.6). which showed no detectable 








Figure 4.6: Binding curve of maltose to MSMEG_6366. Analysis of binding gave no binding coefficients, 
showing there is no effect on intrinsic tryptophan fluorescence upon titration of maltose. N=3 
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Figure 4.7: Binding curves of galactan analogues to MSMEG_6366. A) GlcNAc-Rha-Galf5, B) GlcNAc-Rha-Galf6, 
C) GlcNAc-Rha-Galf7, D) GlcNAc-Rha-Galf8, E) GlcNAc-Rha-Galf9, F) GlcNAc-Rha-Galf12, G) GlcNAc-Rha-Galf14. 
Showing MSMEG_6366 is able to bind to the galatan analogues, with variable binding affinity depending on the 
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Initial characterisation of ligand affinity was conducted using a galactan analogue composed 
of GlcNAc-Rha-Galf6, with the determination of a relatively high affinity interaction with 
MSMEG_6366, Kd: 0.47 µM (Figure 4.6, Table 4.2). This suggests that MSMEG_6366 is able 
to interact in some way to either the linker unit or the galactan chain, as such the use of different 
length polygalactofuranose analogues were tested to attempt to determine the effect of 
extending the chain on the affinity of the protein to the ligand.    
 
Analysis of the ligand binding affinities of MSMEG_6366 (Method 6.21.4, Figure 4.5, Table 
4.2) to various artificially generated galactan analogues further suggest that MSMEG_6366 
interacts with galactan analogues, and therefore with the galactan in vivo, with different 
affinities depending on the length of the poly-galactofuranose chain. However, due to the 
limitations of the experiment not all binding curves achieved saturation, and therefore there is 
significant error in the Kd and Bmax values for these ligands.  
 
The galactan analogue with the highest affinity for MSMEG_6366 was comprised of six 
galactofuranose residues attached to the linking unit. Analysis of the effect of the length of the 
galactofurnaose chain of the ligand on the binding affinity to MSMEG_6366 shows that there 
is no correlation between the length of the analogue and the binding affinity (Figure 4.6). This 
Table 4.1: Binding constants of synthesised galactan analogues to MSMEG_6366. Showing dissociation 
constant (Kd), and maximal change in fluorescence upon saturation of all binding sites (Bmax) and standard error 
of the values. 
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suggests that the effect of increasing the length of the polygalactofuranose chain is not the sole 
factor for the change in the binding affinity. If the chain length was the sole factor this would 
be likely to lead a decrease in the binding affinity upon the sequential extension of 
galacofuranose chain, as the flexibility of the analogue would increase and so there would be 
increased forces acting to break the interactions between MSMEG_6366 and the ligand, 





















Figure 4.8: Galactofuranose chain length plotted against binding affinity to MSMEG_6366. Data does not show 
the predicted inverted bell curve of an optimum chain length with decreased affinity for chain lengths longer or 
shorter than the optimal binding length.  
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4.2.4: Predicted physiochemical properties of galactan analogues against binding affinity 
to MSMEG_6366: 
 
As the chain length of the galactan analogue does not appear to be the sole contributing factor 
in the changes in binding affinity, predictions of the chemical properties were generated to 
attempt to understand the cause for the changes in the affinity between the various galactan 
analogues and MSMEG_6366. The physiochemical properties of the various analogues were 
calculated using the Chemicalize chemoinformatics tool 
(https://chemicalize.com/#/calculation, Method 2.22), resulting in the generation of predictions 
including: isoelectric point, Van der Waals surface area, hydrogen bond donor count, and 
hydrogen bond acceptor count (Table 4.3).  
 
As the binding affinity of the galactan analogues to MSMEG_6366 does not show the predicted 
bell curve where galactan analogues with shorter galf chains show lower affinity, with affinity 
increasing until reaching the optimum chain length before decreasing once extended beyond 
the optimum, the chemical properties of the ligands (Table 4.3), were plotted against Kd in 
order to determine if any of the predicted properties of these molecules would explain the 
unexpected binding affinity data (Figure 4.7).  
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Figure 4.9: Predicted physiochemical properties of galactan analogues plotted against Kd to MSMEG_6366. 
A) number of hydrogen bond donors in blue, number of hydrogen bond acceptors in red, B) minimum 
projection radius in blue, maximum projection radius in red, C) minimum projection area in blue, maximum 
projection area in red, D) number of hydrogen bond donors: number of hydrogen bond acceptors, E) 
topological polar surface area, F) molecular refractivity, G) isoelectric point, H) Van der Waals volume, I) Van 
der Waals surface area in blue, solvent accessible surface area in red, J) polarizability, K) topological polar 
surface area. Showing limited relationship between Kd and the predicted physiochemcical properties of the 
galactan analogues to MSMEG_6366.  
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Comparison of the predicted properties of the ligands against the Kd to MSMEG_6366 resulted 
in no factors giving an R2 value above 0.5 using linear regression, therefore none of the 
predicted values correlate to 50 % of the variance in the experimental data (Table 4.4). That 
the best model for predicting the binding affinity of the ligand is the minimum projection 
radius, suggests that prediction of the properties is not enough to accurately determine cause 
of the change in the binding affinity, or that it is a factor of more than one property. The cause 
of this increase in correlation is that the minimum projection radius shows a small range, with 
only the range of the predicted isoelectric point being smaller (Table 4.4), and therefore the 




Table 4.3: Linear regression analysis of predicted physiochemcial properties of galactan analogues against the 
determined dissociation constant. Calculated R2 giving a range of 0- 1, 0 corresponding to no correlation, and 1 
corresponding to perfect correlation showing no single predicted property of the ligands analysed correlates with 
the binding affinity to MSMEG_6366.  
Linear least squares fit
Hydrogen bond donor count 0.1232
Hydrogen bond acceptor count 0.1232
Topological polar surface area (2) 0.1232
Polarizability (3) 0.1232
Molar refractivity (cm3/mol) 0.1232
Isoelectric point 0.2761
Van der Waals volume (3) 0.1222
Van der Waals surface area (2) 0.1232
Solvent accessible surface area (2) 0.1209
Topological polar surface area (2) 0.1232
Minimum projection area (2) 0.1555
Maximum projection area (2) 0.1635
Minimum projection radius () 0.4943
Maximum projection radius () 0.2269
Hydrogen bond donor/ hydrogen bond acceptor ratio 0.2016
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4.2.5: Structural characterisation of MSMEG_6366: 
 
Attempts to characterise the structure of purified MSMEG_6366 (Method 6.23) both with and 
without ligand present, at various protein concentrations, did not result in the generation of 
protein crystals of a resolution high enough to allow for structural determination. 
 
Attempts at optimisation of the buffer conditions for the protein to form high-resolution 
crystals lead to no detectable increase in organisation of the structure. Attempts to remove the 
MBP-tag in order to remove the flexible linking region between MSMEG_6366 and the MBP-
tag did not yield significant protein cleavage.  
 
4.2.6: Expression and purification of MBP-tagged MSMEG_6369: 
 
Standard in E. coli strains used for the expression of recombinant protein, such as E. coli BL21 
DE3 and E. coli C41 DE3 (Safarpour et al., 2017; Schlegel et al., 2015), did not yield any 
detectable levels of expression upon induction of expression of MSMEG_6369, using Western 
blot at a molecular weight of 74 kDa. However, low level expression of MBP-MSMEG_6369 
was detected in E. coli Shuffle T7 by Western blot (Method 6.21.2), with further investigation 
showing in low level soluble expression of MBP-MSMEG_6369 (Figure 4.8).  
 
Due to the low-level expression and the reduced biomass in the strain able to express detectable 
levels of MBP-MSMEG_6369 present in the clarified lysate of E. coli no purified 
MSMEG_6369 was obtained. Due to the presence of membrane fragments in the clarified 
lysate, we predicted that MSMEG_6369 has inserted into the E. coli cytoplasmic membrane.  
 































Figure 4.10: Western blot of inducible expression of MSMEG_6369 in E. coli K12 Shuffle T7. A) SDS-PAGE 
separation of proteins, B) anti-MBP Western blot of proteins. 1) Protein standard ladder, 2) cell lysate of 
uninducted cells, 3) cell lysate of cells induced with 1 mM IPTG, 4) clarified cell lysate of uninduced cells, 5) 
clarified cell lysate of cells induced with 1 mM IPTG. Showing expression of MBP-tagged MSMEG_6369 present 
in the clarified lysate of E. coli both with and without IPTG, showing some un-induced expression, with increased 
expression upon induction.  
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4.3: Discussion:  
 
The determination of the binding of galactan analogues to MSMEG_6366 when not in a full 
complex lends further support for the identification of Rv3781 and Rv3783 and their M. 
smegmatis orthologs as the transporters for galactan across the inner membrane (Abrahams 
and Besra, 2016; Dianišková et al., 2011). Providing evidence for interactions between the 
transporter and the substrate, that there was no detectable interaction between MSMEG_6366 
and maltose when used as a control supporting that the interactions are not an artefact. 
Additional experiments are required to fully characterise the binding of MSMEG_6366 to these 
ligands as much of the binding data presented is incomplete and would require additional 
binding experiments to confirm and improve the binding data presented as well as the use of 
additional controls including using polysaccharides that are not analogous to galactan as 
controls.  
 
The change in the affinity of the analogues caused by the addition of further galactofuranose 
residues is to be expected, as changes in the length of the ligand are likely to alter the 
interactions between the protein and the solvent. There are likely to be few high energy 
interactions,  in order to allow efficient transport across the membrane binding would likely be 
relatively weak (Cuthbertson et al., 2007).  
 
Further study of the binding affinities of galactan analogues to MSMEG_6366 is required to 
determine the full range of binding affinities, as well as to confirm the binding affinities of 
ligands that did not achieve saturation. One method that potentially would overcome the issues 
encountered with ITF that did not allow for saturation to be achieved would be the use of 
isothermal calorimetry. Additionally extending the galactofuranose chain beyond 14 residues 
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would provide insights into the interactions between MSMEG_6366 and mature galactan 
(Benabdelhak et al., 2003). As the trend of binding constants against length of the 
galctofuranose chain does not follow a clear pattern, determining the effect on the binding for 
GlcNAc-Rha-Galfn, where n is one to the maximal length for mature galactan would potentially 
provide information on the periodicity of the galactan structure as well as aid in understanding 
the interactions between the ligands and MSMEG_6366.  
 
Galactan has been predicted to form a helical structure (Alderwick et al., 2005). However, due 
to the difficulty of structurally characterising polysaccharide structures, caused by the many 
potential hydrogen binding patterns of polysaccharide chains, and the inherent flexibility of 
polysaccharide chains, there is still no experimentally confirmed structure. As such defining 
the full pattern of binding affinities of the different lengths of galactan, in both the M. 
smegmatis and Mtb proteins might provide insight into this structure (Duus et al., 2000). Use 
of the ligands used in this study would potentially reduce the complexity of the process required 
to elucidate the physical structure of galactan as mature galactan contains 30 galf residues. The 
use of shorter analogues would decrease the difficulty of experiments such as 1H-1H nuclear 
overhauser effect spectroscopy (NOESY). NOESY is used to determine the signals that arise 
from protons that are close in space to each other. This would allow for some determination of 
which residues are spatially close together and therefore could give some insight into the 
structure of the molecule, as it would potentially highlight which sugar residues are close to 
each other in solution (Cescutti et al., 2016; Duus et al., 2000; Leeflang et al., 2000).  
 
While it is possible to predict the properties of polysaccharides such as galactan, it is difficult 
to determine how accurate these predictions are, as polysaccharides are generally flexible, and 
therefore difficult to generate crystal structures of. This is difficulty is compounded by the 
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incorporation of water into the structure (Duus et al., 2000). In addition to the use 1H-1H 
NOESY it would be possible to gain insights into secondary structure by labelling 
mycobacterial cells with 13C galactose, and purification of the labelled galactan from the cell 
wall by running NOESY experiments using the NMR detectable 13C, which would potentially 
highlight residues in the galactan chain that are close enough to each other in space to be 
detectable by NMR (Zhang et al., 2019).  
 
While the work presented lends some evidence to the prediction that Rv3781 and Rv3783 are 
involved in the transport of galactan, further work is required to fully characterise these 
proteins. With structural characterisation of these proteins both as a complex and interacting 
either with the artificial galactan analogues utilised in this study, or with galactan purified from 
the mycobacterial cell wall would allow for improved ability to determine the residues involved 
in the interactions between galactan and Rv3781. This would then allow for expression and 
purification of proteins with single amino acid point mutations to confirm these predictions 
(Cox et al., 2016).  
 
As the efforts in this project focussed primarily on the generation of un-cleaved fusion proteins 
and attempts to remove the tag were unsuccessful, further work would likely require the use of 
alternate constructs of both MSMEG_6366 and MSMEG_6369. These constructs should 
express these proteins with a less flexible, and less bulky, tag to reduce the structural variability 
of the protein in solution and therefore potentially improve the ability of the protein to 
crystalize (Smyth et al., 2003).  
 
Further to structural work to characterise these proteins, work to determine the rate of transport 
of galactan across the membrane would allow for a greater understanding of how the 
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mycobacterial cell wall is built, and give further insight into the energy requirements of cell 
wall synthesis on the cell, which to a point is understood due to the size and complexity of the 
unique cell wall structures, however the energy cost of transport of many of the cell wall 
elements has not been characterised (Dong et al., 2017; Touchette and Seeliger, 2017).  
 
While no purified MSMEG_6369 could be generated during this project, inducible expression 
of MSMEG_6369 was achieved. Further work to optimise the expression conditions and 
increase the yield of MSMEG_6369 from what was achieved during this project (Figure 4.10), 
would hopefully allow for purification of MSMEG_6369. Additionally the use of other 
methods of extracting proteins from the membrane may improve the efficiently of protein 
purification (Anandan and Vrielink, 2016; Pandey et al., 2016; Rothnie, 2016). 
 
 Further work to build on this stable protein expression could lead to the generation of an ABC-
transport system, when combined with purification of MSMEG_6366, this would allow for the 
generation of an ATP-turnover assay to calculate the rate of ATP hydrolysis by coupling of 
maintenance of ATP levels by the action of pyruvate kinase conversion of ADP and 
phosphoenyol pyruvate, to pyruvate and ATP. Pyruvate can then be converted to lactate by the 
action of lactate dehydrogenase, which causes NADH to be converted into NAD+. The 
conversion of NADH to NAD+, changes the fluorescence spectrum of the solution, therefore 
allowing the both the detection of ATP turnover, while also maintaining the level of ATP in 
the reaction solution (Rule et al., 2016).  
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The mycobacterial cytoplasmic membrane is a vital component of the mycobacterial cell, with 
both the inner and outer leaflet acting as the site for the synthesis of various cell wall structures. 
The inner leaflet of the cytoplasmic membrane is the site of synthesis for essential cell wall 
compounds, such as the galactan domain of AG, and the lipoglycans (Alexander et al., 2004; 
Birch et al., 2008; Escuyer et al., 2001).  
 
In the last decade numerous publications have revealed the mechanisms of biosynthesis of the 
mycobacterial cell envelope (Harrison et al., 2016; Mishra et al., 2011; Škovierová et al., 2010). 
Most of the discrete enzymes involved in cell envelope anabolism have been characterised by 
either direct biochemical investigation or reverse genetic approaches (Alderwick et al., 2008, 
2005; Cai et al., 2014; Mishra et al., 2012). Many of these enzymes have also been identified 
as having potential to be targeted by small molecule inhibitors.  
 
The nature of scientific investigation dictates that the most experimentally tractable systems 
are usually studied first, due to the relative ease of working with cytosol soluble proteins. This 
has resulted in a significant increase in our understanding of mycobacterial cell envelope 
biosynthetic processes. In contrast, the mechanisms and processes by which cell envelope 
intermediates pass through the cytoplasmic membrane (the primary barrier of the cell) have 
been neglected, largely due to the difficulty in studying complex cell membrane processes 
(Shimizu et al., 2018).  
 
This “final frontier” of mycobacterial physiology deserves significant attention due to its 
importance in the pathway to the establishment of a mature and fully functional cell envelope. 
While there has been much research focussing on the development of anti-mycobacterial 
compounds, the determination of the precise mechanism of action has not always been able to 
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be determined before clinical use (Goude et al., 2009; Safi et al., 2008; Srivastava et al., 2009; 
Tsukamura, 1965). The prime example of this is the use of EMB for the treatment of TB. The 
understanding of how EMB inhibits the essential arabinosyltransferase proteins (EmbCAB) 
remains a point of debate (Alderwick et al., 2007; Belanger et al., 1996; Goude et al., 2009; 
Khoo et al., 1996; Pawar et al., 2019; Takayama and Kilburn, 1989). With initial determination 
of the mechanism of action being determined from the generation of resistant mutations in 
clinical isolates leading to the identification of the EmbCAB proteins as the targets 
(Radmacher, 2005; Safi et al., 2008; Srivastava et al., 2009).  
 
LM and LAM are key immunomodulatory glycoconjugates distributed throughout the 
mycobacterial cell envelope (Pitarque et al., 2008). During the synthesis of LM and LAM, the 
pathways progresses though an undefined translocation system (Figure 1.17). Analogous 
biosynthetic pathways appear in other bacterial organisms with the formation of Lipid A in 
Gram negative species being a prime example (H. Singh et al., 2016; Xie et al., 2015). In Chapter 
2, we sought to identify the protein(s) responsible for moving PIMs across the cytoplasmic 
membrane. This lead to use of the known E. coli lipid A transporter, MsbA to identify Rv1272c 
and Rv1273c as putative homologs in Mtb through bioinformatic analysis (Figures 2.2, 2.3, 
Table 2.1) (H. Singh et al., 2016). The generation and characterisation of a double deletion 
mutant strain in the model organism C. glutamicum, and complementation with the Rv1272c 
and Rv1273c led to the identification of NCgl0925 and NCgl0926 as the components of a 
conserved predicted heterodimeric ABC-transporter in the Corynebacteriales suborder, as the 
complex responsible for the translocation of PIMs (Figures 2.10-12, 2.14, 2.18, 2.20) (Gupta 
et al., 2019; Wang et al., 2010). With future work required to understand the mechanism of 
translocation of PIMs, potentially leading to the generation of an inhibitor capable of disrupting 
this process, either through the development of novel small molecule inhibitors, or through 
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drug repurposing (Cha et al., 2018; Patel et al., 2019; Pushpakom et al., 2019; Singh et al., 
2019). 
  
AG provides the base upon which the mycomembrane is attached (Alderwick et al., 2015). 
EMB has been hypothesised to target the Emb proteins responsible for the extension of the 
arabinan domains of AG and LAM. However the precise mechanism of these interactions 
between Emb and EMB remain unknown (Srivastava et al., 2009). Chapter 3 presents data 
showing the effect of mutations in the Cg-Emb protein leading to restoration of EMB resistance 
in an EMB hypersensitive strain of C. glutamicum. Cell envelope analysis of strains expressing 
Cg-Emb with specific point mutations compared to strains expressing the WT Cg-Emb reveals 
the knock-on effect mutations in Cg-Emb have on the composition of the cell envelope (Figures 
3.4-3.8). As the transmembrane helix domains contained all the SNPs conferring resistance 
highlighting the requirement for the determination of a structure of the EmbCAB proteins in 
mycobacteria, both in the presence of EMB and without EMB to confirm the hypothesis that 
the Emb proteins are the target for EMB as well to improve the understanding of how these 
proteins function (Srivastava et al., 2009). 
 
The AG biosynthetic pathway, requires the translocation of galactan across the cytoplasmic 
membrane for the addition the arabinan domains. The proteins responsible for the export of 
this glycoconjugate precursor have been predicted for almost a decade, however the 
experimental evidence for this prediction has remained inconclusive (Dianišková et al., 2011). 
In Chapter 4, we sought to determine if the predicted M. smegmatis galactan transporter 
interacts with a synthetic galactan analogue. This led to the recombinant expression and 
purification of the soluble NDB (MSMEG_6366) and the determination of the binding 
constants of ligands corresponding to immature galactan chains. This determination of the 
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interaction between MSMEG_6366 and the immature galactan supports the predicted function 
of Rv3781 and Rv3783 as forming the ABC-transporter responsible for the export of galactan. 
Though further investigation into the key residues required for these interactions, as well as 
completion of the determination of the binding constants of curves that did not achieve 
saturation, and how the MSMEG_6366/MSMEG_6369 complex converts the hydrolysis of 
ATP to the translocation of galactan is required to understand how this process is controlled in 
vivo to prevent the translocation of immature galactan. The development of this assay system 
would allow for the targeted development of small molecule inhibitors, as well as the screening 
of clinically available, FDA approved drugs for to act as either scaffolds for alteration, or 
potentially as candidates for drug repurposing (Cha et al., 2018; Patel et al., 2019; Pushpakom 
et al., 2019; Singh et al., 2019). 
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6.1.1: Bioinformatic analysis of MsbA against mycobacterial and corynebacterial 
proteins:  
 
BLASTp analysis of E. coli K12 MsbA primary protein structure against non-redundant protein 
database of Mtb H37Rv. Mycobacterial protein sequences for comparative analysis selected 
from Mycobrowser (https://mycobrowser.epfl.ch/ Kapopoulou et al., 2011). BLASTp analysis 
of primary protein structure identified from the initial BLASTp analysis (Rv1272c and 
Rv1273c) against additional mycobacterial species (M. bovis, M. leprae, M. smegmatis, M. 
marinum) was used to confirm conservation of orthologous genes.  
 
Sequence alignment of selected proteins of interest conducted using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/ Sievers et al., 2011). Sequence alignment of 
protein sequences generated using ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/ Gouet et 
al., 1999).  
 
Topological predictions of proteins predicted to include the number and location of 
transmembrane helices generated using TMHMM 2.0 
(http://www.cbs.dtu.dk/services/TMHMM/), and ExPASy TMPred (https://embnet.vital-
it.ch/software/TMPRED_form.html). 
 
6.1.2: Bioinformatic analysis of predicted mycobacterial galactan transporters:  
 
BLASTp analysis of the primary protein structure of the previously hypothesised M. smegmatis 
galactan transporter (MSMEG_6366, and MSMEG_6369) against non-redundant protein 
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database of Mtb H37Rv, and M. leprae (taxid: 1769). Mycobacterial protein sequences for 
analysis selected from Mycobrowser (https://mycobrowser.epfl.ch/ Kapopoulou et al., 2011).  
 
Sequence alignment of selected proteins of interest conducted using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/ Sievers et al., 2011). Sequence alignment of 
protein sequences generated using ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/ Gouet et 
al., 1999).  
 
Topological predictions of proteins predicted to include the number and location of 
transmembrane helices generated using TMHMM 2.0 
(http://www.cbs.dtu.dk/services/TMHMM/), and ExPASy TMPred (https://embnet.vital-
it.ch/software/TMPRED_form.html). 
 
6.2: Culture conditions of E. coli, C. glutamicum, and M. smegmatis: 
 
M. smegmatis and E. coli grown on lysogeny broth (LB) agar (Difco), at 37 °C for colony 
generation, incubated for three days or one day respectively, unless stated otherwise. M. 
smegmatis and E. coli grown in LB (Difco), at 37 °C, 180 rpm, for liquid culture, unless 
otherwise stated. M. smegmatis liquid culture supplemented with 0.05 % TWEEN-80 to 
prevent clumping. C. glutamicum grown on Brain heart infusion (BHI) agar (Difco), at 30 °C, 
incubated for one day for single colony generation, unless otherwise stated. C. glutamicum 
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6.3.1: Generation of double knockout of MSMEG_5008 and MSMEG_5009 in M. 
smegmatis: 
 
DNA sequence amplified by PCR using purified M. smegmatis genomic DNA Q5 DNA 
polymerase, with high GC enhancer (NEB) annealing gradient 65-79 °C, 45 sec extension time, 
following manufacturers guidelines using the following primers:  
5’- TTTTTTTTCCATAAATTGGCGGCCCGTACTGCAGGACGTGTCGTTC -3’, 
5’- TTTTTTTTCCATTTCTTGGCGACAACAGATCCGCGAACGTCCCGTC -3’,  
5’- TTTTTTTTCCATAGATTGGCGTCTCGCGATCGCGCGTGCGGTGATC -3’, and 
5’- TTTTTTTTCCATCTTTTGGGAGCGACGCGTGATCCACCGCGTCACC -3’.  
 
Modified p0004s plasmid, containing inserted DNA flanking a hyg- sacB insertion element by 
use of Van91I digestion of amplified sequences, inserted into the conditionally replicating 
phasmid phAE159 into its PacI site to yield ph∆MSMEG_5008-5009 (Bardarov et al., 2002). 
Two step homologous recombination using ph∆MSMEG_5008-5009, leading to the 
replacement of the genomic sequence between the amplified sequences with a hyg-sacB 
insertion element replacing the deleted genes and conferring Hygromycin resistance (Bhatt et 
al., 2008) 
 
6.3.2: Generation of C. glutamicum∆NCgl0925- 0926 strain:  
 
Conducted by: J. Marienhagen’s group 
 
pk19mobsacB-∆NCgl0925- 0926 generated using:  
5’- CGTTAAGCTTAGCCGTTCTACGGTTTCCGTTCC -3’ 
Chapter 6:                                                                                                         Materials and methods 
 169 
5’- CCCATCCACTAAACTTAAACAATATCGACCACAGCATGAATGTATTC -3’ 
5’- TGTTTAAGTTTAGTGGATGGGGCGAAAGAAGAATTACAGGCTGACG -3’ and  
5’- GCTTGGATCCTCATGCGCGAAGCCCACCTCAC -3’ 
 
DNA sequence amplified using purified chromosomal DNA extracted from C. glutamicum 
ATCC13032, using Q5 DNA polymerase, with high GC enhancer (NEB) annealing gradient 
65-79 °C, 45 sec extension time. Correct insertion of respective genes inserted confirmed by 
DNA sequencing (Eurofins). Two step homologous recombination using pk19mobsacB-
∆NCgl0925- 0926 replacing the deleted genes, without conferring antibiotic resistance Schäfer 
et al., 1994.  
 
6.3.3: Generation of C. glutamicum∆steA∆ripA MB001: 
 
Conducted by T. Bernhardt’s group 
 
Generation of C. glutamicum∆steA∆ripA as described in Lim et al., 2019. 
 
6.4.1: Generation of EMB resistant C. glutamicum∆steA∆ripA MB001: 
 
Conducted by T. Bernhardt’s group 
 
25 million CFU of C. glutamicum∆steA∆ripA plated on agar plates containing 0.1 µg/ml EMB 
to generate resistant mutants. Mutant generation rate determined at 1 x10-7. 
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6.4.2: Mutation mapping of EMB resistant C. glutamicum∆steA∆ripA MB001: 
 
Conducted by T. Bernhardt’s group 
 
Genomic DNA of C. glutamicum∆steA∆ripA strains resistant to EMB purified and sequenced 
as described in Baym et al., 2015. Single nucleotide polymorphisms identified by comparison 
of the resistant strains and the parental C. glutamicum∆steA∆ripA strain.  
 
6.5: Genomic DNA purification of M. smegmatis:  
 
25 ml of M. smegmatis culture grown to OD600: 0.4- 0.6, centrifuged at 4,000 rpm, RT, 30 
mins. Supernatant removed and pellet re-suspended in 450 µl GTE buffer (25 mM Tris, pH 8, 
10 mM EDTA, 50 mM glucose, 0.1 mg/ml RNAse). 50 µl lysozyme (10 mg/ml) added, 
suspension incubated at 37 °C, overnight. 100 µl 10 % Sodium dodecyl sulphate (SDS), and 
20 µl Proteinase K (15 mg/ml) added and incubated at 55 °C, 3 hours. 10 µl RNAse A (10 
mg/ml) added, and incubated 37 °C, 30 mins. 200 μl 5 M NaCl, 1 ml chloroform: 
isoamylalcohol (24:1) added, and centrifuged 13,000 rpm, 10 mins. Aqueous layer removed 
and added to 0.7 volumes ice cold isopropanol and gently mixed. Suspension centrifuged at 
13,000 rpm, 4 °C, 30 mins, supernatant removed, pellet washed with 700 μl ice cold 70 % 
ethanol. Suspension centrifuged at 13,000 rpm, 4 °C, 30 mins, supernatant removed, pellet 
dried at RT. Pellet re-suspended in 20 ul dH2O, incubated at RT, 15 mins, DNA concentration 
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6.6.1: Generation of competent E. coli: 
 
Single colony of E. coli strain to be made competent selected and used to inoculate 5 ml of 
sterile media, culture then incubated at 37 °C, 180 rpm overnight. 1 ml of culture used to 
inoculate 100 ml of sterile media, and grown at 37 °C, 180 rpm until the culture reaches OD600: 
0.4- 0.8. Culture then centrifuged at 4,000 rpm for 20 mins at 4 °C, supernatant removed. Pellet 
re-suspended in 10 ml ice cold sterile 100 mM CaCl2. Suspension centrifuged at 4,000 rpm for 
20 mins at 4 °C, supernatant removed. Pellet re-suspended in 2.5 ml ice cold sterile 100 mM 
CaCl2, 15 % glycerol and aliquoted into 100 µl fractions. Fractions then flash frozen in liquid 
nitrogen (lqN2) and stored at -80 °C. 
 
6.6.2: Transformation of plasmid into competent E. coli: 
 
Competent E. coli thawed on ice and mixed with 50 ng of plasmid, and incubated on ice for 10 
mins. Cells then heat shocked at 42 °C for 30 seconds, and incubated on ice for 10 mins. 250 
µl of sterile media added and cells incubated at 37 °C for 1 hour before being transferred onto 
agar plates with the appropriate antibiotic for selection of the plasmid (Kanamycin 50 µg/ml, 
Hygromycin B 150 µg/ml, Ampicillin 100 µg/ml). Plates then incubated at 37 °C overnight. 
 
6.6.3: Purification of plasmid from E. coli:  
 
Single colony of E. coli expressing plasmid to be purified used to inoculate 5 ml of sterile 
media and incubated at 37 °C, 180 rpm, overnight. Culture centrifuged at 4,000 rpm for 10 
mins, and supernatant removed. Plasmid extracted using QIAprep spin miniprep protocol 
(Qiagen). 
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6.7.1: Generation of competent C. glutamicum: 
 
500 ml culture of C. glutamicum grown to OD600: 1.75. Culture chilled on ice, and centrifuged 
at 4,000 rpm, 4 °C, 30 min. Supernatant removed, cell pellet washed in 20 ml sterile TG-buffer 
(1 mM Tris-Cl, pH 7.5, 10 % glycerol), cell suspension centrifuged at 4,000 rpm, 4 °C, 30 min. 
Supernatant removed, cell pellet washed in 20 ml sterile TG-buffer. Cell suspension 
centrifuged at 4,000 rpm, 4 °C, 30 min. Supernatant removed, cell pellet washed in 20 ml sterile 
10 % glycerol, cell suspension centrifuged at 4,000 rpm, 4 °C, 30 min. Supernatant removed, 
cell pellet resuspended in 1 ml sterile 10 % glycerol, Cell suspension separated into 100 µl 
aliquots, aliquots flash frozen in lqN2, and stored at -80 °C until needed. 
 
6.7.2: Transformation of C. glutamicum: 
 
1 µg plasmid DNA, mixed with 100 µl competent C. glutamicum on ice, in 1 mm 
electroporation cuvette. Mixture layered with 800 µl ice cold 10 % glycerol. Sample 
electroporated at: 25 µF, 200 Ω, 2500 V. Sample transferred to 4 ml sterile BHI pre-
equilibrated to 46 ˚C, and incubated at 46 ˚C for 6 min. Sample incubated at 30 ˚C, 1- 3 hours. 
Samples centrifuged 3, 500 rpm, 10 min, 4 ˚C. Supernatant removed, cell pellet resuspended 
in remaining liquid, and transferred to BHI + 0.5 M sorbitol agar plates, 25 µg/ml 
spectinomycin. Agar plates incubated 30 ˚C 2 days, and checked for colonies denoting 
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6.8.1: Generation of pEKEx3-NCgl0925- NCgl0926 plasmid:  
 
Conducted by: J. Marienhagen’s group 
 
Primers used:  
5’- GTCGACTCTAGAGGATCCCCAAGGAGATATAGATATGCTGTG-3’ and  
5’- TGAATTCGAGCTCGGTACCCTTATTAGTGATCTCCG-3’ 
 
Gene sequence amplified using purified chromosomal DNA extracted from C. glutamicum 
ATCC13032 using Q5 DNA polymerase, with high GC enhancer (NEB) annealing gradient 
65-79 °C, 190 sec extension time. Correct insertion of respective genes inserted confirmed by 
DNA sequencing (Eurofins).  
 
6.8.2: Generation of pEKEx3-Rv1272c- Rv1273c plasmid: 
 
Conducted by: J. Marienhagen’s group 
 
Primers used:  
5’GTCGACTCTAGAGGATCCCCAAGGAGATATAGATATGCTCCTGGCCCTGCTGC
G-3’ and 
5’- TG AATTCGAGCTCGGTACCCTTATTAGGCCCGCGTCATCTGGTAATAG-3’ 
 
Gene sequence amplified using purified chromosomal DNA extracted from M. tuberculosis 
H37Rv using Q5 DNA polymerase, with high GC enhancer (NEB) annealing gradient 65-79 
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°C, 190 sec extension time. Correct insertion of respective genes inserted confirmed by DNA 
sequencing (Eurofins).     
 
6.9.1: Generation of the pMAL-c2x-MSMEG_6366 plasmid: 
 
MSMEG_6366 gene sequence amplified by PCR using purified M. smegmatis genomic DNA 
with Q5 DNA polymerase, with high GC enhancer (NEB) annealing gradient 65-79 °C, 45 sec 




PCR product generated from purified chromosomal DNA extracted from M. smegmatis MC2 
155 using Q5 DNA polymerase, with high GC enhancer (NEB) annealing gradient 65-79 °C. 
PCR product and pMAL-c2x digested using EcoRI and HindIII, ligated together using T4 
DNA-ligase (NEB) following manufacturer guidelines. Ligation mix transformed into E. coli, 
successful ligation products confirmed by DNA sequencing (Eurofins). 
 
6.9.2: Generation of the pMAL-c2x-MSMEG_6369 plasmid: 
 
MSMEG_6369 gene sequence amplified by PCR using purified M. smegmatis genomic DNA 
with Q5 DNA polymerase, with high GC enhancer (NEB) annealing gradient 65-79 °C, 45 
sec/kb extension time, following manufacturers guidelines, using primers:  
5’- TTTTTTGAATTCATGACTTTCACCGACGCGGCGGCGCAGT-3’ and 
5’- TTTTTTAAGCTTTCAGACCCAGTAGGGCACGCGGCCGCGGT-3’ 
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PCR product generated from purified chromosomal DNA extracted from M. smegmatis MC2 
155. PCR product and pMAL-c2x digested using EcoRI and HindIII, ligated together using T4 
DNA-ligase (NEB) following manufacturer guidelines. Ligation mix transformed into E. coli; 
successful ligation products confirmed by DNA sequencing (Eurofins).  
 
6.10: Growth rate analysis in C. glutamicum: 
 
C. glutamicum strains to be analysed streaked onto BHI agar to generate single colonies. 5 ml 
of media inoculated with single colony, grown to OD600: 1- 2. Culture diluted into 5 ml fresh 
BHI, or BHI + 0.5 M sorbitol, for OD600: 0.05, timepoints measured using OD600.  
 
6.11: Cell surface permeability analysis of C. glutamicum strains: 
 
C. glutamicum cultures grown to OD600: 1- 2. Cells harvested, 4,000 rpm, 5 mins, RT, 
supernatant removed. Cell pellet resuspended and fixed in 2 ml 0.25 % formaldehyde in PBS, 
incubated 1 hour, RT. Fixed cells harvested 4,000 rpm 5 mins, RT, supernatant removed, pellet 
washed twice in PBS. Fixed cells resuspended in PBS to OD600: 1 in either: 0.25 µM 1, 6- 
diphenyl- hexa- 1, 3, 5- triene (DPH) in PBS, or PBS, transferred to 96-well black walled, black 
bottom, flat bottom, microtitre plate, incubated at 37 °C, 1 hour. Fluorescence of cells 
determined at Excitation 350 nm, Emission 450 nm.  
 
Intrinsic fluorescence of cells and of DPH in PBS averaged and subtracted from the 
fluorescence of cells in DPH. Resulting data collected normalised with wild type strain average 
set to 100 %, with fold change of all strains and controls calculated against this value. Statistical 
significance of permeability changes determined using Bonferroni corrected ANOVA. 
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6.12.1: Extraction of C. glutamicum polar-apolar lipids: 
 
50 ml culture grown to OD600: 1- 2, culture centrifuged 4,000 rpm, 30 mins, supernatant 
removed. Pellet resuspended in 10 ml sterile phosphate buffered saline (PBS), centrifuged 
3,000 rpm, 30 mins, supernatant removed. Pellet dried at 50 °C, under nitrogen. Cell pellet 
resuspended in 4 ml petroleum ether 60-80 (PE60), incubated at RT under agitation 1 hour. 
Suspension centrifuged 3,000 rpm, 10 mins, RT. Supernatant, containing external free lipids 
transferred to clean tube, pellet resuspended in 4 ml PE60, incubated at RT under agitation 1 
hour. Suspension centrifuged 3,000 rpm, 10 mins. Supernatant removed and pooled with 
previous extraction, dried at 50 °C, under N2 for apolar outside lipids.  
 
Cell pellet dried and resuspended in 2 ml 10: 1 methanol: 0.3 % NaCl, and 2 ml PE60 added. 
Cell suspension incubated RT, under agitation, 15 mins. Suspension centrifuged at 4,000 rpm, 
5 mins, upper phase, containing the internal non-polar lipids, transferred to clean tube. 2 ml 
PE60, incubated at RT for 15 mins under agitation. Centrifuged at 3,000 rpm, 5 mins, upper 
phase pooled with the previously extracted apolar inside lipids. Sample, and cell pellet dried at 
50 °C, under nitrogen. 
 
Pellet resuspended in 2.3 ml 9: 10: 3 chloroform: methanol: 0.3 % NaCl, incubated at RT, 
under agitation, 1 hour. Suspension centrifuged 3,000 rpm, 15 mins. Supernatant, transferred 
to a clean tube. Pellet resuspended twice in 750 µl 5: 10: 4 chloroform: methanol: 0.3 % NaCl, 
incubated at RT, under agitation, 30 mins. Suspension centrifuged 3,000 rpm, 15 mins. 
Supernatant pooled with previous extractions. 2.6 ml 1: 1 CHCl3: 0.3 % NaCl added to the 
pooled extracts, incubated at RT, 5 mins under agitation. Lower phase, containing polar lipids, 
removed to a fresh tube, dried at 50 °C, under nitrogen. 
Chapter 6:                                                                                                         Materials and methods 
 177 
6.12.2: Extraction of C. glutamicum inner membrane - outer membrane lipids: 
 
50 ml culture grown to OD600: 1- 2, culture centrifuged 4,000 rpm, 30 mins, supernatant 
removed, cell pellet dried under N2 at 50 °C in a glass tube with PTFE cap. Cell pellet 
resuspended in 2 ml dH2O saturated butan-1-ol (approximately 2-3 ml dH2O for every 10 ml 
butan-1-ol), incubated under agitation at RT, 1 hour. Suspension centrifuged, 5 mins, 3,000 
rpm, RT. Supernatant removed and dried under N2 at 50 °C, repeated twice to removed outer 
membrane lipids. Dried extraction washed with 2: 1 CHCl3: CH3OH, to selectively solubilise 
lipids removing contaminating proteins due to differing solubility. 
 
Pellet dried and resuspended in 2 ml 2: 1 CHCl3: CH3OH, under agitation at RT for 1 hour. 
Suspension centrifuged 3000 rpm, 5 mins, RT, supernatant removed and dried under N2 at 50 
°C repeated twice to extract inner membrane lipids. Dried extraction washed with 2: 1 CHCl3: 
CH3OH, to selectively solubilise lipids removing contaminating proteins. 
 
6.12.3: Reverse micellar extraction of surface lipids from C. glutamicum: 
 
50 ml culture grown to OD600: 1- 2, culture centrifuged 4,000 rpm, 30 mins, supernatant 
removed, cell pellet dried under N2 at 50 °C in a glass tube with PTFE cap. Dried cell pellet 
resuspended in 2 ml 10 mM sodium docusate (AOT) in heptane, and incubated under agitation 
2 hours, RT. Cell suspension centrifuged 3,000 rpm, 5 mins, RT, supernatant removed and 
transferred to clean tube, dried under N2 at 50 °C. Process repeated twice, with supernatant 
pooled, to maximise extraction of surface lipids. Extracted lipids resuspended in 500 µl 2: 1 
CHCl3: CH3OH and washed with dH2O in order to remove contaminating docusate.  
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6.12.4: Extraction of C. glutamicum cell wall bound lipids: 
 
Dried delipidated cell pellet resuspended in 2 ml 5 % tetrabutylammonium hydroxide (TBAH), 
incubated 95 °C, overnight. 2 ml H2O, 4 ml dichloromethane, and 50 µl iodomethane added 
and incubated at RT, 30 mins, under agitation. Sample centrifuged, 3,000 rpm, 10 mins, lower 
phase transferred to fresh tube. 4 ml H2O added to removed lower phase, and incubated under 
agitation 30 mins, RT. Sample centrifuged 3,000 rpm, 10 mins, upper phase discarded and 
process repeated. Upper phase discarded, lower phase dried at 50 °C, under N2. Sample 
resuspended in 4 ml diethyl ether, sonicated in sonicating water bath, 5 mins, RT, Suspension 
centrifuged 3,000 rpm, 10 mins, RT. Supernatant transferred to clean tube, and dried at 50 °C, 
under N2 for the fatty acid methylesters (FAMEs) and corynemycolic acid methyl esters 
(cMAMEs). 
 
6.13: Silica column lipid purification 
 
Silica column equilibrated with 3 column volumes 100 % CHCl3. Crude reverse micellar lipid 
extract gently transferred into column. Column sequentially washed with 100 ml of: 100 % 
CHCl3, 98: 2 CHCl3: CH3OH, 95: 5 CHCl3: CH3OH, 93: 7 CHCl3: CH3OH, 90: 10 CHCl3: 
CH3OH, 88: 12 CHCl3: CH3OH, 85: 15 CHCl3: CH3OH, 83: 17 CHCl3: CH3OH, and 80: 20 
CHCl3: CH3OH, collected in 12 ml fractions. Eluted fractions analysed by TLC to determine 
lipid composition, elution fractions containing equivalent lipids pooled, dried under N2, 50 °C 
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6.14.1: Lipid analysis by thin layer chromatography (TLC): 
 
Lipid analysis conducted on F242 silica TLC plates, using various solvent systems. 
Lipids extracted from previously described methods of lipid extraction analysed by 2 
directional (2D) TLC, using various systems: 
 
TLC systems for free and Non-polar lipids 
System Direction 1 solvent system (Times run) 
A PE60: Ethyl acetate 98: 2 (3) 
B PE60: Acetone 92: 8 (3) 
C Chloroform: Methanol 96:4 (1) 
D 
Chloroform: methanol: water 
100: 14: 0.8 (1) 
 
TLC systems for free and Non-polar lipids 
System Direction 2 solvent system (Times run) 
A PE60: acetone 98: 2 (1) 
B  Toluene: acetone 95: 5 (1) 
C Toluene: acetone 80: 20 (1) 
D 
Chloroform: methanol: acetone: water 50: 
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TLC systems for polar lipids 
System Direction 1 solvent system (Times run) 
D 
Chloroform: methanol: water 
100: 14: 0.8 (1) 
E 
Chloroform: methanol: water  
60: 30: 6 (1) 
 
 
TLC systems for polar lipids 
System Direction 2 solvent system (Times run) 
D 
Chloroform: methanol: acetone: water 50: 
60: 2.5: 3 (1) 
E 
Chloroform: acetic acid: methanol: water 
40: 25: 3: 6 (1) 
 
 
Two directional TLCs used for all fractions: 
 
Direction Solvent system (Times run) 
1 
Chloroform: methanol: water  
30: 8: 1 (1) 
2 
Hexane: diethyl ether: Acetic acid 
70: 30: 1 (1)  
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One directional TLC systems used to analyse lipids:  
 
Lipid analysed Solvent system (Times run) 
Fatty acid methyl esters (FAMEs) and 
Mycolic acid methyl esters (MAMES) 
PE60: acetone 
95: 5 (1) 
All extracted fractions 
Chloroform: methanol: H2O 
30: 8: 1 (1) 
All extracted fractions 
Chloroform: methanol: ammonium 
hydroxide (25%): H2O 
65: 25: 0.5: 3.6 (1) 
All extracted fractions 
Chloroform: methanol: ammonium 
hydroxide: ammonium acetate (1 M): 
H2O 
180: 140: 9: 9: 23 (1) 
 
6.14.2: Preparative TLC:  
 
Lipid extraction fraction containing lipid to be extracted run on TLC as described in Method 
6.14.1. TLC imaged using:  0.5% (w/v) DPH in 95:5 CHCl3: CH3CH2OH, lipids visualised by 
UV light excitation: 350 nm, emission: 400-550 nm (visible spectrum). Detectable bands 
marked, and TLC run using solvent system: 100 % PE60 to remove DPH. Silica containing 
desired lipid removed from TLC plate, washed 3 times with 5 ml 2:1 CHCl3: CH3OH, solvent 
removed and dried between washes. The resulting extracted lipid weighed and the lipid identity 
confirmed by TLC (Method 6.14.1) against crude lipid fraction. 
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6.15: Direct infusion mass spectrometry of C. glutamicum lipids: 
 
Lipid samples resuspended to 1 mg/ml in CHCl3: CH3OH (v/v), diluted 1: 10 in 7.5 mM 
ammonium acetate: CHCl3 (2: 1 v/v). Lipid samples analysed using direct infusion electrospray 
mass spectrometry (Orbitrap Elite, Advisor: Nanomate), 1.5 kV. Analysis of collected spectra 
conducted in Xcalibur. 
 
6.16: Lipoglycan extraction from C. glutamicum 
 
Cell pellet from 1 L culture dried at 50 °C, under nitrogen. 4 ml 50 % ethanol added to dried 
cell pellet, and incubated at 80 oC, 2 hours. suspension cooled to RT and centrifuged 4,000 
rpm, 20 mins, RT. Supernatant removed and dried at 50 °C, under N2. 3 ml sterile PBS, added 
and sonicated using sonicating water bath, 10 mins, RT. Sample made up to 50 % phenol, 
incubated 80 oC, 2 hours. Samples cooled to RT, centrifuged 4,000 rpm, 10 mins, aqueous 
phase removed and dialysed in dH2O, using 3.5 kDa membrane. Samples dried under N2, 50 
°C and weighed, resuspended in sterile dH2O at 100 mg/ml. 
 
6.17.1: SDS-PAGE:  
 
SDS-loading buffer (0.375 M Tris, pH 6.8, 12 % SDS, 60 % glycerol, 0.6 M DTT, 0.06 % 
bromophenol blue) diluted 6-fold with samples to be analysed, incubated at 90 °C, 10 min. 5-
20 µl of sample loaded into 10- 12 % polyacrylamide gel (BioRAD), using SDS-running buffer 
(2.5 mM Tris, pH 8.3, 19.2 mM glycine, 0.01 % SDS), samples separated at: 200 V, 50 mAmp, 
35 min.  
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Protein samples to be visualised directly incubated in InstantBlue (Expedeon), RT, > 20 mins, 
with gentle agitation. Lipoglycan samples stained using either silver straining, or Pro-Q 
Emerald 300 protocols, samples for western blot analysis stained using western blot protocol.  
 
6.17.2: Silver staining of lipoglycans 
 
250 µg of purified lipoglycan extraction (Method 6.16) separated by SDS-PAGE (Method 
6.17.1), staining protocol conducted in glass dish as described in the table below. 
 
Step Solution composition 
Duration 
(mins) 
1 50 % Methanol, 12 % Trichloroacetic acid, 2 % CuCl2 > 20 
2 10 % Ethanol, 5 % Acetic acid 10 
3 0.7 % Periodic acid, 40 % Ethanol, 5 % Acetic acid 10 
4 10 % Ethanol 10 
5 Deionised water 20 
6 0.1 % Silver nitrate 10 
7 10 % Di-potassium carbonate 5 
8 2 % Di-potassium carbonate Overnight 
 
6.17.3: Pro-Q Emerald 300 glycoprotein stain 
 
Lipoglycans separated by SDS-PAGE (Method 6. 17.1) stained using 250 µg of purified 
lipoglycans (Method 6.16). Gel containing lipoglycan samples stained using Pro-Q Emerald 
300 glycoprotein staining protocol (Invitrogen).  
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Gel containing run samples fixed in 50 % CH3OH, 5 % acetic acid, 45 min, RT, with gentle 
agitation. Gel washed in 3 % acetic acid, 20 min, RT, gentle agitation, repeated once. Samples 
oxidised using 3 % acetic acid, 2.7 mM periodic acid, 30 min, RT gentle agitation. Gel washed 
with 3 % acetic acid, 20 min, RT, gentle agitation, repeated twice. Samples stained with 50-
fold dilute Pro-Q Emerald 300 stock solution in staining buffer (Invitrogen), 2 hours, RT, 
gentle agitation. Gel washed in 3 % acetic acid, 20 min, RT, gentle agitation, repeated once.  
 
6.17.4: Western blot: 
 
Samples separated by SDS-PAGE transferred onto nitrocellulose membrane following iBlot 
standard protocol (https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/iblot2_device_qrc.pdf). Nitrocellulose membrane blocked in 5 % bovine 
serum albumin (BSA), 0.5 % TWEEN-80, in Tris-buffered saline (TBS, 50 mM Tris, 150 mM 
NaCl), 16 hours, RT, with gentle agitation. Membrane washed with 0.5 % Tween-80 in TBS 
(TBS-T), 10 min, RT, with gentle agitation, repeated twice. Membrane washed with primary 
antibody solution (1: 25,000 anti-MBP antibody: TBS-T + 2.5 % bovine serum albumin 
(BSA)), incubated 2 hours, RT, with gentle agitation. Membrane washed, TBS-T, 10 mins, RT, 
with gentle agitation, repeated twice. Membrane washed with secondary antibody (1: 2,000 
secondary antibody: TBS-T + 2.5 % BSA), incubated 1 hour, RT, with gentle agitation. 
Membrane washed, TBS-T, 10 min, RT, with gentle agitation, repeated twice. Membrane 
visualised using 5-Bromo-4-chloro-3-indolyl-phosphate (BCIP, Thermofisher), incubated RT, 
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6.18.1: Aditol acetates derivatization of extracted C. glutamicum polysaccharides: 
 
10 mg of purified extracted lipoglycan suspended in 250 µl trifluoroacetic acid, incubated 120 
°C, 2 hours, to hydrolyse lipoglycans into component monosaccharides. Monosaccharide 
solution cooled and dried under N2, 50 °C. Monosaccharides resuspended in 50 µl 1:1 10 mg/ml 
NaB2H4 in ethanol: 1 M NH4OH, and incubated 3 hours, RT. Samples dried under N2, 50 °C, 
resuspended in 3 drops acetic acid, dried under N2, 50 °C. Resuspended in 3 drops CH3OH, 
dried under N2, 50 °C. Samples resuspended in 100 µl acetic anhydride, incubated 100 °C, 1 
hour. Sample cooled, 100 µl toluene added, dried under N2, 50 °C. Samples partitioned 2 ml 
CHCl3, 2 ml H2O, organic phase transferred to fresh tube, dried under N2, 50 °C. 
 
6.18.2: Gas Chromatography of aditol acetate derivatised polysaccharides: 
 
Samples analysed using Shimadzu GC-2010 with DB-225 column (Agilent Technologies) ID: 
0.25 mm, length: 30 m, df: 0.15 µm. the oven was programmed to maintain isothermal 
temperature of 220 °C with a run time of 20 mins. Peaks detected by change in µV. Sugar 
composition of samples determined by comparison of retention time of peaks to known 
standards. Ratio of sugars calculated from area under curve of peaks corresponding peaks of 
interest.  
 
6.19: Antibiotic susceptibility of C. glutamicum strains: 
 
C. glutamicum strains to be tested grown from single colonies in 5 ml sterile media to mid-log, 
OD600: 1- 2. Culture diluted to OD600: 0.05, in fresh BHI media.  100 µl of cell culture 
transferred into 96-well microtitre plate containing 5 µl compounds to be tested in 40 % 
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Dimethyl sulfoxide (DMSO), incubated 30 °C, 24 hours. 30 µl 0.02 % resazurin, 12.5 µl 20 % 
TWEEN-80 added to each well, incubated 30 °C, 2 hours. Fluorescence measured at 
Excitation: 544 nm, Emission: 590 nm, 37 °C. Percent survival determined using:  
%	𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙 = +
(𝑋 − 𝑌)
(𝑌 − 𝑍)2 × 	100 
Where X= sample fluorescence, Y= mean of negative controls, and Z= mean of positive 
controls 
 
6.20.1: Membrane purification of C. glutamicum strains: 
 
Cell pellet from 1 L culture of C. glutamicum thawed on ice and suspended in 30 ml lysis 
buffer, culture lysed using French press (1,000 psi, 4 °C, 3 cycles), lysate centrifuged 18,000 
rpm, 4 °C, 45 mins, supernatant removed and centrifuged 100,000 xG, 4 °C, 1 hour. 
Supernatant stored 4 °C, pellet re-suspended in 10 ml lysis buffer at 4 °C. 
 
6.20.2: Cell free Emb activity assay: 
 
 2 µl of 20 mM C8-Araf-Araf (YHF-1) acceptor dried under N2, 2 µl of 2 mM adenosine 
triphosphate (ATP) and nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) 
added and dried under N2. 80 µg of purified corynebacterial membrane (Method 6.20.1) in PBS 
added, 5 µl 14C pRpp in 500 mM sodium acetate corresponding to 50,000 cpm added, volume 
made up to 100 µl, incubated 37 °C overnight. Reaction quenched with 533 µl CHCl3: CH3OH 
(1:1 v/v), centrifuged 13,000 rpm, 5 mins, RT. Supernatant transferred to clean tube, dried 
under N2, 50 °C.  
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Samples resuspended 50 % ethanol, contaminants removed using liquid chromatography- 
strong anion exchange (LC-SAX) column equilibrated in 50 % ethanol, samples recovered with 
2 ml 50% ethanol, dried under N2, 50 °C. Samples resuspended in water: butanol biphasic 
solution, centrifuged 3,000 rpm, 5 mins, RT. Upper phase containing product removed, dried 
under N2, 50 °C. Samples resuspended in 40 µl CHCl3: CH3OH (2: 1 v/v), sample cpm 
determined using 5 % sample volume. 100 % of remaining samples analysed by TLC using 
CHCl3: CH3OH: NH4OH: H2O (70: 25: 0.5: 2.5 v/v/v/v). TLC imaged using X-Ray film 
(Kodak), incubated 1 week, RT. Film imaged. 
 
6.21.1: Expression of recombinant MSMEG_6366: 
 
The pMAL-c2x-MSMEG_6366 plasmid was introduced to E. coli (BL21 DE3) by heat shock 
transformation. Colonies containing the vector selected for using 100 µg/ml ampicillin. Single 
colony used to inoculate 5 ml sterile LB, incubated overnight, 37 °C, 180 rpm. 1 L sterile LB, 
containing 100 µg/ml ampicillin, inoculated with 1 ml culture, incubated 37 °C, 180 rpm, until 
OD600: 0.5- 0.8. Recombinant expression of MSMEG_6366 induced by addition of 1 mM 
isopropyl-beta-D-1-thiogalactoside (IPTG, Bioline), and incubated 16 hours, at 16 ̊ C, 180 rpm. 
Cells harvested at 4,000 rpm, 4 °C, 20 min. Cell pellet was washed with PBS, and stored at -
20 °C.  
 
6.21.2: Expression of MBP-tagged MSMEG_6369 in E. coli: 
 
E. coli Shuffle T7 C3026H cells transformed with pMAL-c4x-MSMEG_6369, streaked out on 
agar, containing 100 µg/ml Amp, incubated at 37 °C overnight, for generation of single 
colonies. Single colony used to inoculate 5 ml sterile media, incubated at 37 °C, 180 rpm, 
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overnight. 1 ml bacterial culture used to inoculate 1 L sterile media, containing 100 mg/ml 
Amp, incubated to reach OD600: 0.4- 0.8. Culture induced with 1 mM IPTG, incubated 16 °C 
overnight. Culture harvested 4,000 rpm, 20 mins, bacterial pellet washed with sterile PBS, 
harvested 4,000 rpm, 20 min. 100 ul of E. coli cell pellet resuspended in 1.9 ml lysis buffer (50 
mM Tris pH 7.5, 300 mM NaCl), with 0.5 g 0.1 mm diameter glass beads (Thistle Scientific), 
cells lysed using bead beater (MP Bio) 3 cycles, 6 m/s, 30 seconds on, 1 minute off on ice. 
Aliquot of cell lysate sample tested removed, stored on ice for analysis by SDS-PAGE. Cell 
lysate centrifuged, 14,500 rpm, 4 °C, 30 min. Cell lysate and clarified cell lysate analysed 
separated by SDS-PAGE, analysed for expression of MBP-tagged protein by western blot.  
 
6.21.3: Purification of recombinant MBP-tagged MSMEG_6366: 
 
E. coli BL21 (DE3) cell pellets from 1 L cultures expressing MBP-tagged MSMEG_6366 
thawed and resuspended in 35 ml lysis buffer (50 mM Tris pH 7.5, 300 mM NaCl). Cells were 
sonicated using a probe sonicator, 13 Amplitude microns, 30 seconds ON, 30 seconds OFF, 10 
cycles, on ice. Cell lysate centrifuged 18,000 rpm, 60 mins, 4 °C. Supernatant removed and 
passed through 0.22 µM filter. Clarified lysate washed over 1 ml MBP-trap column pre-washed 
in lysis buffer. Flow through collected, column washed with 50 column volumes lysis buffer. 
Protein eluted with 10 column volumes lysis buffer containing 10 mM maltose. Sample purity 
determined by SDS-PAGE electrophoresis. Sample concentration determined by addition of 
100 µl Bradford reagent (Bio-Rad), to 2 µl protein sample, A595 absorbance measured. Protein 
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6.21.4: Ligand binding assay of MSMEG_6366 using Intrinsic tryptophan fluorescence: 
 
Purified protein diluted to 0.5 µM, on ice, protein equilibrated to 22 °C. Fluorescence measured 
Ex: 280 nm, Em: 350 nm, 22 °C. 0.5 mM ligand, diluted in isotonic buffer, titrated into protein. 
Sample mixed, 1 min, to allow binding equilibrium and thermal equilibration. Measurement 
repeated n=3.  
 
6.21.5: Analysis of ligand binding data: 
 
Raw data adjusted to compensate for dilution of protein by ligand using:  
𝑋 =
𝐹 ×	(500 + 𝑣𝑜𝑙𝑢𝑚𝑒	𝑙𝑖𝑔𝑎𝑛𝑑	𝑎𝑑𝑑𝑒𝑑)
𝑖𝑛𝑖𝑡𝑖𝑎𝑙	𝑣𝑜𝑙𝑢𝑚𝑒  
Where F= sample fluorescence.  
Volume corrected data normalised against initial fluorescence at 450 nm of sample, Kd and 
Bmax calculated using Michealis-Menten non-linear regression analysis in Graphpad Prism 5.  
 
6.22: Prediction of chemical properties of galactan analogues: 
 
Chemical structures of galactan analogues produced using ChemDraw Professional 17.1 
(PerkinElmer). Chemical structures used to generate SMILES structures of galactan analogues. 
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6.23: Protein crystallization of MBP-tagged MSMEG_6366: 
 
Sitting drop vapour diffusion method of protein purification using the commercially available 
protein crystallography screens: JCSG+, MIDAS, and Morpheus. Reservoir volume of 40 µl 
used, 0.3 µl of MSMEG_6366 at variable concentrations (20 mg/ml, 15 mg/ml, and 10 mg/ml) 
in 50 mM Tris pH 7.5, 300 mM NaCl, with 0.3 µl of reservoir solution, and incubated at 18 
°C. Drops screened for crystal formation, conditions showing crystal growth optimised by 
varying precipitant concentration and pH depending on the condition, typically varying 
precipitant concentration with 12 conditions tested, with the original condition being the centre 
of the range each condition being 1- 2 % different from the neighbouring conditions, and 
varying pH with 8 conditions tested alongside precipitant conditions, with pH conditions being 
0.1 pH units different from neighbouring conditions.  
 
6.24: Sprays and reagents: 
 
Phosphomolybdic acid (MPA) staining solution: 5 % MPA (w/v), in ethanol. a-napthol 
staining solution: 2.4 % a-napthol (w/v), 10 % sulfuric acid (v/v), 87.6 % ethanol (v/v).  
Reagents supplied by Sigma-Aldrich unless stated otherwise.  
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Transmembrane helix predictions of MsbA and Mycobacterial and corynebacterial 
homologs. 
 
TMPred output of E. coli MsbA: 
TMHMM output for E. coli MsbA: 
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TMPred output for M. tuberculosis Rv1272c: 
 
TMHMM output for M. tuberculosis Rv1273c: 
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TMPred output for M. tuberculosis Rv1273c: 
 
 
TMHMM output for Rv1273c:  
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TMPred output for M. bovis Mb1303c: 
 
 
TMHMM output for M. bovis Mb1303c: 
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TMPred output for M. bovis Mb1304c: 
 
TMHMM output for M. bovis Mb1304c: 
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TMPred output for M. leprae ML1113c: 
 
TMHMM output for M. leprae ML1113c: 
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TMPred output for M. leprae ML1114c: 
 
 
TMHMM output for M. leprae ML1114c: 
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TMPred output for M. marinum MMAR_4147: 
 
 
TMHMM output for M. marinum MMAR_4147:  
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TMPred output for M. marinum MMAR_4148: 
 
 
TMHMM output for M. marimum MMAR_4148:  
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TMPred output for M. smegmatis MSMEG_5008:  
 
 
TMHMM output for M. smegmatis MSMEG_5008: 
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TMPred output for M. smegmatis MSMEG_5009: 
 
 
TMHMM output for M. smegmatis MSMEG_5009: 
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TMPred output for C. glutamicum NCgl0925: 
 
 
TMHMM output for C. glutamicum NCgl0925: 
 
Appendix 1:                                   Prediction of number and position of transmembrane helices 
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TMPred output from C. glutamicum NCgl0926: 
 
 
TMHMM output from C. glutamicum NCgl0926: 
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Transmembrane predictions of predicted galactan ABC-transporter proteins. 
 
TMPred output of M. tuberculosis Rv3783: 
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TMPred output of M. smegmatis MSMEG_6369:  
 
 
TMHMM output of M. smegmatis MSMEG_6369:  
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TMPred output of M. tuberculosis Rv3781:  
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TMPred output of M. smegmatis MSMEG_6366:  
 
 
TMHMM output of M.smegmatis MSMEG_6366:  
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 Aditol acetate derivatized lipoglycan extract from WT C. glutamicum:   
 
 
Aditol acetate derivatized lipoglycan extract from C. glutamicumDNCgl0925-NCgl0926: 
Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
2/8/2019  11:52 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
3 2
Sample Name: 2 Injection Volume: 5.0  
Vial Number: 3 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate Dilution Factor: 1.0000  
Recording Time: 17/6/2019 12:35 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.40      n.a. 1507080.00 68623.7 7.38    n.a.
2  12.59      n.a. 7363614.00 415524.3 44.69    n.a.
3  13.53      Galactose 1403601.00 94634.6 10.18    n.a.
4  13.60      n.a. 161046.00 6098.4 0.66    n.a.
5  14.16      Glucose 562564.00 47328.8 5.09    n.a.
6  14.35      n.a. 131851.00 6699.9 0.72    n.a.
7  14.63      n.a. 597322.00 41675.8 4.48    n.a.
8  15.13      n.a. 431931.00 30629.4 3.29    n.a.
9  15.44      n.a. 88015.00 7536.1 0.81    n.a.
10  17.13      n.a. 139383.00 12323.9 1.33    n.a.
11  17.83      n.a. 1040034.00 149875.1 16.12    n.a.
12  18.93      n.a. 143139.00 35141.4 3.78    n.a.
13  19.70      n.a. 69275.00 7406.4 0.80    n.a.
14  19.92      n.a. 57128.00 6356.4 0.68    n.a.
Total: 13695983.00 929854.36 100.00    0.000 
















Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:Alditol Acetate 06_26 Page 1-1
16/9/2019  3:18 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
15 0
Sample Name: 0 Injection Volume: 5.0  
Vial Number: 10 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acet te I Ban width: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 27/6/2019 9:47 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.28      n.a. 275857.00 15041.3 2.66    n.a.
2  12.45     n.a. 8709729.00 502606.2 89.03    n.a.
3  14.93      n.a. 293524.00 19818.6 3.51    n.a.
4  17.58     n.a. 76797.00 6333.5 1.12    n.a.
5  19.31      n.a. 209197.00 20748.2 3.68    n.a.
Total: 9565104.00 564547.77 100.00    0.000 















Operator:Shimadzu  Timebase:GC2010_ YSTEM1   Sequence:Alditol Acetate 06_26 Page 1-1
16/9/2019  3:18 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
15 0
Sample Name: 0 Injection Volume: 5.0  
Vial Number: 10 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Ban width: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1. 000  
Recording Time: 27/6/2019 9:47 Sample Weight: 1. 000  
Run Time (min): 2 .00 Sample Amount: 1. 000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.28      n.a. 275857.00 15041.3 2.66    n.a.
2  12.45      n.a. 8 0 729.00 5 2606.2 89.03    n.a.
3  14.93      n.a. 293524.00 9818.6 3.51    n.a.
4  17.58      n.a. 76797.00 6333.5 1.12    n.a.
5  19.31      n.a. 209197.00 20748.2 3.68    n.a.
Total: 95651 4.00 6454 .77 1 .00    .000 










1 , ,000 Alditol Acetate 06_26 #15 [mo ified by Shimadzu] 0 FIDµV
min
1 - 9.284




Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:23 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
3 2
Sample Name: 2 Injection Volume: 5.0  
Vial Number: 3 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Al itol ce ate I Bandw dth: n.a.
Quantif. M thod: Alditol Acetate Dilution Factor: 1.000   
Recording Time: 17/6/2019 12:35 Sample Weight: 1.000   
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.40      n.a. 1507080.00 68623.7 9.31    n.a.
2  12.59      n.a. 7363614.00 415524.3 56.39    n.a.
3  14.63      n.a. 597322.00 41675.8 5.66    n.a.
4  17.13      n.a. 139383.00 12323.9 1.67    n.a.
5  17.83      n.a. 1040034.00 149875.1 20.34    n.a.
6  18.93      n.a. 143139.00 35141.4 4.77    n.a.
7  19.70      n.a. 69275. 0 7406. 1.01    n.a.
8  19.92      n.a. 57128.00 6356.4 0.86    n.a.
Total: 10916975.00 736927.07 100.00    0.000 

















Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:23 PM
Default Tes /Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
3 2
Sample Name: 2 Injectio  Volume: 5.0  
Vial Number: 3 Chann l: FID
Sample Type: unk own Wavelengt : n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate Dilution Factor: 1.0000  
Recording Time: 17/6/2019 12:35 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.40      n.a. 150708 .00 68623.7 9.31    n.a.
2  12.59      n.a. 7363614.00 415524.3 56.39    n.a.
3  14.63      n.a. 597322.00 41675.8 5.66    n.a.
4  7.13      n.a. 139383.00 12323.9 1.67    n.a.
5  17.83      n.a. 1040034.00 149875.1 20.34    n.a.
6  18.93      n.a. 143 39.00 35 1.4 4.77    n.a.
7  19.70      n.a. 69275. 0 7406.4 .01    n.a.
8  19.92      n.a. 57 28.00 6356. 0.86   n.a.
Total: 10916975.00 73692 .07 1 .00    .000 
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Aditol acetate derivatized lipoglycan extract from C. glutamicum DNCgl0925-NCgl0926 
pEKEx3: 
 
Aditol acetate derivatized lipoglycan extract from C. glutamicum DNCgl0925-NCgl0926 
pEKEx3- NCgl0925-NCgl0926: 
EV
Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:25 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
4 3
Sample Name: 3 Injection Volume: 5.0  
Vial Number: 4 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate Dilution Factor: 1.0000  
Recording Time: 17/6/2019 12:59 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.16      n.a. 1322958.00 62789.3 7.68    n.a.
2  12.60      n.a. 11138419.00 719493.5 88.05    n.a.
3  14.61      n.a. 471535.00 34875.3 4.27    n.a.
Total: 12932912.00 817158.07 100.00    0.000 















Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:25 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
4 3
Sample Name: 3 Injection Volume: 5.0  
Vial Number: 4 Channel: FID
Sample Type: unknown Wavelength: n.a.
C ntrol Program: Alditol Ac tate I Ban width: n.a.
Quantif. Method: Alditol Ac tate Dilution Factor: 1. 000  
Recording Time: 17/6/2019 12:59 Sampl  Weight: 1. 000  
Run Time (min): 20.00 Sample Amount: 1. 000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.16      n.a. 1322958.00 62789.3 7.68    n.a.
2  12.60      n.a. 11138419.00 719493.5 88.05    n.a.
3  14.61      n.a. 471535.00 34875.3 4.27    n.a.
Total: 1 3 912.00 817158.07 100.00    0.000 
















Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:27 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
5 4
Sample Name: 4 Injection Volume: 5.0  
Vial Number: 5 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate Dilution Factor: 1.0000  
Recording Time: 17/6/2019 13:23 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.39      n.a. 1302776.00 65615.0 7.76    n.a.
2  12.60      n.a. 11802907.00 739953.2 87.56    n.a.
3  14.61      n.a. 508142.00 39516.7 4.68    n.a.
Total: 13613825.00 845084.88 100.00    0.000 














Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:27 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
5 4
Sample Name: 4 Injection Volume: 5.0  
Vial Number: 5 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate Di ution Factor: 1.00 0  
Recording Time: 17/6/2019 13:23 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.39      n.a. 1302776.00 65615.0 7.76    n.a.
2  12.60      n.a. 11802907.00 739953.2 87.56    n.a.
3  14.61      n.a. 508142.00 39516.7 4.68    n.a.
Total: 13613825.00 845084.88 100.00    0.000 
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Aditol acetate derivatized lipoglycan extract from C. glutamicum DNCgl0925-NCgl0926 
pEKEx3- rv1272c-rv1273c 
 
Aditol acetate derivatized lipoglycan extract from C. glutamicum∆steA∆ripA: 
Rv comp
Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:28 PM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
6 5
Sample Name: 5 Injection Volume: 5.0  
Vial Number: 6 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate Dilution Factor: 1.0000  
Recording Time: 17/6/2019 13:47 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.15      n.a. 1310824.00 61915.8 6.13    n.a.
2  12.60      n.a. 12527413.00 859781.8 85.07    n.a.
3  14.60      n.a. 415909.00 31493.0 3.12    n.a.
4  17.78      n.a. 267500.00 26364.7 2.61    n.a.
5  18.72      n.a. 65875.00 16007.2 1.58    n.a.
6  19.61      n.a. 84909.00 8929.8 0.88    n.a.
7  19.86      n.a. 53882.00 6189.9 0.61    n.a.
Total: 14726312.00 1010682.17 100.00    0.000 
















Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_17 Page 1-1
16/9/2019  3:28 PM
Default Test/Integration
Chromeleon (c) Dionex 996-2006
Version 6.80 SR8 Build 2623 (156243)
6 5
Sample Name: 5 Injection Volume: 5.0  
Vial Number: 6 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate Dilution Factor: 1.0000  
Recording Time: 17/6/2019 13:47 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.15      n.a. 1310824.00 61915.8 6.13    n.a.
2  12.60      n.a. 12527413.00 859781.8 85.07    n.a.
3  14.60      n.a. 415909.00 31493.0 3.12    n.a.
4  17.78      n.a. 267500.00 26364.7 2.61    n.a.
5  18.72      n.a. 65875.00 16007.2 1.58    n.a.
6  19.61      n.a. 84909.00 8929.8 0.88    n.a.
7  19.86      n.a. 53882.00 6189.9 0.61    n.a.
Total: 14726312.00 1010682.17 100.00    0.000 
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 Aditol acetate derivatized lipoglycan extract from C. glutamicum∆steA∆ripA EmbG411S: 
  
Aditol acetate derivatized lipoglycan extract from C. glutamicum∆steA∆ripA EmbP414T: 
S22
Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:39 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
10 7
Sample Name: 7 Injection Volume: 5.0  
Vial Number: 8 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 19:02 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.29      n.a. 676948.00 32449.4 20.68    n.a.
2  12.58      n.a. 697604.00 33654.4 21.45    n.a.
3  12.82      n.a. 11798.00 2214.9 1.41    n.a.
4  13.66      n.a. 164840.00 12033.0 7.67    n.a.
5  14.06      n.a. 365672.00 20890.7 13.31    n.a.
6  14.27      n.a. 108473.00 6049.6 3.86    n.a.
7  15.26      n.a. 124611.00 12382.9 7.89    n.a.
8  17.58      n.a. 368537.00 31598.6 20.14    n.a.
9  19.66      n.a. 56659.00 5644.2 3.60    n.a.
Total: 2575142.00 156917.64 100.00    0.000 















Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:39 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
10 7
Sample Na e: 7 I jection Volume: 5.0  
Vial Number: 8 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Diluti n Factor: 1.0000  
Recording Time: 26/6/2019 19:02 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
  9.29      n.a. 676948.00 32449.4 20.68    n.a.
2  12.58      n.a. 697604.00 33654.4 21.45    n.a.
3  12.82      n.a. 11798.00 2214.9 1.41    n.a.
4  13.66      n.a. 164840.00 12033.0 7.67    n.a.
5  14.06      n.a. 365672.00 20890. 13.31    n.a.
6  14.27      n.a. 1 8473.00 6049.6 3.86    n.a.
7  15.26      n.a. 124611.00 12382.9 7.89    n.a.
8  17.58      n.a. 368537.00 31598.6 20.14    n.a.
9  19.66      n.a. 56659.00 5644.2 3.60    n.a.
Total: 2575142.00 156917.64 100.00    0.000 
















Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:40 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
7 5
Sample Name: 5 Injection Volume: 5.0  
Vial Number: 6 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 17:50 Sample Weight: 1.0000  
Run Time (min): 0.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.44      n.a. 39586.00 4269.2 11.91    n.a.
2  12.43      n.a. 311231.00 14998.1 41.84    n.a.
3  14.18      n.a. 75949.00 5278.3 14.73    n.a.
4  15.27      n.a. 151192.00 11297.5 31.52    n.a.
Total: 577958.00 35843.15 100.00    0.000 














Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:40 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
7 5
Sample Name: 5 Injection Volume: 5.0  
Vial Number: 6 Channel: FID
Sample Type: unk own Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 17:50 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.44      n.a. 39586.00 4269.2 11.91    n.a.
2  12.43      n.a. 311231.00 14998.1 41.84    n.a.
3  14.18      n.a. 75949.00 5278.3 14.73    n.a.
4  15.27      n.a. 151192.00 11297.5 31.52    n.a.
Total: 577958.00 35843.15 100.00    0.000 
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 Aditol acetate derivatized lipoglycan extract from C. glutamicum∆steA∆ripA EmbA453V: 
 
 Aditol acetate derivatized lipoglycan extract from C. glutamicum∆steA∆ripA EmbA453E: 
Emba453 S1
Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:42 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
4 2
Sample Name: 2 Injection Volume: 5.0  
Vial Number: 3 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 16:38 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.45      n.a. 51867.00 6710.5 16.75    n.a.
2  12.44      n.a. 270032.00 13508.7 33.72    n.a.
3  14.20      n.a. 145865.00 9859.8 24.61    n.a.
4  15.29      n.a. 135385.00 9978.0 24.91    n.a.
Total: 603149.00 40057.07 100.00    0.000 













Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:A DITOL ACETATE 06_26 Page 1-1
2/8/2019  11:42 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
4 2
Sampl  Name: 2 I jection Volume: 5.0  
Vial Number: 3 Channel: FID
Sample Type: u known Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 16:38 Sample Weight: 1.0000  
Run Time (min): 20.00 Sa ple Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.45      n.a. 51867.00 6710.5 16.75    n.a.
2  12.44      n.a. 270032.00 13508.7 33.72    n.a.
3  14.20      n.a. 145865.00 9859.8 24.61    n.a.
4  15.29      n.a. 135385.00 9978.0 24.91    n.a.
Total: 603149.00 40057.07 100.00    0.000 














Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:41 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
6 4
Sample Name: 4 Injection Volume: 5.0  
Vial Number: 5 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acet te I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 17:26 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.30      n.a. 152044.00 7070.0 3.08    n.a.
2  12.44      n.a. 2204270.00 103448.6 45.08    n.a.
3  13.28      n.a. 133013.00 8352.6 3.64    n.a.
4  13.47      n.a. 84272.00 8769.5 3.82    n.a.
5  14.08      n.a. 84164.00 7484.2 3.26    n.a.
6  14.49      n.a. 796971.00 52614.2 22.93    n.a.
7  15.28      n.a. 127957.00 10385.7 4.53    n.a.
8  17.63      n.a. 219770.00 22415.7 9.77    n.a.
9  18.49      n.a. 88544.00 8949.0 3.90    n.a.
Total: 3891005.00 229489.54 100.00    0.000 











Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:41 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
6 4
Sample Name: 4 Injection Volume: 5.0  
Vial Number: 5 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 17:26 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.30      n.a. 152044.00 7070.0 3.08    n.a.
2  12.44      n.a. 2204270.00 103448.6 45.08    n.a.
3  13.28      n.a. 133013.00 8352.6 3.64    n.a.
4  13.47      n.a. 84272.00 8769.5 3.82    n.a.
5  14.08      n.a. 84164.00 7484.2 3.26    n.a.
6  14.49      n.a. 796971.00 52614.2 22.93    n.a.
7  15.28      n.a. 127957.00 10385.7 4.53    n.a.
8  17.63      n.a. 219770.00 22415.7 9.77    n.a.
9  18.49      n.a. 88544.00 8949.0 3.90    n.a.
Total: 3891005.00 229489.54 100.00    0.000 











Appendix 3:     Gas Chromatography spectra or derivatized C. glutamicum lipoglycan extracts 
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 Aditol acetate derivatized lipoglycan extract from C. glutamicum∆steA∆ripA EmbP505L: 
  
Aditol acetate derivatized lipoglycan extract from C. glutamicum∆steA∆ripA EmbS528A: 
S3
Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:41 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
5 3
Sample Name: 3 Injection Volume: 5.0  
Vial Number: 4 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 17:02 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.31      n.a. 134110.00 6430.0 2.65    n.a.
2  12.45      n.a. 3165353.00 154533.8 63.63    n.a.
3  14.02      n.a. 179532.00 12969.2 5.34    n.a.
4  14.29      n.a. 54231.00 4261.0 1.75    n.a.
5  14.49      n.a. 339778.00 31352.1 12.91    n.a.
6  15.28      n.a. 146668.00 11027.0 4.54    n.a.
7  17.63      n.a. 120778.00 10799.0 4.45    n.a.
8  18.50      n.a. 42372.00 11480.4 4.73    n.a.
Total: 4182822.00 242852.72 100.00    0.000 













Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:41 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
5 3
Sample Name: 3 I jection Volume: 5.0  
Vial Number: 4 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Diluti n Factor: 1.0000  
Recording Time: 26/6/2019 17:02 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amount: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.31      n.a. 134110.00 6430.0 2.65    n.a.
2  12.45      n.a. 3165353.00 154533.8 63.63    n.a.
3  14.02      n.a. 179532.00 12969.2 5.34    n.a.
4  14.29      n.a. 54231.00 4261.0 1.75    n.a.
5  14.49      n.a. 339778.00 31352.1 12.91    n.a.
6  15.28      n.a. 146668.00 11027.0 4.54    n.a.
7  17.63      n.a. 120778.00 10799.0 4.45    n.a.
8  18.50      n.a. 42372.00 11480.4 4.73    n.a.
Total: 4182822.00 242852.72 100.00    0.000 














Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:39 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
9 6
Sample Name: 6 Injection Volume: 5.0  
Vial Number: 7 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 18:38 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amou t: 1.0000  
No. Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
1  9.29      n.a. 305067.00 14606.4 9.30    n.a.
2  12.42      n.a. 1111650.00 53371.7 33.98    n.a.
3  12.58      n.a. 392939.00 19231.4 12.24    n.a.
4  13.67      n.a. 86638.00 6307.9 4.02    n.a.
5  14.06      n.a. 149693.00 8626.3 5.49    n.a.
6  14.47      n.a. 351250.00 21770.6 13.86    n.a.
7  15.26      n.a. 153849.00 13357.5 8.50    n.a.
8  17.59      n.a. 221445.00 19803.0 12.61    n.a.
Total: 2772531.00 157074.82 100.00    0.000 














Operator:Shimadzu  Timebase:GC2010_SYSTEM1   Sequence:ALDITOL ACETATE 06_26 Page 1-1
2/8/2019  11:39 AM
Default Test/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 SR8 Build 2623 (156243)
9 6
Sample Name: 6 Injection Volume: 5.0  
Vial Number: 7 Channel: FID
Sample Type: unknown Wavelength: n.a.
Control Program: Alditol Acetate I Bandwidth: n.a.
Quantif. Method: Alditol Acetate 2 Dilution Factor: 1.0000  
Recording Time: 26/6/2019 18:38 Sample Weight: 1.0000  
Run Time (min): 20.00 Sample Amou t: 1.0000  
No  Ret.Time Peak Height Area Rel.Area Amount 
min Name µV µV*min %
  9.29      n.a. 3 5067.00 14606.4 9.30    n.a.
2  12.42      n.a. 1111650.00 53371.7 33.98    n.a.
3  12.58      n.a. 392939.00 19231.4 12.24    n.a.
4  13.67      n.a. 86638.00 6307.9 4.02    n.a.
5  14.06      n.a. 149693.00 8626.3 5.49    n.a.
6  14.47      n.a. 351250.00 21770.6 13.86    n.a.
7  15.26      n.a. 153849.00 13357.5 8.50    n.a.
8  17.59      n.a. 221445.00 19803.0 12.61    n.a.
Total: 2772531.00 157074.82 100.00    0.000 









1,400,000 ALDITOL ACETATE 06_26 #9 [modified by Shimadzu] 6 FIDµV
min
1 - 9.291
2 - 12.418
3 - 12.578
